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ABSTRACT 
Oral drug delivery is acknowledged by many as the idyllic method of drug delivery due to its versatility and convenience 
of administration. Nevertheless, the bioavailability of drugs delivered via the oral route remains disputed. Classically, 
conventional marketed drug delivery systems release drugs in inconstant and unpredictable manners, leading to sub-
therapeutic and in some cases toxic drug doses. Consequently, patient compliance is compromised, in turn having an 
effect on the success of the therapeutic intervention in question. One such limitation occurs in the treatment of 
Schizophrenia, with patients unable to comply with treatment due to multiple administration requirements. Sulpiride, an 
antipsychotic agent, displays notable efficiency in reducing both positive and negative symptoms of Schizophrenia.  
However, sulpiride has a low bioavailability and thus therapy requires the use of large doses, and hence multiple 
administrations. In addition, a large percentage of Schizophrenic patients present with concomitant mood disorders, 
namely ‘Schizoaffective’ disorder, which further necessitates the use of mood stabilizing agents. As a result, patien ts 
end up with a huge pill burden and are unable to comply with therapy and this leads to reduced clinical outcomes.  
A dual layered, xerogel-bioadhesive intestinal patch drug delivery system (ODLS) was thus designed, formulated, and 
evaluated for the site-specific delivery of two bioactives in the treatment of Schizophrenia with concomitant mood 
disorders in a time controlled-idiosyncratic manner. Ultimately easing compliance to complicated treatment regimens, 
enhancing bioavailability and improving patient compliance. The ODLS essentially comprises of a bi-layered tablet, 
layer one comprised of a sustained release semi-interpenetrating polymer network (s-IPN) xerogel and a layer two of 
embedded pulsatile release bioadhesive intestinal patches, with the system as a whole enteric coated for protection. 
Intestinal patches encompassed in layer two are fabricated of a backing layer, a drug loaded layer, a mucoadhesive 
layer, and a mucus cleaving layer. The ODLS employs a combination of sustained and pulsatile drug release 
mechanisms, in addition to intestinal retentive mechanisms. Furthermore, the system physically protects the drug 
delivery system from acidic or proteolytic degradation within the human gastro-intestinal tract. The present study utilized 
the use of bioadhesion for site-specific and gastro retentive drug delivery, with crosslinking being employed for rate-
modulated drug delivery. Sulpiride and sodium valproate were selected as model drugs for the sustained release xerogel 
layer and the pulsatile bioadhesive patch layer respectively in this study as sulpiride is an antipsychotic with low 
bioavailability yet good antipsychotic activity and sodium valproate is the mainstay drug treatment for mood disorders 
in schizophrenia. Therefore, sulpiride would profit from the sustained release as it would improve bioavailability and 
hence patient compliance, whereas sodium valproate would benefit from the pulsatile release so as to avoid the well-
known resistance to therapy due to prolonged exposure to drug. Thus these drugs would gain benefit from the site-
specific controlled drug delivery offered by the ODLS.  
The primary aim of the sustained release s-IPN xerogel was to ensure delayed release of drug over 24 hours thus 
decreasing the need for multiple administrations and to maintain a steady state drug concentration. Film casting, a 
versatile technique was utilized in the fabrication of polymeric films to develop the bioadhesive intestinal patches. 
Preliminary in vitro investigations led to identification of a combination of polymers and crosslinking agent best suited 
to develop the system. A central composite design was employed for system optimization. The xerogel layer 
demonstrated that zero-order drug release was achieved after the crosslinking procedure. Delayed drug release 
fundamentally decreases the number of doses required daily and thus patient compliance and clinical efficacy is 
improved. The pulsatile release layer displayed distinct triphasic drug release after assembly of the intestinal patches, 
pulsatile release of drugs fundamentally reduced resistance to drug therapy as well as reducing pill burden. 
Furthermore, in vitro analysis of the ODLS showed that the xerogel layer behaved superiorly in terms of controlling drug 
delivery in a site-specific and prolonged fashion in comparison to a marketed gold standard. There exists no gold 
standard for pulsatile delivery of sodium valproate hence the pulsatile layer was tested against the marketed standard 
administered as a single dose. In vitro findings were substantiated by in vivo analysis in a white pig model. Results 
indicated that the systemic bioavailability of sulpiride was higher than the gold standard and drug release was prolonged 
in a zero-order fashion over 24 hours. Sodium valproate released in a triphasic manner over 24 hours thus reducing the 
risk of treatment resistance and decreased pill burden.  
To summarize, the ODLS was able to overcome the many challenges associated with oral drug delivery in 
schizoaffective disorder, by simplification of complicated treatment regimens, and hence improving bioavailability of 
drug delivery orally. The benefits associated with oral drug delivery have evidently been exploited by the present study, 
producing a versatile drug delivery system which can successfully deliver two bioactives simultaneously via 
individualistic release patterns, thus treating both conditions with a single oral dosage form with a single daily 
administration.  
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CHAPTER 1 
INTRODUCTION AND MOTIVATION FOR STUDY 
 
1.1. Background to the Study 
Consideration of the absorption of oral dosage forms is a crucial forethought in drug delivery 
system development. Oral routes are favored for being less invasive, being a more physiologically 
natural route leading to ease of administration and improved patient compliance. Nonetheless, in 
comparison to entry of drug into direct systemic circulation via intravenous dosing, there exist 
additional factors affecting the availability of drugs after oral administration (Musther et al., 2014).  
These factors include, degradation within the gastrointestinal tract (GIT), metabolism within the 
gut wall and liver, permeability through the gastrointestinal epithelium, as well as inadequate drug 
release from the delivery system (Musther et al., 2014). In addition, if the drug is not released in 
sufficient concentrations at the site of absorption, the drug will be unable to reach effective plasma 
concentrations to accomplish the anticipated therapeutic outcome (Davis, 2005). The oral 
bioavailability of many drugs is further compromised in drugs classified as Narrow Absorption 
Window (NAW) drugs, where the therapeutic window of several drugs is restricted by their short 
circulating half-life and absorption via a well-defined segment of the GIT (Streubel et al., 2006). 
Once the dosage form passes the absorption window, the drug becomes neither bioavailable nor 
clinically effective (Bakde et al., 2012). Many drugs are poorly absorbed or sensitive to the gastric 
environment; thus conventional oral delivery systems need to undergo modifications or novel drug 
delivery systems need to be designed and developed so as to efficiently administer NAW drugs 
(Shen and Mitragotri, 2002; Bakde et al., 2012). Additionally, it has been shown that drug efflux 
pumps such as the P-glycoprotein (P-gp) (an ATPase, energy-dependent transmembrane drug 
efflux pump) plays a vital role in modifying the pharmacokinetics of many drugs and is thereby 
related to the observed poor bioavailability (Varma et al., 2003). It has gradually been attaining 
significance in research aimed at enhancing drug absorption due to its distribution at the site of 
drug absorption (Varma et al., 2003).  
Pharmacokinetic limitations posed by narrow absorption windows and efflux pumps lead to 
frequent dosing of various drugs to attain the required therapeutic effect. This results in pill 
burdens and thus reduced patient compliance (Bakde et al., 2012). Patients with chronic illness 
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often present with concomitant conditions, hence requiring a greater number of drugs and thus 
problems with adherence to treatment becomes a greater challenge. One crucial contributing 
factor of adherence to treatment is a simplified dosing schedule and frequency of drug 
administration. Numerous comprehensive review studies have advocated that adherence is 
superior to drugs that have a once daily dosing schedule compared with those requiring multiple 
doses (Kruk and Schwalbe, 2006). Many studies have been conducted on the possibility of simple 
dosing regimens, where a delivery system has the ability to deliver multiple drugs for an extended 
period of time, thereby reducing the administration dose and frequency (Kruk and Schwalbe, 
2006). The above detailed limitations to oral drug delivery are further outlined in Figure 1.1 with 
the corresponding strategies employed to overcome them.  
An idyllic drug delivery system ought to achieve two requisites, 1) to deliver drug at a specified 
rate over the duration of treatment, and 2) allow for site-specific targeting. These requirements 
lead to the necessity for controlled release technologies that are able to improve therapeutic 
efficiency of a drug via precise spatial targeting, thereby decreasing the dose and number of oral 
administrations (Varma et al., 2004).  
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Figure 1.1: Illustration of various restrictions to oral drug delivery and studies conducted to 
overcome them.  
RESTRICTIONS POSED TO ORAL DRUG DELIVERY AND 
APPLIED DDS TECHNOLOGIES 
Low Aqueous 
Solubility 
Polyamidoamine (PAMAM) 
dendrimers, shown to enhance the 
solubility of drugs with poor solubility 
(D’ Emanuele A et al., 2004). 
Solid-lipid nanoparticles employed to 
improve solubility and absorption of poorly 
soluble drugs (Beloqui A et al., 2013).  
 N-octyl-o-sulfate chitosan micelles 
have been observed to increase oral 
absorption of paclitaxel (Moa R et al., 
2011).  
Punitive Gastric 
Environment  
Cationic liposomes of a mannose derivative 
and lipid A as an effective cold chain 
unrequired oral mucosal vaccine drug delivery 
system (Wang N et al., 2014).  
Self- microemulsifying drug delivery system of 
model protein drug Lueprorelin, protection 
against enzymatic degradation (Hintzen F et 
al., 2014).    
Layer-by-Layer (LBL) construct composed of casein 
protected iron oxide nanoparticles, loaded with 
doxorubicin, displays stability in enzymatic and 
acidic gastric conditions (Huang J et al., 2015). 
Efflux Pumps 
Polyamidoamine dendrimers transport 
drug across epithelial cells, capable of 
crossing paracellular and transcellular 
pathways (D’Emanuele A et al., 2004).  
Nanolipid carriers enhance 
bioavailability of poorly water-
soluble compounds using 
saquinavir, a P-gp substrate 
(Beloqui A et al., 2013). 
Polysaccharides, Polyethylene glycol, Gellan 
Gum, inhibit P-gp efflux and increase 
substrate drug bioavailability (Gaikwad et al., 
2012).    
Narrow 
Absorption 
Window 
Oral Multiparticulate gastroretentive 
dosage forms for sustained drug 
release (Pund S et al., 2011).    
Gastroretentive technologies to 
prolong GIT residence time and 
thus increase absorption (Streubel 
A et al., 2006). 
Low Mucosal 
Permeability Alkylmaltosides are effective non-
toxic permeability enhancers 
(Peterson S.B et al., 2012). 
Gemcitabine prodrugs D-and L 
configuration amino acids increase 
mucosal permeability of drugs (Tsume 
Y et al., 2014).  
Inconstant Drug 
Release 
Liquefied gas based delivery system for 
oral drug delivery. Capsule shaped 
system with capillary component for 
controlled drug release (Haznar-Garbacz 
D et al., 2012). 
Electroencapsulation of mesoporous 
silicon (Psi) nanoparticles to allow for time 
and site-specific drug release (Roine J et 
al., 2012). 
Complex 
Treatment 
Regimens: 
Improved 
patience 
Multidrug oral drug delivery system, 
decreases pill burdens and thus frequency 
of administration, therefore improved 
patience compliance (Prabakaran et al., 
2004). 
Dendrimers used in oral drug delivery due 
to improved bio distribution and 
pharmacokinetic profiles of carrier drugs 
(Mignani et al., 2013). 
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Amongst others the most common technologies developed to achieve controlled drug release 
include bilayered tablets, gastroretentive systems, and polymer matrices. The introduction of 
matrix tablets in the context of controlled drug release systems has provided a revolution for novel 
drug delivery technology of pharmaceutical salience. The rate of drug release from a matrix 
system is governed by the type and amount of polymer utilized in the formulation process (Modi 
et al., 2011; Korbely et al., 2012).  
Schizophrenia is a neurodegenerative disorder associated with reduced mental abilities and the 
decreased level of social functioning due to the occurrence of symptoms such as hallucinations, 
delusions and emotional affect. Of significant importance in the treatment of schizophrenia is non-
adherence to therapy, which leads to relapse and hospitalization thereby causing greater costs 
being incurred in treatment programs and poor prognosis. Researchers have thus suggested that 
the use of long-acting controlled drug delivery systems may significantly improve compliance 
(Olivares et al., 2009), hence the need for zero-order sustained release delivery systems in the 
treatment of schizophrenia becomes apparent.  
However, schizophrenia is known to commonly present as schizoaffective disorder, which is 
defined as an acute concomitant mood syndrome presenting with a fundamental schizophrenic 
symptom (Levinson et al., 1999). Treatment of schizoaffective disorder thus requires combination 
therapy so as to combat symptoms of schizophrenia and the mood disorder, thus the concurrent 
use of antipsychotics and mood stabilizing agents. Mood stabilizing agents employed easily 
undergo degradation by metabolic enzymes and thereby develop resistance thus requiring three 
times a day dosing to prevent treatment resistance and non-adherence due to the higher risk of 
adverse effects.  
This results in complex treatment regimens which patients find difficult to adhere to, thus the use 
of time-programmed (pulsatile) drug delivery systems is useful as it reduces the number of 
administrations required.  
Pulsatile drug delivery systems allow for the release of drug immediately after a defined lag time 
according to circadian rhythms or dosing requirements. This pattern of drug delivery becomes 
useful in the case of chronic therapy as drug resistance and side effects are often seen, the 
likelihood of such effects are less with pulsatile delivery systems as the desired concentration of 
drug is released only at predetermined time intervals (Mandal et al., 2010; Rasve et al., 2011).  
Overall, pulsatile release systems have been designed due to the subsequent reasons (Nagar et 
al., 2010):  
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i. Chronopharmacotherapy of disease states, in which circadian rhythms play a vital role in 
disease pathophysiology. 
ii. To circumvent degradation of drugs within the upper GIT. 
iii. Programmed drug delivery, due to the fact that continuous drug release leads to 
instabilities in normal feedback mechanisms within the body and the development of drug 
resistance.  
iv. For drugs that develop biological tolerance, and are targeted to specified sites in the GIT.   
Various formulation techniques exist for the development of pulsatile drug delivery system; they 
are generally classified as single-unit and multiple-unit systems. However, they function on the 
same rudimentary principles of erosion and dissolution; swelling and alterations in membrane 
permeability (Roy and Shahiwala, 2009). 
One possible relatively unexplored approach to pulsatile drug delivery is the use of bioadhesive 
intestinal multilayered patch systems. Patches comprise of layers of thin, flexible polymeric films; 
when the patch attaches to the intestinal wall, drug flows through the epithelial lining into 
circulation at a rate controlled by the film that is preprogrammed to maintain drug at an effective 
level (drug loaded layer) (Tao and Desai, 2005). 
Membranous drug delivery systems such as intestinal patches have the advantage of being 
layered with the incorporation of various excipients into the different layers, where the layers of 
the system can perform differing functions, including drug encapsulation, protection of the system, 
and mucoadhesion, therefore allowing for gastric retention (Shen and  Mitragotri, 2002; Tao and 
Desai, 2005).  
So as to overcome the challenges of oral drug delivery, the drug delivery system proposed in the 
present thesis is designed to deliver two bioactives targeted to the intestine, for a prolonged period 
of time via idiosyncratic or individual drug release patterns i.e. sustained (zero-order) and pulsatile, 
within a single dosage form; in interest of overcoming the drawbacks observed in the treatment 
and clinical outcomes of patients with schizoaffective disorder. The proposed oral dual layered s-
Interpenetrating Polymer Network (s-IPN) xerogel-bioadhesive intestinal patch oral drug delivery 
system (ODLS), consists of a dual layered tablet of which layer one comprises the s-IPN xerogel 
matrix allowing for site-specific sustained release of sulpiride an antipsychotic  and layer two 
comprises the embedded bioadhesive multilayered intestinal patches for pulsatile release of 
valproic acid, with each patch consisting of a mucus cleaving layer, bioadhesive layer, drug loaded 
layer and a backing layer.  
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1.2. Rational and Motivation for the Study 
Schizophrenia is one of the major psychiatric disorders that have been shown to greatly impair 
the quality of life of patients and their caregivers, creating an enormous financial burden on society 
(Peuskens et al., 1999). As noted previously non adherence to therapy is a common cause for 
relapse leading to greater costs incurred in treatment programs and poor prognosis. Research 
has indicated the use of sustained drug delivery systems may considerably advance compliance 
(Olivares et al., 2009). 
Sulpiride is effective in the treatment of acute and chronic schizophrenia, poor lactation, 
depression, anxiety, tardive dyskinesia and tension (Soares et al., 2011), with a low bioavailability 
of 30 % (Chitneni et al., 2011). Psychiatric therapy with sulpiride involves high dosages of up to 
2400mg/day thus requiring multiple administrations in a day (Barnes et al, 2006; Rossiter and 
Blockman, 2010). Therefore the issue of diminished patient compliance is evident. In addition, it 
is has been ascertained that a majority of  schizophrenic patients present with concomitant mood 
disorders which is collectively known as schizoaffective disorder; defined in Chapter 1, Section 
1.1. Treatment of schizoaffective disorder entails combination therapy so as to combat symptoms 
of schizophrenia and the co-occurring mood disorder, thus concurrent use of antipsychotics and 
mood stabilizing agents such as valproic acid is a necessity. This places a huge pill burden upon 
the patient or caregiver and thus leads to reduced patient compliance and hence poor clinical 
outcomes.  
Thus a dual site-specific delivery system would allow for the delivery of two therapeutic agents in 
a single dosage form, as a once daily dose, hence improving the bioavailability and patient 
compliance; with no risk of drug interactions occurring despite dual delivery within a single dosage 
form. The proposed  ODLS can successfully achieve such individualistic drug delivery, whereby 
the system releases sulpiride (antipsychotic) in a sustained manner from the s-IPN xerogel and 
valproic acid (mood stabilizing agent) in a pulsatile release pattern via intestinal patches at 
different absorption sites in the intestine via bioadhesion of the respective carrier systems. 
Furthermore, the ODLS has further therapeutic applications, as illustrated in Figure 1.2. 
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Figure 1.2: Potential applications of the ODLS.  
 
1.3. Mechanism by which Dual Drug Delivery will be achieved with the ODLS 
The diagrammatic representation of the ODLS in Figure 1.3a represents the dual layered oral drug 
delivery system, with layer 1 comprising the s-IPN xerogel for zero-order sustained release, and 
layer 2 consisting of embedded bioadhesive multilayered intestinal patch for pulsatile release. 
Figure 1.3b illustrates the layers of the intestinal patch with i) being the N-acetyl cysteine mucus 
cleaving layer ii) the Lectin conjugated bioadhesive layer iii) Crosslinked Eudragit RS 100: Alginate 
drug loaded layer and iv) Ethyl cellulose impermeable backing layer. Once the dosage form is 
ingested, the enteric coated tablet will pass into the intestine protected, in the vicinity of the small 
intestine the enteric coating will dissolve away and the dual layered tablet will divide into the s-IPN 
xerogel and intestinal patch components respectively; both components attach to the intestinal 
wall via a process of mucoadhesion. Layer one, which is the s-IPN xerogel will release drug in a 
controlled manner over 24 hours, while layer 2 comprising of the three multilayered bioadhesive 
patches will be released from the tablet via erosion. The released patches will adhere to the 
intestinal wall via mucus cleaving initiated by the N-acetyl cysteine layer and later by the lectin 
POTENTIAL THERAPEUTIC 
APPLICATIONS OF THE ODLS 
 
 
 
Incorporation of other bioactive 
agents with poor bioavailability. 
The system may be applied to the 
delivery of bioactives that require 
high daily therapeutic doses and 
thus necessitate multiple 
administrations.  
The system is applicable to drugs that 
require controlled delivery over a prolonged 
period of time by employing the proposed s-
IPN xerogel. 
The delivery of bioactives site-
specifically to the intestine via pH 
responsive polymers enteric 
coating. 
Delivery of combination therapy in a single 
dosage form, yet allowing individualistic 
delivery mechanisms (e.g. congestive 
heart failure (diuretic+ACE inhibitor) or 
HIV/AIDS (stavudine+lamivudine). 
Enhanced drug delivery via site-specific 
delivery of bioactives requiring gastric retention 
such as pulsatile release systems employing 
the proposed mucoadhesive multilayered 
intestinal patches.  
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conjugated bioadhesive layer; drug release will be modulated by the degree of crosslinking within 
the respective drug loaded layers, to allow for pulsatile release. Leakage and loss of drug into the 
intestinal contents will be prevented by the impermeable backing layer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Componential configuration of the ODLS prototype, where a) represents the dual 
layered oral drug delivery system and b) represents the multilayered bioadhesive intestinal patch 
with its respective polymeric film layers.  
 
In an effort to improve bioavailability, patient compliance, and evade drug resistance, the proposed 
ODLS employed technology outlined in Figure 1.4 to develop a single dosage form for segregated 
idiosyncratic drug delivery.  
Mucus Cleaving Layer 
Mucoadhesive Layer 
Drug Loaded Layer 
Backing Layer  
Embedded bioadhesive 
multilayered patch 
Layer 2: Multilayered bioadhesive intestinal patches 
(pulsatile release of bioactive 2) 
Layer 1: s-IPN xerogel matrix 
(sustained release of bioactive 1) 
a) 
 
 
 
 
 
b) 
i. 
ii. 
iii. 
iv. 
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Figure 1.4: Technology utilized to enhance bioavailability in the development of the ODLS.  
 
 
 
 
 
 
 
Mucoadhesion-Mucus 
Cleavage 
 Site-specific drug 
delivery.  
 Isolated and 
idiosyncratic drug 
delivery-no drug 
interactions. 
 Gastroretentive 
thus retains DDS 
at site of 
absorption for 
prolonged time 
period.  
Crosslinking- s-IPN 
 Drug entrapped in 
polymer 
networks-
prolonged drug 
delivery time, one 
tablet, once daily-
improved 
compliance.  
 Averts variable 
and excessive 
drug release.  
Protective Coating 
 Physical 
protection of DDS 
from the harsh 
environment of 
the stomach. 
 Unidirectional 
release via 
impermeable 
backing layer-thus 
improved 
absorption and 
bioavailability.  
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1.4. Novelty of the Study 
The novelty of this study lies in the mode of idiosyncratic/individualistic drug delivery, which was 
achieved via the use of two novel drug delivery strategies. The dual component system will be 
able to avoid high pill burdens, reduced patient compliance, poor bioavailability and treatment 
resistance by administering two bioactive agents in a single dosage form; yet, allowing individual 
release kinetics suited to the treatment regimens of each. Furthermore, the formulation process 
involved the novel crosslinking of poly (ethylene) oxide with gellan Gum employing epichlorohydrin 
as the crosslinking agent to form a semi-interpenetrating polymer network xerogel, which in turn 
allowed for zero-order sustained drug release kinetics. The incorporation of lecithin as an excipient 
within the xerogel further added to the novelty as the model drug, sulpiride is a known substrate 
of the P-glycoprotein (P-gp) efflux transporter and lecithin is a known inhibitor of the P-gp 
transporter along with the other polymers utilized in the formulation thus improving bioavailability 
even further. Novelty of the system was extended with the design and fabrication of the 
multilayered bioadhesive intestinal patches, with the innovation laying in the use of N-acetyl 
cysteine within the mucus cleaving layer and lectins being conjugated to the mucoadhesive layer 
to enhance bioadhesion and thus retention time of the intestinal patches allowing for pulsatile 
release over 12 hours; which is highly beneficial in schizoaffective disorder, with drug resistance 
arising with the use of valproic acid. The development of the dual layered tablet encompassing 
both systems greatly reduces the number of administrations required to a single dose daily and 
thus increases compliance, reduces the risk of resistance and improves clinical outcomes.  
1.5. Aim and Objectives of the Study 
Aim: Pharmaceutical fabrication and prototyping of an adaptable multifunctional double layered 
semi-IPN xerogel-bioadhesive intestinal patch matrix tablet (ODLS) for the treatment of 
schizophrenia and associated mood disorder to improve versatility and multifunctionality of 
currently available treatment regimens. The proposed ODLS ensures idiosyncratic release of the 
incorporated drugs via the mechanism illustrated in Figure 1.5.  
The aforementioned ODLS will be formulated to meet the following design criteria:  
1. For purposes of sustained release the matrix tablet component should allow for sufficient 
drug entrapment within the xerogel pores so as to allow for prolonged delivery rates.  
2. The crosslinked xerogel in combination with lecithin should improve the bioavailability of 
the bioactive. 
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3. The candidate drug must remain protected from enzymatic degradation within the gastro-
intestinal tract until it is in contact with the site of delivery which is the small intestine.  
4. For purposes of pulsatile release the intestinal patch component should be sufficiently 
bioadhesive to allow for prolonged residence time in the small intestine.  
5. To allow for adequate drug absorption, drug leakage from the intestinal patch component 
should be prevented.  
6. To attain pulsatile release of the drug from the intestinal patch component, drug should be 
efficiently trapped in a drug loaded layer, thereby controlling drug release profiles. 
Objectives: 
For pragmatic fulfillment of the aim and design strategy, the following objectives are apparent:  
i)  To design and formulate a novel physically stable s-IPN xerogel matrix through the process of 
crosslinking which results in the sustained zero-order release of entrapped drug.  
ii) To characterize the s-IPN xerogel matrix component of the ODLS, the following tests will be 
conducted: Fourier Transform Infrared (FTIR) Spectroscopy; Scanning Electron Microscopy 
(SEM) imaging; Differential Scanning Calorimetry (DSC). 
iii) To design and fabricate the novel bioadhesive multilayered intestinal patch component of the 
ODLS via a process of crosslinking and solvent casting, for pulsatile release of entrapped drug.  
iv) To characterize the bioadhesive multilayered intestinal patch component, the following tests 
were conducted: Fourier Transform Infrared (FTIR) Spectroscopy; Scanning Electron Microscopy 
(SEM) imaging; Differential Scanning Calorimetry (DSC), and Rheology.  
v) Swelling and erosion studies were conducted on the s-IPN xerogel and the bioadhesive patches 
to evaluate the rate of polymer swelling and erosion and its possible effect on drug release.  
vi) Clinical potential of the prototype ODLS components, based on their ability to meet the design 
criteria in vitro, will be ascertained in the Large White Pig model in terms of in vivo release kinetics 
and biocompatibility. 
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c) 
a) 
 
b) 
d) 
The pulsatile release bioadhesive intestinal patch layer 
detaches and undergoes disintegration, releasing the 
embedded intestinal patches, which in turn adhere to the 
intestinal wall and release drug respectively in a time 
controlled manner over 12 hours.  
The sustained release s-IPN xerogel matrix layer of the dual 
layered tablet detaches upon swelling and attaches to the 
intestinal wall and continues to release drug over a 24 hour 
period.  
Enteric coating of the ODLS swells, and 
protects the system from the gastric 
environment.  
The ODLS passes 
through the stomach 
unchanged, thus 
preventing drug release 
or degradation.  
Figure 1.5: Schematic illustration depicting mechanism of drug release from the ODLS; a) xerogel matrix; b) adhesive 
intestinal patch layer; c) illustration of individual patch archetype; and d) dual layered oral dosage form (ODLS). 
 
2, 10, and 18 hour 
release patches. 
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1.6. Synopsis of the Thesis 
Chapter One of this thesis provides an introduction and background to this study and highlights 
the rationale, aim, objectives, novelty and potential beneficial applications of this study.   
Chapter Two of this thesis provides a comprehensive literature review, focusing on the presence 
and function of P-glycoprotein efflux transporters in the intestine and Blood Brain Barrier. It further 
describes the role of P-gp in limiting the oral bioavailability of drugs that are substrates, and 
approaches investigated in the management of other disease states in terms of polymers and drug 
delivery systems which are capable of P-gp inhibition or by-pass; and their possible application in 
the treatment of schizophrenia.  
Chapter Three of this thesis describes the pre-formulation and development of the s-IPN xerogel 
component of the ODLS; and the preliminary formulation methods investigated. In addition, 
formulation parameters were established to allow for Construction of a Central Composite Design.  
Chapter Four of this thesis describes the preparation of variants of the s-IPN xerogel as 
constructed according to a randomized, Face-centered Central Composite Design. In addition, 
physiomechanical and physiochemical characteristics were analyzed in order to determine the in 
vitro performance in simulated intestinal conditions. 
Chapter Five of this thesis describes the preparation of the optimized s-IPN xerogel component 
of the ODLS via Response Surface Methodology. The applicability of the design was analyzed. 
Furthermore, comprehensive in vitro physiomechanical and physiochemical evaluation was 
analyzed.  
Chapter Six of this thesis describes the pre-formulation and development of the bioadhesive 
multilayered intestinal patch components; namely the mucoadhesive and drug loaded layers of 
the ODLS. It describes the film formation techniques, and provides an overview of the parameters 
affecting film formation as well as an introduction to mucoadhesion, including the various 
mechanism of mucoadhesion. It further details the fabrication of variants of the respective 
bioadhesive multilayered intestinal patch layers as constructed according to a randomized, Face-
centered Central Composite Design, 
Chapter Seven of this thesis describes optimization using Response Surface Methodology. 
Furthermore, in vitro physiomechanical and physiochemical characterization of the system was 
analyzed to determine the in vitro performance.  
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Chapter Eight of this thesis describes the preparation of the remaining layers of the bioadhesive 
multilayered intestinal patch component of the ODLS. It includes a comparative analysis of the 
ODLS components with a marketed ‘gold standard’ formulation in terms of both in vitro and in vivo 
drug release behavior. Furthermore, it contains an explanation of the in vivo animal studies 
undertaken in the large pig model. Assessment of the ODLS’s biocompatibility and drug release 
behavior were highlights in this chapter. In addition, dosage administration and blood sample 
collection procedures are described.  
Chapter Nine of this thesis presents the conclusions and recommendations for future work.  
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1.7. Concluding Remarks 
This chapter aimed to highlight the limitations and challenges associated with oral drug delivery, 
particularly the effects of poor oral drug bioavailability and the most common approaches to 
overcome these limitations. In addition, the rationale, aim, objectives, and novelty of the current 
study was discussed. The focus of the chapter was a description of the ODLS, with specific 
emphasis on the architectural assembly and functioning of the various components. The need and 
advantages of such systems in the treatment of schizoaffective disorder due its respective clinical 
limitations were also addressed.  
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CHAPTER 2 
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in 
Pharmacoresistant Schizophrenia Therapy 
 
2.1. Introduction  
 The effectiveness of drug treatments for numerous disease states such as cancer, infectious 
diseases, and central nervous system (CNS) disorders (epilepsy, depression, and schizophrenia) 
is limited by poor therapeutic outcomes or drug resistance. The outcomes of drug treatment can 
be viewed as an interchange of several gene products that have an effect on pharmacokinetics 
and pharmacodynamics. These gene products mainly include metabolizing enzymes and drug 
transporters and alterations within any of these gene products may lead to a reduction in clinical 
outcomes (Löscher and Potschka, 2005). In particular, the clinical treatment and management of 
CNS disorders necessitate that a sufficient amount of drug must enter the brain. The use of oral 
drug delivery systems is beneficial in the treatment of neurodegenerative disorders as compliance 
to therapy becomes challenging (Nassar et al., 2009). However, an imperative factor determining 
the entry of drug molecules into the brain via oral administration is its absorption through the 
intestinal epithelium and the permeability of the blood-brain barrier (BBB). Passive diffusion across 
the intestinal epithelium is dependent on many physiochemical characteristics of drugs such as 
lipophilicity, molecular weight, and hydrophobic bonding (Takano et al., 2006). The same principle 
applies to passive diffusion across the BBB, although passive diffusion across the BBB is limited 
to small lipophilic molecules. Active efflux of the drug into the intestine and from BBB endothelium 
back into the blood are the most important mechanisms underlying reduced brain uptake of active 
drug molecules post oral dosing (Elsinga et al., 2004). 
 
The development of drug delivery systems involved in the treatment of neurodegenerative 
disorders requires a vital consideration of achievable brain concentrations. Factors that impact the 
brain uptake and concentrations of drugs include (i) the extent of intestinal absorption after oral 
administration, (ii) the rate and extent of transport across the BBB into the brain, (iii) metabolic 
stability of the drug, and (iv) the active transport out of the intestine and brain endothelium via 
efflux pump transporters. There are three classes of transporters that have been associated with 
the efflux of drugs-monocarboxylic acid transporters, organic ion transporters, and multidrug 
resistance transporters. This remarkable system of transporters provides a viable mechanism 
through which the permeation of CNS targeted drugs into the brain is effectually decreased. The 
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action of these efflux transporters at the level of the intestine and BBB may be demonstrated 
clinically as the reduced effectiveness of drug therapy targeted at CNS disorders (Taylor, 2002). 
 
In addition, various multispecific transport proteins have also been identified within the intestine 
and BBB. Some of these belong to the ATP-binding cassette (ABC) superfamily of transporters 
with P-glycoprotein (P-gp), multidrug resistance associated protein (MRP), and breast cancer 
resistance protein (BCRP) as representative examples (Elsinga et al., 2004; van Wetering et al., 
2009). P-gp is a membrane transporter of the ABC superfamily located within both the intestinal 
epithelium and the BBB thus playing a dynamic role in the bioavailability of orally administered 
drugs employed in the treatment of neurodegenerative disorders (Demeule et al., 2002]. We 
propose that drug molecules intended for the treatment of CNS disorders must be capable of 
bypassing the P-gp efflux pump at the intestinal and BBB levels so as to attain effective brain 
concentrations. 
 
Regardless of the vast advances in brain research outputs, neurodegenerative and psychiatric 
disorders remain the world’s leading causes of disability, morbidity, and mortality (Lalatsa et al., 
2011). Dysfunctions in the P-gp efflux transporter have already been suggested to play a role in 
the development of neurodegenerative disorders, such as Parkinson’s and Alzheimer’s diseases. 
Genetic variations in theMDR1 gene associated with reduced P-gp function at the BBB have been 
related to a higher risk of Parkinson’s disease. The reduced function of the P-gp efflux pump has 
been noted in most neurodegenerative disorders. It has been hypothesized that the decreased P-
gp function in the BBB may increase the risk and hence the incidence of neurological diseases 
(Bartels et al., 2009). In schizophrenia genetic variations of the ABCB1 (ATP-binding cassette 
subfamily B) gene also known as the MDR1 (multidrug resistance) gene have been described as 
the predisposing factors for schizophrenia and other neurodegenerative diseases. They have also 
been employed as determinants of treatment response to antipsychotics (Lin et al., 2006). As in 
other neurodegenerative diseases the BBB may be compromised by way of the inflammatory and 
neurodegenerative processes (Stolp and Dziegielewska, 2009); hence the functionality of P-gp is 
influenced by the inflammatory responses (Roberts and Gorlski, 2008). As discussed previously, 
there exists a reduction of P-gp function in progression of neurodegenerative diseases. 
Conversely, there is evidence of increased P-gp function in patients presenting with schizophrenia 
(Bartels et al., 2008). 
 
Schizophrenia is a neurodegenerative disorder that is known to affect approximately 1% of the 
world’s population (van Os et al., 2010), with a further 25% of patients approximated to be afflicted 
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by the disease experiencing non-remitting sickness (Pharoah et al., 2006). The disorder is 
characterized by disturbances of perception, thought, and volition, with significant impairment in 
social and occupational functioning. Studies have shown that roughly 10% of schizophrenic 
patients commit suicide. A recent study showed that more than 70% of patients diagnosed with 
chronic schizophrenia discontinued their antipsychotic drug therapy, due to poor effectiveness or 
tolerability (Nnadi and Malhotra, 2007; American psychiatric association, 1994; Kulhara et al., 
2001; Khin et al., 2012; Kingdon et al., 2010; Falkai and Möller, 2012; Insel, 2010). 
 
Schizophrenia is clinically characterized by the incidence of symptoms such as hallucinations and 
delusions which are collectively termed “positive” symptoms whereas symptoms pertaining to 
expression of emotional dullness and social withdrawal are recognized as “negative” symptoms 
(Pharoah et al., 2006). Figure 2.1(a) diagrammatically depicts the symptom cascade. 
Schizophrenia is widely characterized via a successive course that involves three distinct phases, 
namely, phase 1 (premorbid) defined by cognitive, motor, and societal dysfunction, phase 2 
(prodromal) which is characterized by weakened positive symptoms and accompanying 
deteriorating functionality, and phase 3 (plateau) in which the positive psychosis defining 
symptoms are less conspicuous and the negative symptoms including cognitive deficits are 
generally predominant (Tandon et al., 2009). Figure 2.1(b) illustrates the clinical stages of 
schizophrenia progression. 
 
It has been discovered that “pharmacoresistant schizophrenia” is a noteworthy obstacle to the 
successful management of the disease within the clinical setting. The prevalence of 
pharmacoresistant schizophrenia is understood to be approximately 12.9 to 48% of all 
schizophrenic patients and persists regardless of the use of drug combination treatment regimens 
with possible therapeutic efficacy. Majority of patients presenting with treatment resistant 
schizophrenia are on atypical antipsychotic medication. Recent in vitro studies have shown that 
drugs such as amisulpride, risperidone, quetiapine, and clozapine have a varying degree of affinity 
for the P-gp efflux transporter (Bebawy and Chetty, 2008; Boulton et al., 2002; El Ela et al., 2004). 
An additional study was conducted to determine the effect that cyclosporine A, a P-gp inhibitor, 
has on the brain uptake of amisulpride (a recognized P-gp substrate). In vitro and in vivo results 
displayed that amisulpride when co-administered with 50mg/kg of cyclosporine A showed an 
increase and prolonged antipsychotic effect. The area under the curve (AUC) in serum and the 
brain was increased in cyclosporine co-treated rats. These data points indicated a 
pharmacokinetic interaction between cyclosporine A and amisulpride which is most likely due to 
P-gp inhibition (Schmitt et al., 2006). Thus, the expression and function of the P-gp efflux 
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transporter have been recently implicated in the occurrence of pharmacoresistant schizophrenia. 
Antipsychotic drugs have also been shown to stimulate the catalytic activity of P-gp providing 
additional evidence of the participation of P-gp-mediated drug extrusion processes in restraining 
CNS penetration of these drugs. It has been suggested that some of the principles observed with 
the combination treatment of P-gp-mediated drug resistance in cancer may be applied to elucidate 
the involvement of P-gp in drug-resistant schizophrenia. There exists a greatly emergent body of 
evidence supporting the role of P-gp on the efflux of antipsychotic agents from the BBB; however 
limited consideration has been focused on the modulation of P-gp function by polymeric materials, 
excipients, and drug delivery systems used in other P-gp modulated treatment-resistant disease 
states (Bebawy and Chetty, 2008). 
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Figure 2.1: (a) Description of the aetiological complexity of schizophrenia (van Os et al., 2010) 
(b) Stages of schizophrenia progression (Tandon et al., 2009).  
 
 
2.2. Structure and Function of the Intestine and P-gp Intestinal Expression in Drug Delivery 
The absorption of drugs via the oral route is always under examination due to the fact that good 
bioavailability indicates that the drug is able to reach systemic circulation. Oral drug absorption is 
affected by both drug properties and the physiology of the gastrointestinal tract (GIT) (Pang, 2003). 
Oral bioavailability is a collective outcome of fraction absorbed, fraction escaping gut-wall 
elimination, and the fraction avoiding hepatic elimination. The factors that affect the bioavailability 
are divided into physiological, physiochemical, and biopharmaceutical factors (El-kattan and 
Varma, 2012). The sequence of actions determining the systemic availability of drug molecules 
subsequent to their oral administration is well acknowledged. However, for particular drugs, the 
process leading to drug absorption and bioavailability is complex. Certain mechanisms may 
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involve poor drug solubility, poor permeability, degradation (enzymatic/ non-enzymatic), and first 
pass hepatic metabolism (Takano et al., 2006). Following oral dosing, drug molecules cross the 
luminal membrane via a diversity of mechanisms that comprise of passive diffusion or active 
transport. Passive diffusion is divided into two pathways, the paracellular and transcellular 
pathway, in which the paracellular pathway drug molecules are absorbed via diffusion and 
convection volume flow through the water filled intercellular space (El-kattan and Varma, 2012). 
 
The active transport pathway is mediated by transporters and is divided into influx and efflux. The 
applicability of the various routes is determined by the compounds physiochemical properties and 
their relative affinity for various transport proteins. Enterocytes express several transporters 
belonging to the Adenosine triphosphate (ATP) binding cassette (ABC) superfamily and solute 
carrier (SC) super families, on the apical and basolateral surface of membranes with the function 
of influx and efflux of endogenous substances. A wide diversity of transporters are expressed in 
enterocytes; however, only a select few have been implicated in the intestinal absorption of drugs. 
ABC transporters utilize ATP to power the transport and are thus called primary active 
transporters. Solute carrier (SLC) transporters employ ion gradients (H+, Na+, and Ca++) across 
the membrane by active carriers. ABC transporters that are expressed in the intestine include P-
glycoprotein (P-gp), breast cancer resistant protein (BCRP), and multidrug resistance protein 
(MRP), which are localized on the brush border membrane of enterocytes. Efflux transporters 
mechanistically limit the enterocytic levels of their respective substrates by reducing uptake and 
facilitating efflux, whereas SLC transporters which include peptide transporter (PepTI) and organic 
anion polypeptide transporter (OATP1A2) amongst others are secondary active transporters that 
employ energy coupling mechanisms ( El-kattan and Varma, 2012; Schlessinger et al., 2013). 
 
During oral absorption, in addition to the physical processes mentioned above (solubility, 
permeability, etc.), P-gp mediated efflux across the apical membrane has an effect on the rate 
and concentration of drug diffusing across the basolateral membrane and thus entering general 
circulation from the intestine. It has been estimated that 50–60% of new and 40–50% of existing 
drugs molecules are lipophilic in nature and more than 25% of these agents are known P-gp 
substrates (Nassar et al., 2009). Pumps in the intestinal epithelium transport substrates from the 
intestinal lumen to the general blood circulation (Wagner et al. P-gp identifies with a diversity of 
structurally and pharmacologically dis, 2001) similar hydrophobic substances. The P-gp efflux 
pump transporter restricts the influx into and facilitates efflux from enterocytes of its substrates. 
Therefore, the P-gp efflux transporter is recognized as a determining factor of oral bioavailability 
and intestinal efflux of drugs (Takano et al., 2006). In the human intestine, P-gp is highly expressed 
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on the apical surface of superficial columnar epithelial cells of the colon and ileum (Figure 2.2) 
while expression decreases proximally into the jejunum, duodenum, and stomach (Takano et al., 
2006). 
Since the oral route of drug administration is the most preferred as previously mentioned, it is vital 
to overcome the absorption barrier posed by the P-gp efflux transporter (Nassar et al., 2009). 
Additionally, as discussed earlier P-gp plays a role in restricting cellular uptake of drugs from the 
general blood circulation into the brain due to its presence within the BBB as well. Research 
outputs have shown that intestinal P-gp can be inhibited by various compounds resulting to an 
increase in oral absorption of P-gp substrate drugs (Takano et al., 2006). 
 
 
Figure 2.2: Drug Efflux by P-glycoprotein in the intestine (Estudante et al., 2013). 
 
Physiological factors that influence oral drug absorption are absorption rate of a drug, which is a 
function of drug absorption via the GIT and gastro intestinal transit time, which influences the 
systemic exposure of rapidly, dissolved, and highly absorbed drugs. Intestinal transit time impacts 
the absorption of drugs with limited mucosal permeability and carrier-mediated uptake and drugs 
that are subjected to intestinal degradation. In addition, the degree of ionization plays a key role 
in determining drug dissolution rate and the passive permeability across the GIT. The pH at the 
absorption site is also a vital factor in allowing or inhibiting the dissolution and absorption of many 
ionizable drugs (El-kattan and Varma, 2012). 
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In addition, there are biopharmaceutical factors that influence oral drug absorption; amongst these 
is the salt form of a drug molecule which changes the coulombic attraction between the drug 
molecule and its respective counter ion thus altering the potential energy when in a solid state. 
This is usually associated with an alteration of the pH of the diffusion layer at the surface of the 
dissolving solid, thereby greatly increasing the solubility of the drug molecule. The amorphous 
form alternatively tends to improve the dissolution rate and solubility significantly compared to its 
crystalline form which increases the rate and degree of oral absorption (El-kattan and Varma, 
2012). Apart from these mechanisms, the small intestine has the ability to metabolize drugs via a 
diversity of pathways involving phase I and phase II reactions, which in turn may cause a restriction 
in oral bioavailability. CYP3A4 is the most abundant cytochrome P450 enzyme within the intestinal 
enterocytes that is implicated in the metabolic elimination of many drugs (El-kattan and Varma, 
2012). 
2.3. Structure and Function of the BBB and P-gp Expression in Drug Delivery 
The BBB is a specialized system of capillary endothelial cells as shown in Figure 2.3, which assists 
in protecting the brain from harmful substances within the blood stream, while supplying the brain 
with nutrients that are necessary for proper function. The BBB has many functions, including 
maintenance of the internal environment of the brain, protection of the brain from fluctuations in 
ionic composition, and drainage of cerebrospinal fluid and interstitial fluid. Due to its protective 
function the BBB restricts transport of substances into the brain via both the physical (tight 
junctions) and the metabolic (enzyme) barriers (Kaur et al., 2008; Hawkins and Davis, 2005). 
 
 
24 
 
 
Figure 2.3: Schematic representation of the cross section of the BBB cerebral capillary (Blasi et 
al., 2007). 
 
The BBB is composed of a monolayer of brain capillary endothelial cells. The limitation of drug 
uptake by the BBB arises via the presence of tight junctions between adjacent capillary endothelial 
cells and the relative lack of fenestrae as well as pinocytotic vesicles within the endothelial cell 
monolayer. In turn, brain capillary endothelial cells are surrounded by an extracellular matrix, 
pericytes, and astrocyte foot processes. Once a drug molecule enters the brain, either via 
transport across the BBB after systemic administration or by direct administration into the CNS, 
the drug may return to the blood via three ways: (1) It may pass through the capillary endothelial 
cells of the brain, (2) cross the epithelial cells of the choroid plexus, (3) or return to systemic 
circulation by bulk flow of cerebrospinal fluid that effectively results in reabsorption at the 
arachnoid villi (Taylor, 2002). The BBB is known to express a high degree of active efflux 
transporter proteins, including, as mentioned previously, P-gp, MRP-1, and BCRP. Lipophilic 
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molecules of approximately 500–600 Daltons may diffuse passively into the CNS. However, the 
vast majority of molecules of a molecular weight greater than 600 
Daltons do not cross the BBB (Figure 2.4). Therefore in order to reach the brain, most drug 
molecules must cross the BBB via an interaction with specific transporters occurring at the luminal 
surface of the endothelial cells (Löscher and Potschka, 2005; Löscher and Potschka, 2005 (2); 
Löscher and Potschka, 2005 (3); Lee et al., 2001).  
 
Figure 2.4: Respective locations of the drug efflux proteins on brain capillary endothelial cells that 
collectively form the BBB (Löscher and Potschka, 2005 (3).   
 
The pharmacodynamics and pharmacokinetics of CNS targeted drugs are determined by their 
unbound concentrations in the extracellular fluid of the brain. Several in vivo and in vitro 
procedures are accessible to study these properties. The efflux transport across the BBB is an 
imperative process utilized in the explanation of the mechanism of the apparent restricted cerebral 
distribution of drugs after their systemic administration. To examine the BBB efflux transport 
mechanism under in vivo conditions, an intracerebral microinjection technique has been 
developed and newly estimated as the BEI (Brain Efflux Index). BEI is defined as the relative 
percentage of drug that is effluxed from the ipsilateral (does not cross the opposite hemisphere of 
the amount of drug injected into the cerebrum as shown: 
 
26 
 
𝐵𝐸𝐼% =
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑓𝑓𝑙𝑢𝑥𝑒𝑑 𝑎𝑡 𝑡ℎ𝑒 𝐵𝐵𝐵
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝐵𝐵𝐵 
× 100  
Equation 2.1 
However, limitations of the BEI method are that only one data point may be obtained for a single 
intracerebral injection, and the concentration the drug in the cerebrum cannot be accurately 
determined (Misra et al., 2003). The net uptake of a drug molecule by the brain via the BBB 
depends on the overall difference between the uptake and efflux processes (Table 2.1) Brain 
uptake of drug molecules is controlled by various factors, including the systemic disposition of the 
drug as well as the properties of the endothelial cells. Thus, permeability of endothelial cells and 
their ability to metabolize drugs actively regulate the amount of drug crossing the BBB in both 
directions (Schermann, 2002). 
Table 2.1: The net uptake of bioactive by the brain depends on the difference between the influx 
and efflux processes (Schermann, 2002)   
Blood Lumen Endothelial Cell Extracellular Fluid 
(i) Blood systemic exposure Influx Clearance  
(ii) Drug blood cell and 
protein binding 
(i) Drug permeability Drug disposition 
 (ii) Drug metabolism  
 Efflux Clearance  
 
In recent years it has become well perceived that the activity of the P-gp in the BBB plays a 
restrictive role with regard to the net cerebral uptake of many therapeutic drugs. Owing to its 
unspecific substrate affinities, P-gp restricts the achievable cerebral concentration of various 
medications and may be a crucial factor in the phenomenon of pharmacoresistance 
(La Foug’ere et al., 2010; Schinkel, 1999; Aller et al., 2009). P-gp is a prototypical multidrug 
resistance (MDR) transporter; its discovery was based on its ability to confer drug resistance to 
cancer cells. P-gp, a phosphoglycoprotein, acts as an unrestrained energy-dependent efflux pump 
(Taylor, 2002). Given that P-gp efflux accountability can be a key obstacle for CNS therapeutic 
drugs to cross the BBB and reach the target, the interactions of the CNS targeted drugs with the 
P-gp transporter may lead to the lack of CNS activity as a result of the minimized brain penetration. 
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Therefore the estimation and understanding of the significance of P-gp mediated efflux transporter 
have become an important stage in the discovery and development of CNS delivery strategies 
(Miller et al., 2008). 
2.4. P-gp Efflux Transporter Structure and Mechanism of Action 
In response to the inefficiency in conventional delivery mechanisms, a great amount of research 
efforts have lately focused primarily on the development of new strategies to allow for a greater 
efficacy in the delivery of drug molecules to the CNS. In particular, these research efforts have 
focused on the modulation of P-gp efflux transporters within the BBB (Gabathuler, 2010). P-gp is 
presently the most widely studied member of the ABC transporter family and has been shown to 
transport an extensive list of substrates with a great degree of structural diversity (Matsson et al., 
2009). P-gp is a type of energy-dependent ATPase transmembrane drug efflux transporter. It is a 
1280-long amino acid glycoprotein, expressed as a single chain structure containing two 
homologous portions of equal length, each portion consisting of 6 transmembrane domains and 
two ATP binding regions separated by a flexible polypeptide linker portion (Varma et al., 2003; 
Rosenberg et al., 2003), (Figure 2.5 (a), (Aouali et al., 2005; Sharom, 2014). 
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Figure 2.5: (a) Structural configuration of P-gp, MRP, and BCRP (Aouali et al., 2005) (b) 
Diagrammatic representations of the “Vacuum Cleaner” and Flippase model of P-gp function 
(Sharom, 2014). 
 
There are numerous models to explain the mechanism of efflux by the P-gp transporter. The three 
most predominant models, pore, flippase l, and the hydrophobic vacuum cleaner model, are 
commonly used to explain the mechanism of efflux (Figure 2.5 (b). The vacuum cleaner model 
hypothesizes that P-gp recognizes substrates embedded in the inner leaflet of the plasma 
membrane; the substrate is then transported through the protein channel out of the cell (Sharom, 
2014). Within the perspective of this model, P-gp binds directly to the substrate molecules that are 
located on the plasma membrane and pumps them out of the cell by recognizing the substrates 
as foreign bodies (Fardel et al., 1996). The pore model is described as an interaction of P-gp with 
29 
 
drugs within the boundaries of the cytosol, followed by efflux out of the cell via protein channels. 
The hypothesized flippase model explains drug efflux as a “flipping” of drug molecules from the 
inner leaflet to the outer leaflet of the cell against a concentration gradient. These drug molecules 
then undergo diffusion to reach the extracellular space (Fardel et al., 1996). However, the flippase 
model is the most generally received model and increasing amounts of evidence have made it the 
most favoured amongst all (Constantinides and Wasan, 2007; Higgins and Gottesman, 1992; 
Sauna et al., 2001). 
2.5. P-gp in Schizophrenia Therapy 
Antipsychotic drugs and other pharmacological agents used to treat psychiatric illness must cross 
the BBB to reach the target sites within the CNS to be able to exert their therapeutic effects. 
Antipsychotic drugs are crucial treatment options for symptoms of schizophrenia. The first 
generation or conventional antipsychotics include drugs that have high affinity antagonism of 
dopamine D2 receptors. The second generation antipsychotics or atypical agents include drugs 
with a lower D2 receptor affinity and a far greater affinity for other neuroreceptors (Wang et al., 
2009). Recently, it has become progressively evident that drug transporters situated within the 
BBB play a fundamental role in the pharmacokinetics of several drugs with therapeutic 
implications. There are strong indications for an impaired integrity of the BBB in schizophrenia, 
such as increased intracerebral concentrations of the soluble intercellular adhesion molecule-1 
(sICAM). Furthermore, the concentration of immunoglobulin and albumin is raised in cerebrospinal 
fluid in 30% of schizophrenic patients. P-gp function has been reported to be reduced in the 
progression of neurodegenerative diseases (de Klerk et al., 2010). 
Wang and co-workers (Wang et al., 2004) conducted a study employing the abcb1a/b knockout 
mouse model with a functional deficiency in P-gp. By utilizing ATPase activity as a marker for P-
gp activity, an in vitro study provided evidence that various atypical antipsychotic drugs such as 
risperidone and olanzapine may be effectively effluxed by P-gp. In a subsequent in vivo study 
utilizing the abcb1a gene knockout mouse model, results depicted that P-gp restricted the brain 
penetration of olanzapine, as the resulting brain concentration was 3-fold higher in the abcb1a 
knockout mice than as the comparative control mice (Wang et al., 2004). Risperidone is an atypical 
antipsychotic drug that has potent antagonistic affinities toward serotonin 5-HT2 and dopamine 
D2 receptors. Risperidone is recognized for its effectiveness against both positive and negative 
symptoms of schizophrenia. An in vitro study by Nakagami and co-workers (Nakagami et al., 2005) 
of the activity of P-gp against a range of antipsychotic agents showed that P-gp is likely to influence 
the absorption of all atypical antipsychotics to various degrees (Nakagami et al., 2005). 
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In addition to other studies relating to P-gp function the activity of the P-gp transporter at the level 
of the BBB can be studied in vivo via Positron emission tomography (PET) with [11C] verapamil 
as a PET tracer. PET seems to be a suitable means of in vivo valuation of P-gp functionality in 
humans and allows for the quantification of BBB/P-gp function in neurodegenerative disorders. 
The PET brain imaging study with the use of [11C] verapamil as a radiotracer was conducted on 
schizophrenic patients and a comparative healthy control group. Data obtained from the study 
showed a regionally reduced [11C] verapamil uptake within the temporal cortex and basal ganglia 
of schizophrenic patients versus healthy controls. These results have been interpreted as an 
increase in P-gp function in the brain of schizophrenic patients. These findings are of immense 
worth since an increase in P-gp function may be pertinent for the clinical progression of 
schizophrenia. An increase in P-gp function leads to reduced uptake of antipsychotic agents and 
may thus be associated with poor clinical outcomes (de Klerk et al., 2010). 
A further study by Kirschbaum and co-workers (Kirchbaum et al., 2008) found that the ATPase 
activity assay displayed high affinity of the antipsychotic risperidone for P-gp. In vivo studies 
conducted in mice and humans revealed variations in brain and serum concentrations for both 
risperidone and its active metabolite, 9-hydroxyrisperidone, which was recently approved as a 
new antipsychotic paliperidone. In comparison, the conventional antipsychotic haloperidol which 
displays a high antagonistic activity at dopamine D2 receptors is poor substrate of Pgp. 
Behavioural changes in the mdr 1a/1b knockout mice in comparison to the wild-type mice allow 
for the investigation of P-gp-dependent variations in the expression degrees of the CNS which 
leads to functional dispositions. Motor impairment on a rotarod physical task is characteristic of 
antipsychotic related D2 receptor antagonism [de Klerk et al., 2010; Kirschbaum et al., 2008) 
This very hypothesis was applied to mdr 1a/1b and wild-type mice after administration of either 
the known substrate risperidone or a poor substrate haloperidol. Results revealed distinctively 
different profiles in motor effects by the antipsychotic drug risperidone which was dependent on 
P-gp expression. Brain concentrations of risperidone and its 9-hydroxyrisperidone metabolite were 
10-fold higher for the first three hours in knockout mice versus wild-type mice. The increased 
concentration reflects the change in dose response seen in the behavioural task. The results 
establish for the first time the strong association between physical functionality and P-gp-
dependent brain concentrations. Pharmacokinetic data of this study displayed a 10-fold higher 
brain level of risperidone and a 20-fold higher brain level of 9-hydroxyrisperidone in mdr1a/1b mice 
as compared to wild type mice. Conclusively, antipsychotic drugs are effectively transported by 
the P-gp efflux transporter (Kirschbaum et al., 2008). 
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In conclusion, an additional study was conducted on the atypical antipsychotic aripiprazole. To 
assess the role of Pgp in the distribution and penetration of aripiprazole within the BBB, mice 
deficient in the P-gp gene were dosed intraperitoneally with 2 𝜇g/g of aripiprazole. Wild type mice 
were administered the same dose as the gene deficient mice. The results showed that deficiency 
of P-gp had a drastic effect on drug concentrations within the brain. Thus aripiprazole has been 
characterized as a transportable substrate of P-gp (Wang et al., 2009). 
2.6. P-gp Substrates and Inhibitors 
In an attempt to estimate the effects of P-gp in vivo, a range of in vitro P-gp assays have been 
developed so as to categorize compounds as P-gp substrates or inhibitors (Table 2.2). One such 
assay is the Transwell-based assays using polarized cell lines such as Madin-Darby Canine 
kidney (MDCK) cell line. The MDCK cell line may be stably transfected with human MDR1 
orMdr1a. Comparing the efflux ratios betweenMDR1- MDCK and MDCK, Transwell assays are 
able to provide a measure of the specific human P-gp-mediated efflux activity (Kirschbaum et al., 
2008). 
Table 2.2: Brief overview of P-gp inhibitors/substrates and the corresponding IC50 values of 
inhibitors. 
Potent (P) inhibition (IC50 < 10 𝜇M), moderate (M) inhibition (10 𝜇M ≤ IC50 < 50 
 
 
Inhibitor IC50 References  
Haloperidol Potent (Doan et al., 2002)  
Fluoxetine 
Chlorpromazine 
Paroxetine 
Sertraline 
 
Moderate  
(Doran et al., 2005; 
Doan et al., 2002) 
 
Risperidone  
9-hydroxyrisperidone 
Sulpiride  
Zolpidem 
 
Low 
(Doran et al., 2005; 
Doan et al., 2002) 
 
Loperamide*  (Doran et al., 
2005) 
 
Verapamil*  
Quinidine* 
Moderate (Feng et al., 2008; 
Doran et al., 2005) 
 
Prednisone* Low Doran et al., 2005)  
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Another generally used P-gp in vitro assay is the P-gp ATPase assay for assessing drugs that 
demonstrate P-gp interactions as substrates. The standard reagent of the ATPase assay is a 
membrane preparation from insect cells that are vastly expressive of human P-gp. Functional 
human P-gp will transport P-gp substrates across the membrane thus resulting in the release of 
inorganic phosphates (Feng et al., 2008). In addition, the in vitro calcein AMP-gp inhibition assay 
can be utilized to detect compounds that inhibit the P-gp-mediated efflux, via employing a 
fluorescent P-gp substrate, calcein. The calcein assay is capable of differentiating between 
various Pgp inhibitors from non-inhibitors by measuring the resultant fluorescence of calcein (Feng 
et al., 2008) 
A further in vitro approach in studying the P-gp activity is the use of P-gp knockout mice in 
comparison to wild-type mice. P-gp knockout mice are genetically modified animals in which both 
genes that are homologous to the human MDR1 gene have been disrupted, resulting in a viable 
line of animal models. An assessment of the brain plasma area under the curve (AUC) ratio in 
knockout mice as compared to wild type mice has become a standard experimental methodology 
to determine whether P-gp-mediated efflux poses a possible obstacle to the activity of CNS 
targeted drugs in vivo (Löscher and Potschka, 2005; Doran et al., 2005; Hitchcock, 2012). 
P-gp exhibits significant capability to bind and transport a wide range of structurally and 
functionally dissimilar compounds. Typical drug substrates include typical and atypical 
antipsychotics as well as anticancer agents. P-gp also interacts with yet another group of 
hydrophobic agents, known as chemomodulators, that is, calcium channel blockers and 
phenothiazine’s. Chemomodulators belong to two categories, those that are transport substrates 
themselves and thereby compete for efflux and those that exert their effects by binding to and 
blocking drug efflux without themselves being transported out of the cell (Bebawy and Chetty, 
2008). 
In general, P-gp can be inhibited via (i) blocking the drug binding site 
competitively/noncompetitively/allosterically, (ii) by interfering with ATP hydrolysis, and (iii) by 
altering the integrity of the cell membrane lipids (Varma et al., 2003) Based on their specificity and 
affinity, P-gp inhibitors are categorized into three generations: First generation inhibitors are 
pharmacological actives, which are in clinical use for other indications but have been shown to 
inhibit P-gp. Second and third generation inhibitors specifically modulate P-gp, with the second 
generation inhibitors lacking the pharmacological activity of its first generation counterparts and 
with a higher affinity for P-gp. The third generation inhibitors have a 10-fold higher affinity and 
potency to inhibit P-gp (Bebawy and Chetty, 2008). 
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2.7. Novel Drug Delivery Systems and Pharmaceutical Excipients Capable of CNS and 
Intestinal Delivery via P-gp Bypass or Inhibition with a Potential Applicability in 
Schizophrenia Therapy 
2.7.1. Formulation excipients utilized as P-gp inhibitors. 
Approaches to bypass the P-gp efflux pump may be to combine the target drug with either another 
P-gp pump substrate or an inhibitor; on the other hand there is the novel approach of combining 
the active drug molecule with a lipid or polymer excipient which is capable of P-gp inhibition. The 
initial approach is effective in its inhibitory potential; however it involves the use of a second 
pharmaceutically active agent that increases the risk of drug-drug interactions; thus in retrospect 
the use of inhibitory excipients has nonspecific pharmacological action and therefore the possibility 
of systemic effects and drug interactions is eliminated (Constantinides and Wasan, 2007). 
2.7.2. Chemosensitizers  
Chemosensitizers, also termed reversal agents, are one such approach; they inhibit the efflux 
pump and increase the absorption of drugs intracellularly; and thus the co-administration with 
clinically relevant compounds has become a common practice (Gohel et al., 2011). 
Chemosensitizers function by acting as competition at the P-gp substrate binding site or by 
blockade of ATP hydrolysis; drugs such as verapamil, cyclosporine A, and antisteroidal agents 
such as tamoxifen are classified as 1st generation P-gp modulators. However high concentrations 
of these agents are required for this purpose and thus lead to pronounced side effects; thus the 
development of 2nd generation chemosensitizers was prompted. This nevertheless proved to 
exhibit the same limitations. 
To circumvent limitations observed with the 1st and 2nd generation P-gp chemosensitizers, 3rd 
generation chemosensitizers have been developed utilizing the supremacy of combinational 
chemistry and Structure Activity Relationships (SARs). These agents are non-competitive 
inhibitors that result in alterations in protein conformation, thus modulating P-gp substrates; they 
include elacridar and tariquidar amongst others (Montesinos et al., 2012). Further research 
conducted depicted evidence that drug delivery systems in combination with P-gp modulators 
could considerably enhance pharmacokinetics of the P-gp modulator and in addition reduce the 
pharmacokinetic interactions with P-gp substrates. Cremophor EL was one of the excipients 
employed in the above mentioned study which showed promising activity as a P-gp modulator 
(Montesinos et al., 2012). Furthermore, in an experimental study conducted by Choo and co-
workers tariquidar, a P-gp modulator in combination with propylene glycol, 5% dextrose, and 
ethanol, was able to inhibit P-gp function at the BBB in high doses (Choo et al., 2006), thus 
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displaying a possible application in improving CNS permeability of drugs employed in 
neurodegenerative diseases. In another research study it has been shown that GF120918 
(elacridar) a known 3rd generation P-gp modulator is capable of increasing the brain uptake of 
paclitaxel (P-gp substrate) 5- fold (Kaur et al., 2009). 
2.7.3. Natural polymers  
The natural gums are classified as polysaccharides that consist of multiple sugar groups that 
bonded together to create much larger molecules; they offer the advantages of being sustainable, 
biodegradable, and biologically safe; these natural gums are known to form gels that depict a high 
degree of network formation. Gums are capable of undergoing grafting and crosslinking reactions 
and through such reactions they may form hydrogels, xerogels, and nanoparticles which have a 
very important function in the inhibition of the P-gp efflux transporter (Choo et al., 2006). Chitosan, 
a cationic polysaccharide in combination with nucleotides to form nanosystems, may enhance the 
permeability of drug molecules into the CNS via opening of tight junctions, and the formulation of 
nanosystems incorporating chitosan and nucleotides will enable this purpose (Werle and Bernkop-
Schnürch, 2008). Natural polymers such anionic gums, for example, xanthan and gellan gum, as 
well as alginates, have been shown to inhibit the action of the P-gp efflux pump at concentrations 
of 0.05% and 0.5mg/mL, respectively (Hunter et al., 1994). In the presence of xanthan gum studies 
have shown increased concentration of P-gp substrates such as vinblastine and doxorubicin. 
Alginate flavicam demonstrated an increase in the intracellular concentration of doxorubicin in 
everted gut sac cells (Werle, 2008). 
2.7.4. Synthetic polymers 
Synthetic polymers are synthesized via polymerization reactions and the modification of natural 
polymers or via the complexation of natural polymers with naturally occurring agents such as fatty 
acids (Werle, 2008). Synthetic polymers such as PEG 400, at concentrations between 1 and 20%, 
increased accumulation of digoxin due to the inhibition of the P-gp drug efflux pump (Shen et al., 
2006; Hugger et al., 2002). Similar studies conducted employing Pluronic P85 and Vitamin E D-
𝛼-Tocopheryl polyethylene glycol 1000 succinate on the digoxin uptake in rats have further proven 
that pluronic blocked copolymers are capable of inhibiting the P-gp efflux pump and enhancing 
substrate uptake (Johnson et al., 2002). Furthermore, studies have shown that pluronic P85 has 
an inhibitory action on the ATPase enzyme that is involved in the functioning of the P-gp efflux 
pump proteins, thus resulting in inhibitory reactions between these proteins and the P-gp 
substrates (Batrakova et al., 2001). In a study conducted by Batrakova and co-workers who have 
shown the increased brain concentration of digoxin in mdr1 knockout mice and wild type mice 
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treated with Pluronic P85, it was clearly demonstrated that Pluronic P85 delayed the residence 
time and concentration of digoxin in the brain (Batrakova et al., 2001). Commonly occurring 
polymers that act as P-gp inhibitors are listed in Table 2.3. 
Table 2.3: Summarized list of polymer & surfactant P-gp inhibitors and their mechanism of action. 
Polymer and Surfactant based 
P-gp efflux Inhibitors 
Applications References   
Natural Polymers:    
Xanthan Gum  
Gellan Gum 
Alginates 
Inhibition of the P-gp 
efflux transporter by the 
presence of 
polysaccharide d-
mannose monomers, 
increasing 
concentration of 
substrates e.g. 
vinblastin and 
doxorubicin. 
(Hunter et al., 
1994) 
 
Synthetic Polymers:     
PEG 400 
PEG-PEI 
PEG 300 
Changes the 
microenvironment of 
Caco-2 cell 
membranes, leading to 
modifications in 
membrane fluidity. 
(Hunter et al., 
1994; Werle, 
2008) 
 
Pluronic®  P85 Results in ATPase 
inhibition and ATPase 
reduction. As well as 
membrane fluidization. 
(Werle, 2008; 
Hugger et al., 
2002; Johnson et 
al., 2002) 
 
Thiomers Thiol groups interact 
with cysteine in the P-gp 
transmembrane 
channel, forming 
disulfide bonds. Thus 
the allosteric change 
blocks efflux.  
(Batrakove et al., 
2001) 
 
 
Research studies have been conducted to evaluate the inhibitory properties of PEG on the P-gp 
efflux pump. The study involved the grafting PEG to polyethyleneimine (PEI) and then undergoing 
a thiolation reaction employing 𝛾- thiobutyrolatone to formulate a novel grafted thiomer. The 
grafted PEG was then evaluated based on its effect on the transport of Rhodamine–123, a well-
known P-gp substrate. Results depicted that the cellular uptake of Rhodamine-123 was improved 
with the grafted-thiolated PEG as compared to free drug solutions. 
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Oral administration of many drug substances is limited due to the poor bioavailability and systemic 
uptake which is directly linked to the presence and action of the P-gp efflux pump. In an attempt 
to overcome this limitation there has been the development of P-gp pump inhibitors; however due 
to the abovementioned set back of requiring high doses, none of them have been approved for 
oral administration due to the risk of systemic side effects. Thus polymeric Pgp inhibitor 
incorporation into drug delivery systems as excipients provides a valuable approach; they show a 
high inhibitory potential and due to their great molecular weights they are not absorbed from the 
gastrointestinal system and thus eliminate any possible systemic effects. Previous studies 
determined the inhibition of P-gp by PEG’s by their effect on the elevated permeability of substrate 
drug molecules such as taxol and doxorubicin within caco-2 monolayers (Iqbal et al., 2010). 
PEGylated sorbitans that are esterified with fatty acids are commonly known as polysorbates. The 
most extensively studied group of the Polysorbates is polyoxyethylene sorbitans monolaurates, 
known by the trade name Tween; these agents have been found to enhance the accumulation of 
daunorubicin within tumor cells (Werle, 2008). 
Poloxamers also fall within the category of synthetic polymers and are also known as Pluronics. 
Specifically, Pluronic P85 has been studied for its inhibitory effect on the function of the P-gp efflux 
pump. Two main areas that P85 is used for its inhibitory properties are in the BBB and cancer 
chemotherapy (Werle, 2008). The mechanism of inhibition has been dedicated to a reduction in 
ATP and inhibition of ATPase enzymes as well as lipid membrane fluidization (Batrakova et al., 
2001; Batrakova et al., 2001(2). Pluronic brings about a reduction in ATP levels within bovine 
endothelial cells; the ATP depletion was reasoned to be as the result of the inhibition of cellular 
metabolism (Batrakova et al., 2004). 
Additionally, mixed micelles synthesized from a combination of poloxamer 407 and D-𝛼-
Tocopheryl polyethylene glycol 1000 succinate (TPGS 1000) have the potential of elevating the 
clinical efficiency of drugs by increasing the amount of drug in the interior of the cell by inhibiting 
P-gp efflux transporters (Saxena and Hussain, 2012). TPGS 1000 is classified as a water soluble 
vitamin that consists of a lipophilic head and hydrophilic PEG tail. The mechanism by which TPGS 
1000 inhibits the P-gp pump has been proposed as a combination of membrane fluidization, ATP 
depletion, and prevention of substrate binding. Research on the effect of pluronic block polymers 
on the accumulation of digoxin has proven the hypothesized inhibition of Pgp efflux transporters 
by Pluronic polymers. The treatment of various substrates with Pluronic polymers displayed an 
increase in apical to basolateral transport, thus displaying Pgp inhibition (Werle, 2008; Batrakova 
et al., 2001; Batrakova et al., 2001(2).   
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Thiomers, yet another group of synthetic polymers, are characterized as polymers containing a 
thiol moiety within their chemical structure; the presence of the thiol moiety allows for the formation 
of disulfide bonds between the cysteine groups, of the P-gp pump, for example, 𝛼 
chitosanthiobutylamidine (Werle and Hoffer, 2006). The mechanism of thiomer mediated inhibition 
of the P-gp efflux pump is depicted in Figure 2.6. Improved transmucosal transport of Rhodamine-
123 a P-gp substrate in the company of thiolated chitosan, produced by linking of amino groups 
of chitosan and thiol groups (Bernkop-Schnurch et al., 2003), was displayed by Bernkop-Schnurch 
et al. due to P-gp transporter inhibition. Thiomers are not absorbed from the GIT due to their high 
molecular weight; therefore systemic side effects are eliminated and their use as pharmaceutical 
excipients for their P-gp inhibitory properties is greatly beneficial (Iqbal et al., 2010). As described 
above the P-gp efflux pump is made up of 12 transmembrane units; these units in turn form 
channels through which P-gp substrates pass through to exit the cell; two of the 12 units display 
cysteine subunits. Thiomers are theorized to enter the channels of the P-gp pump and thereafter 
form disulfide bonds with the cysteine subunits; in this manner the transport of drug molecules out 
of the cell is hindered and thus there is an inhibition of P-gp efflux pump action (Werle and 
Bernkop-Schnurch, 2008). Thiolated chitosan is a directly compressible excipient which may 
therefore be formulated into matrix tablets (Bernkop-Schnurch et al., 2003). 
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Figure 2.6: Mechanism of inhibition of the P-gp efflux pump (Kumar and Sinha, 2013)  
 
2.7.5. Solvents and surfactants  
Both surfactants and solvents act by interaction with the polar heads of the lipid bilayers thereby 
adjusting hydrogen bonding and ionic forces and have the potential to insert themselves between 
the nonpolar tails of the lipid bilayer. These interactions cause the fluidization of the lipid 
membrane and thus P-gp inhibition. Non-ionic surfactants such as Tween and Span possess Pgp 
transporter inhibitory potential; these agents are also hydrophobic and thus rendered less toxic 
(Bansal et al., 2009). Surfactants are furthermore important in the formulation process of 
nanoparticles. Various research outputs have shown that the efficiency of surfactants as P-gp 
inhibitors is based on their respective chemical structures. Surfactants such as Solutol HS15, 
Tween 80, and Cremophor EL contain Polyethylene glycol on the hydrophilic portions of their 
structures, which have displayed the ability to increase intracellular concentrations of epirubicin in 
human colorectal carcinoma cells, thereby confirming that surfactants act as P-gp modulators 
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(Montesinos et al., 2012). In a study conducted by Rege and co-workers (Rege et al., 2002) the 
effect of Tween 80, Cremophor EL, and vitamin E TPGS on the P-gp efflux transporter in caco-2 
cell monolayers was investigated. Results showed that all three surfactants inhibited P-gp and 
Tween 80 and Cremophor EL increased the apical to basolateral permeability of Rhodamine 123 
(P-gp substrate) within a concentration range of 0-1mM. Whereas vitamin E TPGS contributed an 
inhibitory effect at a concentration of 0.025mM (Rege et al., 2002). 
2.8. Drug Delivery Systems with P-gp Modulatory and Enhanced Intestinal Absorption 
Applications 
The following section will focus on the strategic design of drug of delivery systems studied for their 
aptitude to enhance bioactive delivery through the intestinal epithelia by P-gp modulation and/or 
inhibition with a future applicability in schizophrenia therapy. 
2.8.1. Bestatin-improved intestinal absorption by co-administration of a P-gp inhibitor.  
A study by Huo and co-workers (Huo et al., 2013) has shown the enhancement effect of P-gp 
inhibitors on the intestinal absorption of bestatin. The study showed that when bestatin and 
cyclosporine A were co-administered orally, the resultant plasma concentration of bestatin was 
considerably increased. Cyclosporine A and Verapamil, commonly utilized P-gp inhibitors, can 
eliminate the efflux pump mediated by P-gp, resulting in improved intestinal absorption of the co-
administered P-gp substrate. The study by Huo and co-workers (Huo et al., 2013) displayed a 
90% increase in bestatin intestinal absorption seen in the Cmax and AUC with the addition of 
cyclosporine A (Huo et al., 2013). 
2.8.2. Enhanced intestinal absorption of ganciclovir by P-gp inhibition using 
pharmaceutical excipients 
Several studies have shown that P-gp inhibitors such as verapamil and cyclosporine A are capable 
of enhancing the bioavailability of a variety of drugs. However, such inhibitors are 
pharmacologically active agents and thus may cause toxic effects. In addition, these agents are 
absorbed into the bloodstream and can interact with P-gp in other organs that it is expressed in. 
On the other hand, pharmaceutical excipients, which are utilized as inert excipients in drug delivery 
formulations, are being investigated as superior class of P-gp inhibitors. Several studies have 
shown that these excipients can greatly improve the intestinal absorption of a wide range of drugs 
by P-gp inhibition.  
These excipients are non-absorbable; thus there will be no unnecessary P-gp inhibition in other 
organs. A study conducted by Li and co-workers (Li et al., 2011) studied the effects of common 
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excipients on the intestinal absorption of ganciclovir, a substrate of P-gp in rats. The in vitro 
transferal from mucosa to serosa as well as the in situ transepithelial permeation was evaluated. 
Selected excipients within a concentration range of 0.1–1% w/v were shown to increase the 
concentration of ganciclovir transported in an everted gut sac model. Results depicted a significant 
increase in permeability of ganciclovir by all excipients employed in the study. The effects of EL-
35 and F-68 were dose-dependent but that of PEG 400 and Tween 80 were not. The results 
observed confirm that the improvement of intestinal absorption of ganciclovir via the use of 
excipients is due to inhibition of P-gp inhibition mediated drug efflux. The mechanism of F-68 
inhibition of P-gp is due to its blocking effect on the binding site of the Pgp efflux transporter, 
whereas PEG 400, tween-80, and EL-35 are due to alteration in the membrane fluidity of P-gp (Li 
et al., 2011). 
2.8.3. Self-emulsifying drug delivery systems 
This is another drug delivery approach that may prove useful in bypassing the P-gp pump due 
mainly to the presence of surfactants such as Tween 80 that have been identified as P-gp 
inhibitors (Rege et al., 2002). SMEDD’s consisting of vitamin E (oil phase) and surfactants have 
been shown to enhance the solubility and bioavailability of paclitaxel (a P-gp substrate) owing to 
their P-gp inhibitors activity. An advantage of using SMEDD’s is their capability to incorporate and 
solubilize high concentrations of P-gp inhibitors. Many studies have been conducted to improve 
the oral bioavailability of this chemotherapeutic agent so as to increase clinical outcomes; it has 
been proven that P-gp plays a vital role in the bioavailability of paclitaxel; the study conducted by 
Woo and co-workers shows that the use of KR-30031 a verapamil analogue with P-gp inhibitory 
effects in combination with paclitaxel improved the bioavailability of the later (Woo et al., 2003). 
Nanocapsules have been used as a drug delivery system to improve the oral bioavailability of the 
P-gp substrate Tacrolimus, which was incorporated into nanocapsules with the use of 
polymethacrylate polymers. Results depicted that the bioavailability was between a ranges of 
2.45- and 4.9-fold compared to the commercially available formulation (Nassar et al., 2009). 
8.2.4. Double coated nanocapsules for enhanced intestinal absorption and bioavailability 
of a P-gp substrate 
An experimental study performed by Nassar and co-workers (Nassar et al., 2009) proposes the 
use of double coated nanocapsules to improve the bioavailability of a P-gp substrate, Tacrolimus. 
Using caco- 2 cells and intestinal rat segment the effect of encapsulation of Tacrolimus on P-gp 
was evaluated. The double coated nanocapsules prevented its molecular recognition by the Pgp 
efflux transporter in caco-2 cells. The conclusive results show that the nanocapsule delivery 
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system is a great platform for intestinal absorption of lipophilic drugs which are P-gp substrates. 
The oral bioavailability of Tacrolimus was 4.9- and 2.45-fold greater when compared to a marketed 
product (Nassar et al., 2009). 
2.8.5. Novel polymeric P-gp inhibitor for enhanced intestinal drug delivery 
Many drugs are unable to be administered via the oral route owing to poor absorption into the 
systemic circulation due to intestinal P-gp efflux pumps. In order to circumvent this obstacle many 
types of efflux pump inhibitors have been developed. Yet, many of these inhibitors have not been 
approved for oral use due to their systemic side effects. A noteworthy alternative would be 
polymeric based efflux pump inhibitors, displaying greatly efficient inhibitory action and no 
systemic side effects because it is unabsorbed into the intestine due to its high molecular mass. 
In a study conducted by Iqbal and co-workers (Iqbal et al., 2010) a novel thiolated copolymer, 
thiolated PEG-g-PEI copolymer, was synthesized. The novel thiolated copolymer showed a 
significantly greater effect on the intestinal absorption of Rho- 123, a P-gp substrate as compared 
to other P-gp inhibitors. In addition, the thiolated copolymer was able to increase the intestinal 
uptake of Rho-123 up to 3.26-fold in comparison to a system lacking a P-gp inhibitor. In addition 
to enhancing the absorption of Rho-123 the novel thiomer was also capable of decreasing the 
basolateral to apical transport across the rat intestinal mucosa segment. The study has thus 
provided evidence that the novel thiomer has a great applicability in improving bioavailability of P-
gp substrate drugs (Iqbal et al., 2010). 
2.8.6. Influence of intestinal P-gp on absorption of furosemide a P-gp substrate  
Furosemide is a loop diuretic employed in the clinical treatment of congestive heart failure and 
hypertension. Pharmacokinetics of furosemide show that it has incomplete absorption from the 
gastrointestinal tract after oral dosing. P-gp efflux pumps have been implicated as the possible 
cause for reduced absorption; however no complete evidence exists. The intestinal absorption of 
furosemide was evaluated in the presence and absence of verapamil utilizing the rat intestinal sac 
model in an experimental study conducted by Al-Mohizea (Al-Mohizea, 2010). 
Results obtained from the study depict low drug permeability in the non-everted rat intestinal sac. 
This replicates the drug transference from the mucosal to serosal region which imitates the in vivo 
environment. In contrast, when observed in the everted rat intestinal sac, drug displayed a 
noticeably greater transport as compared to transport across the non-everted intestinal sac. These 
results clearly indicate the involvement of the P-gp pump and because the defined function of the 
P-gp efflux transporter is to pump drug back into the intestine subsequent to absorption, the 
observed outcomes indicate a greater transintestinal permeation from the serosal to mucosal 
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region. The ratio of serosal to mucosal and mucosal to serosal permeability was discovered to be 
5.6 and this was advocated for the possible role of P-gp efflux transporter in the intestinal uptake 
of furosemide. The effect of verapamil hydrochloride, a P-gp efflux pump inhibitor, on furosemide 
absorption was employed to confirm the results obtained from the intestinal sac model experiment. 
It was shown that the presence of verapamil increased the mucosal to serosal transport of 
furosemide noticeably compared to the control lacking verapamil. This observation is due to the 
inhibitory effect of verapamil on the P-gp efflux pump, which prevents transport of drug back into 
the mucosal region. The ratio of serosal to mucosal and mucosal to serosal permeability was 
reduced from 5.6 in the absence of verapamil to 1.28 in its presence. These results confirm the 
mechanistic effect of the P-gp efflux pump on intestinal absorption. Furthermore, the current study 
evaluated the effect of Tween 80 and HP𝛽CD, two commonly employed pharmaceutical 
excipients, on the intestinal uptake of furosemide. The results displayed a permeation 
improvement effect for Tween 80 but not for HP𝛽CD. This in turn inferred a substantial increase 
in the mucosal to serosal permeability of furosemide. Tween 80 was shown to decrease the ratio 
of serosal: mucosal to mucosal: serosal permeability (5.6 to 1.08). This provides evidence that 
Tween 80 is a noteworthy P-gp efflux pump inhibitor (Al-Mohizea, 2010). 
2.9. Drug Delivery Systems with P-gp Modulation and Enhanced BBB Absorption 
The following section will focus on drug delivery systems that have been studied for their unique 
ability to enhance BBB permeability of drug agents via P-gp inhibition and/or bypass with a 
prospective application in schizophrenia therapy. The effective non-invasive treatment of 
neurological diseases is frequently restricted by poor access of bioactives into the central nervous 
system (CNS). Many therapeutic agents do not freely permeate into brain tissue due to the 
presence of the BBB and its associated P-gp efflux pump transporter. Recent advances in drug 
delivery technology have provided promising solutions to overcome these challenges. 
The use of drug delivery systems with the ability to bypass or inhibit the P-gp efflux transporter 
has shown a great improvement in CNS bioavailability and hence enhanced therapeutic 
outcomes. Furthermore, nanocarriers ranging from polymeric nanoparticles, solid lipid 
nanoparticles, liposomes, dendrimers, and micelles have been studied for their ability to deliver 
CNS therapeutics and have displayed success in the treatment of CNS diseases such as brain 
tumors and alzheimer’s (Wong et al., 2012) Hence, we propose the use of these delivery systems 
in the treatment of schizophrenia so as to bypass the BBB and its efflux transporters. 
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2.9.1. Nanocarriers 
Nanoparticles can gain access to the brain via numerous mechanisms. These mechanisms acting 
either alone or in combination can explain the transport of therapeutically bioactive agents across 
the BBB: (i) adsorption and pooling of nanoparticles in the capillaries of the brain, followed by 
adsorption to the capillary wall, which provides a concentration gradient across the blood 
capillaries located in the brain cells; therefore this may enhance the transport of bioactives across 
the endothelial cell monolayer and thus increase the uptake of the bioactive into the brain, (ii) 
receptor-mediated endocytosis of nanoparticles across the BBB, followed by internalization of the 
complex and release of the bioactives within brain cells, (iii) transcytosis, nanoparticles with bound 
bioactives, which can undergo transcytosis through the endothelial cell monolayer and gain 
access to the brain capillaries, (iv) inhibition of the P-gp efflux transporter and coating 
nanoparticles with specific Pgp inhibitory substances, such as polysorbate 80 that may possibly 
inhibit the P-gp, (v) membrane permeabilization effect that involves solubilization of the endothelial 
cell lipids via the use of surfactants, which leads to membrane fluidization and enhanced 
permeability of the BBB, and (vi) disruption of the BBB, thus opening tight junctions located 
between endothelial cells of the BBB; nanoparticles may assist in permeation of bioactives through 
tight junctions (Agarwal et al., 2009). 
Nanocarriers are colloidal systems that include polymeric micelles, nanoparticles, lipid 
nanocapsules, and liposomes among others. Many of these systems have been designed and 
developed for indications in various CNS disorders to enhance brain uptake of the CNS targeted 
bioactives via Pgp transporter activity modulation. 
2.9.2. Surfactant-polymer nanoparticles overcome P-gp-mediated drug efflux 
Nanoparticles improve the therapeutic efficacy of an encapsulated drug by increasing and 
prolonging the delivery of the drug within the cell. Aerosol OT-alginate nanoparticles were 
employed in evaluating their delivery capabilities in brain tumor cells overexpressing P-gp. 
Rhodamine 123 and doxorubicin were employed as model P-gp substrates. Uptake studies using 
Rhodamine loaded nanoparticles showed a substantial increase in drug accumulation in resistant 
cells. The energy-dependent nanoparticle accumulation within cells proposes the contribution 
endocytosis in nanoparticle uptake. Nanoparticle doses of greater than 200 𝜇g/mL were shown to 
be the minimum concentration to improve drug accumulation (Chavanpatil et al., 2007; Fortuna et 
al., 2011).  
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2.9.3. Lipid-based nanoparticles  
Paclitaxel loaded lipid nanoparticles (Figure 2.7) utilizing Brij 78 displayed IC50 values 9-fold 
greater than when formulated with taxol. The study established that lipid nanoparticles were able 
to inhibit the synthesis of the microemulsion precursor. Temporary and reversible reductions in 
ATP were observed with blank nanoparticles and free Brig 78.Therefore, the greater degree of P-
gp substrate accumulation was elucidated by a synergistic combination of nanoparticle with Brig 
78, where nanoparticles improve the brain uptake of the bioactive by partially bypassing the P-gp 
transporter and drug efflux is restricted via the release of Brig 78 from the nanoparticles 
(Constantinides and Wasan, 2007; Montesinos et al., 2012; Mandal et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: TEM images of lipid based nanoparticles; arrows show the lipid bilayer thickness 
(Mandal et al., 2013).  
 
In other studies, lipid nanocapsules loaded etoposide were synthesized due to their hypothesized 
reversal of multidrug resistance by the use of P-gp inhibitory surfactants during formulation.  
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P-gp inhibitory activity of the etoposide loaded lipid nanocapsules was independent of size. The 
proposed mechanism was cell uptake followed by intracellular P-gp inhibition thus allowing for a 
higher intracellular drug concentration (Lamprecht and Benoit, 2006). In a further research study 
the formulation of lipid nanocapsules was achieved by the use of tricaprylic acid, polyethylene 
glycol 660, and soybean lecithin, for the delivery of the therapeutic agent, paclitaxel, to caco- 2 
cells; results showed that the oral bioavailability of paclitaxel was greatly improved possibly due 
to the ability of lipid nanocapsules to inhibit the P-gp efflux activity; this mechanism is primarily 
due to the fact that the surface layer of nanocapsules being phospholipids thus resulting in P-gp 
inhibition via P-gp substrate site competition (Roger et al., 2010). 
2.9.4. Transferrin-conjugated nanoparticles for delivery across the BBB. 
 Transferrin-conjugated nanoparticles of poly (lactide) - D-𝛼-Tocopheryl polyethylene glycol 
succinate diblock copolymer were formulated via the nano precipitation method with encapsulated 
docotaxel. Results from the study showed via IC50 data that transferrin-conjugated nanoparticles 
were 23.4–229% more efficient than the control, PLGA nanoparticles. Thus based on results 
obtained transferrin conjugated nanoparticles showed to be effective in delivery of drugs across 
the BBB (Gan and Feng, 2010). 
2.9.5. Paclitaxel-polymer micelles to overcome multidrug drug resistance (MDR). 
Micelles form from the spontaneous association of amphiphilic copolymers in aqueous phase and 
are characterized by a diameter no greater than 100 nm (Figure 2.8). The attractive force that 
leads to micellization is based on the interaction between the electrostatically neutral and 
hydrophobic portions of the copolymer. Self-assembly of the micelle only begins when the 
copolymer concentration reaches a threshold value generally referred to as the critical micelle 
concentration (CMC) (Wang et al., 2011). 
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Figure 2.8: TEM micrographs showing the surface morphology of drug loaded micelles (Wang et 
al., 2011)  
 
Verapamil is a known P-gp inhibitor as well a reversal agent used in reversal of resistance 
associated with P-gp. Within the context of this study, paclitaxel, a P-gp substrate, in combination 
with verapamil, was encapsulated into micelles utilizing DOMC-FA (deoxycholic acid methylated 
chitosan-Folic acid). Resulting data showed that the conjugation of folate on to micelles displayed 
a higher brain tumor cell uptake of the loaded micelles, possibly via folate receptor-mediated 
endocytosis. Micelles consisting of the combination of verapamil and paclitaxel showed a higher 
cellular accumulation of paclitaxel as compared to micelles lacking verapamil (Danson et al., 
2004). 
In another study, mixed micelles of hydrophobic and hydrophilic pluronic L61 and F127 with 
encapsulated doxorubicin were formulated. Results observed depicted elevated cellular 
concentrations of drug to P-gp inhibition displayed via modification of intracellular drug transport 
(Fortuna et al., 2011). 
2.9.6. Polyethylene glycol-660 hydroxystearate nanocapsules 
Nanocapsules encapsulated with etoposide (substrate) in combination with P-gp inhibiting 
surfactants, namely, PEGHS (polyethylene glycol-660 hydroxystearate), were formulated with 
results depicting an increased bioavailability of etoposide (Roger et al., 2010; B’eduneau et al., 
2006). Further studies showed that lipid nanocapsules of paclitaxel formulated by triglycerides of 
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capric and caprylic acids increased the uptake of drug molecules by MDR1 cells; the half-life of 
paclitaxel was also prolonged from 21 minutes initially to 5 hours (Wong et al., 2012). 
2.9.7. Immunoliposomes in bypassing P-gp  
The overexpression of P-gp has been associated with the development of multidrug resistance in 
cancer cells. Methods employed in overcoming the multidrug resistance frequently involve the co-
administration of inhibitors of the P-gp transporter (Figure 2.9(a). Within the context of this study, 
the hypothesis that immunoliposome-based drug delivery systems may be employed as 
alternatives to overcome multidrug resistance has been explored. Since immunoliposomes 
penetrate target cells via receptor-mediated endocytosis, which in turn allows for the bypass of 
membrane related P-gp transporters, targeting of immunoliposomes was accomplished by via the 
use of an antitransferrin receptor monoclonal antibody (OX26 
MAb).The incorporation of radiolabelled digoxin andOX26- immunoliposomes improved the 
cellular uptake of digoxin by a factor of 25 in immortalized rat brain endothelial cells. The cellular 
uptake as well as intracellular accumulation of the digoxin loaded liposomes was determined by 
acid washing of the cells and further confirmed via confocal microscopy studies. This in vitro study 
proposes that immunoliposome based drug delivery systems can be utilized to bypass P-gp and 
therefore deliver bioactives to the cytosol of target cells (Huwyler et al., 2002). Furthermore there 
is the novel approach of combining substrates and P-gp inhibitors within liposomal delivery 
systems; clinical trials were performed via the formulation of liposomes encapsulating PSC 8339, 
a recognized P-gp efflux inhibitor in combination with the drug molecule, doxorubicin; results 
observed depicted an increase in drug delivery potential with no alteration to the pharmacokinetic 
or pharmacodynamic character of the drug molecule (Krishna et al., 1999; Lee et al., 1992). 
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Figure 2.9: (a) (A) P-gp interacts with substrates in the plasma membrane and digoxin (substrate) 
is effluxed from the lipid bi-layer. (B) Cellular uptake of digoxin facilitated by Immunoliposomes-
targeted to transferrin receptor and taken up via receptor-mediated endocytosis (Huwyler et al., 
2002) (b) (A) 2D Schematic representation of a dendrimer. (B) 3D representation of a dendrimer 
(Svenson, 2009).  
 
2.9.8. PAMAM-drug complex for delivery across the BBB 
Dendrimers are defined as synthetic macromolecules that have a well-defined structural 
configuration. It is made up of a centrally located core and branched units that stem from the core 
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(Figure 2.9 (b) (Werle, 2008; Gillies and Fr’echet, 2005).The mechanism by which dendrimers 
inhibit P-gp is via endocytosis; the dendrimer passes into the cell interior; this inhibition process 
could be due to cell membrane alterations and ATPase inhibition; research has shown that P-gp 
substrates that are encapsulated within dendrimers show an increased intracellular concentration 
(Gohel et al., 2011). Polyamidoamine (PAMAM) dendrimers belong to a new avenue of P-gp 
inhibition research; these dendrimers are known to improve the solubility of low solubility drugs. 
In the current study doxorubicin was chosen as the bioactive agent. Polyamidoamine (PAMAM) 
dendrimers were exploited as an effective carrier of doxorubicin. Data obtained from the 
fluorescence intensity assay and fluorescent microscopy displayed that cellular uptake of the 
PAMAM-doxorubicin complex was 6-fold greater than that of free doxorubicin. These results 
provide evidence that the novel PAMAM-bioactive complex is a simple yet highly efficacious 
system, with a great capability to cross the BBB and thus delivery CNS targeted drug successfully 
(Cui et al., 2009). 
Propanolol, a P-gp substrate, was encapsulated within PAMAM dendrimers, due to its poor 
solubility. Conjugation of propanolol with PAMAM dendrimers was found to allow for bypass of the 
P-gp efflux pump and therefore enhance the drug concentration within target cells (D’Emanuele 
et al., 2004; Svenson, 2009). 
2.9.9. Poly (D, L-lactide) nanosuspensions of risperidone.  
Nanosuspensions are dispersed systems comprising fine particles of drug molecules in the form 
of crystals. Nanosuspensions are known commonly to incorporate highly lipophilic compounds; 
these therapeutic agents are stabilized in solution via the use of surfactants. The large surface 
area afforded by the fine particles assists in enhancing bioavailability to the brain tissue, 
atovaquone coated by polysorbates in the form of a nanosuspension increased activity in mice 
presenting with encephalitis (Wong et al., 2012). Employing Pluronic F-68 (P-gp inhibitor) 
nanosuspensions were formulated containing risperidone and poly-lactide; they have been found 
to display better clinical outcomes in psychotic disorders via P-gp inhibition (Muthu and Singh, 
2009). 
2.9.10. Natural Vesicular Exosomes as Drug Delivery Systems to Possibly Bypass P-gp 
Efflux.  
Extracellular vesicles are defined as cell derived membrane vesicles with a characteristic 
(phospho) lipid bilayer that allows for cell to cell communication. Microvesicles are sized between 
50 and 2000 nm, whereas exosomes are between 40 and 150 nm. Exosomes are produced by 
the formation of intraluminal vesicles in multivesicular bodies. Fusion of multivesicular bodies with 
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the plasma membrane results in secretion of intraluminal vesicles which are in turn referred to as 
exosomes once released into the extracellular space. Due to their respective sizes and natural 
functionality, microvesicles and exosomes seem to be model candidates for drug delivery (van der 
Meel et al., 2014). A study conducted by van Dommelen and co-workers provided the initial 
evidence of biotechnological modification of vesicular exosomes; immature dendritic cells was 
derived from mouse bone marrow as a source of exosomes. These were then loaded with 
exogenous siRNA for delivery. The BBB was chosen as the target site due to it being a vital 
obstacle to the delivery of drugs to the CNS. The study displayed specified delivery of siRNA to 
neurons in the brain with no corresponding toxicity. In another study performed, exosomes were 
used to deliver anti-inflammatory drugs to the brain via the intranasal route. It was proven that 
exosomes administered in this manner are potential delivery vehicles for small molecules, by 
enhancing biological stability and passage across the BBB; these systems may be extended to 
include a wider range of therapeutic agents (Dommelen et al., 2012). Findings from research 
studies conducted thus far indicate that a vesicular exosomal-based formulation could be a 
valuable implement in future for the treatment of neurodegenerative disorders (Haney et al., 2015). 
A comprehensive summary of the various drug delivery systems, polymers, and drugs employed 
in their formulation process and their respective applications is provided in Table 2.4. 
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Table 2.4: Summary of reviewed systems. 
 
DRUG DELIVERY SYSTEM POLYMER DRUG APPLICATION References  
Nanocarrier (Nanospheres)  Polyethylene glycol  
Polybutylcyanoarylate, Alginate, 
Polyethylene glycol, poly lactic –co- 
glycolic acid, poly lactic acid. 
Doxorubicin, Clozapine, Methotrexate, 
Saquinavir, zidovudine 
Drug molecule is delivered to the cell 
nucleus and thus avoids recognition by 
the BBB and intestinal p-gp efflux 
pump.  
(Wong et al., 2012; Wong et al., 2006; Kuo and Chen, 
2006).  
Liposomes  Phospholipids and Cholesterol Epirubicin, Cisplatin, Methotrexate, 
Doxorubicin 
Inhibits p-gp efflux transporter by 
interaction with phospholipids, the 
system may also incorporate p-gp 
inhibitors. 
(Krishna et al., 1999; Lee et al., 1992).  
Polymer Nanoparticles Acrylic polymers such as poly-butyl-
cyanoacrylate( PBCA)  
Loperamide and Doxorubicin Bypasses the p-gp due it its nanosize.  (Wong et al., 2006) 
Dendrimers  Mannosylated poly(propyl eneimine), 
Polyethylene glycol-poly (amidoamine) 
Vinblastine, Doxorubicin and 
Propranolol (intestinal) 
Inhibits p-gp efflux by bypassing the 
pump  
(Gillies and Fr’echet, 2005; Cui et al., 2009; 
D’Emanuele et al., 2004). 
Nanogels  Cationic and non- ionic polymers , 
NVP/NIPAM 
Anti-sense phosphorothioate 
oligonucleotides (SODN), 5-
Fluorouracil 
Allows for the incorporation of p-gp 
inhibitors.  
Polysorbate coating of nanogel 
increases brain accumulation from 
0.18 to 0.52%.  
(Wong et al 2012; Yallapu et al., 2011).  
Micelles Pluronics® L61 and F127, P85 Doxorubicin, Digoxin, Paclitaxel, 
Ritonavir, Vinblastine 
1. Inhibits p-gp efflux and also involves 
intracellular drug transport modification 
thereby avoiding the p-gp efflux pump. 
2. Drug permeability in monolayered 
BBB model by P-gp substrates 
increased from 1.6 to 29 fold. No 
change in digoxin concentration in 
mdr1 knockout mice.  
  
(Wong et al., 2012; Nasongkla et al., 2006; Mo et al., 
2011).  
   
Hydrogels  (hydroxypropyl) methacrylamide Cyclosporine A and Doxorubicin Inhibits the p-gp efflux transporter by 
incorporation of drugs such as 
cyclosporine A that are p-gp inhibitors.  
(Kim and Chu, 2000).  
Lipid Nanocapsule PEG- HS (poly ethylene glycol- 660 
hydroxy Stearate), poly-methacrylate 
polymers and HPMC  
Triglycerides of capric and caprylic 
acids, Solutol 
Etoposide and Tacrolimus 
 
 
 
Paclitaxel 
1. Inhibits p-gp efflux by incorporation 
of surfactant based p-gp inhibitors.  
2. Paclitaxel uptake increased in 
MDR1 expressing cells, the half-life in 
brain prolonged from 21min to ˃ 5h.  
(Wong et al., 2012; Roger et al., 2010) 
 
Self- emulsifying drug delivery systems  Poly-methacrylate polymers  
 
Medium chain triglyceride, PEG 400, 
Polysorbate 80, Cremophor EL 
 
 
 
 
 
Capmul MCM-C8, CremophorEL and 
Pluronic L-121 
Paclitaxel and Tacrolimus 
 
Penfluridol (Schizophrenia therapeutic 
agent)  
 
 
 
 
 
 
Irinotecan 
Inhibits p-gp efflux by incorporation of 
surfactant based p-gp inhibitors e.g. 
Tween  
 
Enhances solubilization of drug and 
thus effective brain concentrations.  
 
 
Increased oral bioavailability by P-gp 
modulation  
(Zhuang et al., 2011; Negi et al., 2013) 
 
Nano suspension  Pluronic® F68 Resperidone  p-gp efflux inhibition by employing 
polymers that inhibit the p-gp 
transporter, such as Pluronic® 
(Muthu and Singh, 2009).  
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2.10. Concluding Remarks 
Central nervous system (CNS) disorders such as schizophrenia are becoming increasingly 
prevalent, with limitations in social and physical functionality of patients being reduced. Treatment 
outcomes associated with schizophrenia therapy are reduced due to pharmacoresistance, which 
leads to a reduction in patient compliance. The P-glycoprotein (P-gp) efflux transporter located 
within the blood-brain barrier restricts the uptake of drugs and other molecules within the CNS; 
furthermore it has been implicated in the occurrence of pharmacoresistant schizophrenia. 
Therefore, research studies conducted in regards to the role of the P-gp transporter in CNS drug 
delivery prove to be a noteworthy avenue so as to improve schizophrenia treatment outcomes. 
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CHAPTER THREE 
PRELIMINARY FORMULATION AND CHARACTERIZATION OF THE 
EPICHLOROHYDRIN-CROSSLINKED semi- INTERPENETRATING POLYMER 
NETWORK XEROGEL MATRIX 
 
3.1. Introduction  
Drug release from a suitable dosage form at predetermined times and rates, presents as a primary 
challenge for pharmaceutical scientists. Despite significant progress being made in the field of 
controlled drug release, numerous objectives still remain to be investigated for treating chronic 
clinical pathologies. Among the variety of natural and synthetic polymers that may be employed 
in formulations aimed to optimize drug release rates, polysaccharides are of particular interest. 
This is due to the fact that polysaccharides are abundant and have a great diversity of composition 
and characteristic properties that allow for tailored modifications. Furthermore, hydrogels 
composed of crosslinked polysaccharides have been commonly researched and evaluated for 
their use in novel controlled drug release dosage forms (Coviello et al., 2007). In addition, modified 
hydrogels, such as xerogels, which is broadly defined as an open network formed by the removal 
of all solvents and swelling agents from a gel, resulting in a porous structure (Rey-Raap et al., 
2015) which may be exploited in the controlled and site-specific delivery of drugs.  
Over the last decade, carbohydrate and biodegradable polymers have been expansively 
employed in the development of controlled release formulations for drugs with short plasma half-
life. Among the array of polymers utilized, hydrophilic biopolymers are the most appropriate for 
oral applications in regard to their merits in contrast with synthetic polymers. The significance of 
biocompatible and biodegradable polymers is constantly increasing within the pharmaceutical 
industry due to their ability to form crosslinked 3-dimensional network gels. Systems derived from 
such reactions have been given a great amount of attention as a potential strategy to deliver drug 
molecules in a controlled release manner (Banerjee et al., 2010). In this respect Interpenetrating 
Polymer Networks (IPNs) and semi-Interpenetrating Polymer Networks (s-IPNs) have arose as 
novel and innovative biomaterials for drug delivery (Liu and Park, 2009).These network systems 
display physio-chemical properties that may be significantly different from those of the 
macromolecular constituents. Polymer network properties can be modified and tailored by the type 
of polymer and its respective concentration, by the crosslinking method employed as well as the 
preparation procedure utilized (Matricardi et al., 2013). 
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IPNs are defined as combinations of two or more polymer networks synthesized in juxtaposition 
(Sperling et al., 1994). The IUPAC definition for an IPN is “A polymer comprising two or more 
networks which are at least partially interlaced on a molecular scale but not covalently bonded to 
each other and cannot be separated unless chemical bonds are broken. A mixture of two or more 
preformed polymer networks is not an IPN” the last statement of this definition focuses on the 
point that the difference between an IPN and a blend. The polymer entanglement of crosslinked 
polymer in an IPN results in miscibility as compared to the incompatible polymer blends (Matricardi 
et al., 2013). Types of IPNs are outlined in Figure 3.1.  
Semi-IPNs differ from IPNs in the sense that they comprise of one linear polymer entrapped within 
the network of another polymer. The IUPAC definition for an s-IPN is “A polymer comprising one 
or more linear or branched polymer(s) characterized by the penetration on a molecular scale of at 
least one of the networks by at least some of the linear or branched macromolecules” s-IPNs are 
distinguished from IPNs due to the fact that its constituent linear or branched polymers can be 
separated from the constituent polymer network without breaking chemical bonds (Chikh et al., 
2011).  
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Table 3.1: Summary of the common advantages and features of IPNs (Banerjee et al., 2010).  
Advantages of IPNs Characteristic Features of IPNs 
1) When an IPN gel is synthesized from two 
polymers at a specified temperature, the 
physical phase separation amid the individual 
polymers would be virtually improbable due to 
the zero-viscosity of the gel.  
 
1) Undergoes swelling in solvents without 
dissolving.  
 
2) IPN formulations are good candidates in 
taking advantage of synergistic 
characteristics from individual polymers 
involved in its formulation process.  
 
2) Systems formed from IPNs benefit from the 
properties that are representative of each 
polymer employed.  
 
3) IPNs have been shown to improve the 
phase stability of the resultant biomaterial.  
 
3) Polymer comprising two or more polymer 
networks which are partially interpenetrating 
on a molecular level but are not necessarily 
covalently bonded to each other and may or 
may not be separated unless chemical bonds 
are broken depending on the type of IPN 
formed.  
 
4) IPNs enhance the mechanical properties of 
the resultant system.  
 
4) IPNs have been indicated in the design and 
development of controlled release drug 
delivery systems.  
 
5) Any present thermodynamic incompatibility 
may be overcome via interlocking of network 
segments, which is produced by mixing. 
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Figure 3.1: Types of IPNs (Chikh et al., 2011; Banerjee et al., 2010).   
Interpenetrating 
Polymer Network 
(IPN) 
Chemical Bonding  
Covalent 
Non- Covalent  
s-IPN: comprises of two individual 
polymer systems that are 
crosslinked to form a single polymer 
network.  
s-IPN: is one in which only 
one of the polymers are 
crosslinked. 
Full IPN:  two individual 
polymers are 
independently 
crosslinked.  
Arrangement Pattern 
 Novel IPN: two polymer 
networks which are partially 
interlaced on a molecular level 
but not covalently bonded, and 
cannot be separated without 
breaking chemical bonds.  
 Sequential IPN: second polymeric 
network component is polymerized upon 
complete polymerization of the first 
polymeric network component.  
 s- IPN: one polymer 
component is crosslinked, 
leaving the other in a 
linear form.  
 Simultaneous IPN: both polymeric 
components’ interior networks are 
polymerized concurrently.  
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IPN based drug delivery systems are specifically designed to deliver drugs at a predetermined 
rate with minimal fluctuations for a desired duration.  
-Tablets 
IPNs formulated as oral dosage forms such as tablets has displayed great potential for controlled 
drug release. IPNs prepared from chitosan and Carbopol polymer complexes may be used as a 
sustained release matrix tablet. The solid structure of the IPN based tablets has shown great in 
vivo drug release potential via blending of hydrophilic polymer complexes with a hydrophobic 
polymer (Ghada and Mina, 2008). 
-Sheets/Films 
Polymeric sheets or films are commonly prepared via solvent casting methods. Their applications 
vary from transdermal to buccal drug delivery. A polymeric biomaterial comprising an 
interpenetrating network of a polyol (allyl carbonate) and an epoxy resin prepared via polymerizing 
the poly (allyl carbonate) by radical initiation and partially polymerizing an epoxy resin forming 
solution via acid catalysis has been applied as a wound dressing (Banerjee et al., 2010).  
-Sponges 
IPN based sponges have the ability to easily absorb large amounts of tissue exudates, allow for 
smooth adherence to a wet wound site, while keeping the wound site dry and providing protection 
against physical harm and secondary bacterial infection. IPN sponges have been employed 
successfully in the treatment of severe burns as well as a dressing for a wide array of other wound 
types (Kim et al., 2007). 
-Hydrogel 
Hydrogels are commonly used as drug carriers due to the ease of manufacturing and 
administration. The advantage of hydrogels for their clinical applications is their ability to produce 
a large surface area. The combination of natural and synthetic polymers provides mechanical 
stability and biological acceptance, in addition, acquiring synergistic characteristics of both 
polymers (Suri and Christine, 2009). 
3.1.1. Preliminary formulation design 
The rational identification of a candidate system for further optimization was the elemental focus 
of the current chapter. The subsequent experimental studies were conducted to provide a logical 
comparison of the effect of crosslinking on the chemical structure of the formulated xerogel, 
textural analysis of the xerogel matrix, surface morphological analysis to determine the resultant 
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surface structure, and dissolution studies of the various preliminary formulations developed; in 
addition, to determine their respective potential in designing a targeted sustained release drug 
delivery system.  
Preliminary formulation studies involved, evaluating the selected polymers for their chemical 
structure, morphological surface structure, tensile strength and dissolution characteristics. Further 
modifications and inclusion of excipients was then undertaken to develop a candidate system. The 
identification of variables with upper and lower limits was paramount for further optimization of the 
s-IPN xerogel component of the ODLS.   
3.2. Materials and Methods 
3.2.1. Materials 
Biocompatible and biodegradable polymers investigated included poly (ethyleneoxide) (PEO) 
(Polyox™, WSR303) and Gellan gum (GG) (Gelzan™CM) obtained from Sigma Aldrich (Pty) Ltd. 
(St Louis, MO, USA). Sulpiride employed as the model drug and epichlorohydrin (EPI) 99% used 
as a crosslinking agent were purchased from Sigma Aldrich (Pty) Ltd. (St Louis, MO, USA). 
Lecithin sourced from Merck (Pty) Ltd. (Modderfontein, South Africa) was used as a formulation 
excipient to enhance bioavailability. Carboxymethylcellulose sodium (CMC) and magnesium 
stearate utilized within the tablet forming process were purchased from Sigma Aldrich (Steinham, 
Germany). All other reagents employed were of analytical grade and used without further 
purification. De-ionized water was obtained from a Milli-Q water purification system (Milli-Q, 
Millipore, Billerica, MA, USA).Phosphate buffered saline (PBS) was prepared using sodium 
hydroxide (NaOH, Mw=40.00g/mol) and sodium chloride (NaCl, Mw=58.44g/mol) obtained from 
Saarchem (Wadeville, Gauteng, South Africa), hydrochloric acid (HCl, 32%w/v) purchased from 
Rochelle Chemicals (Johannesburg, South Africa) and potassium dihydrogen phosphate 
(KH2PO4, Mw=136.09g/mol) obtained from Riedel-de Haen (Sigma-Aldrich Laborchemikalein 
GmbH, Germany) in double-deionized water (Milli-Q System, Millipore, Bedford MA, USA). 
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3.2.2. Polymer blending and crosslinking  
Polymeric solutions of poly (ethyleneoxide) (Polyox®), 1-2.5 %w/v and gellan gum 0.5-1%w/v were 
prepared using deionized water (Rowe et al., 2006). The Polyox® and Gellan gum solutions were 
combined in 1:4 ratios and allowed to stir on a magnetic stirrer for 30 minutes until homogenous. 
Thereafter 5M NaOH (1.2mL) was added to the gel and stirred till homogenous, after which 
epichlorohydrin (EPI) (0.4-0.8 %v/v), a crosslinking agent, was added drop wise to the blend using 
a syringe. Formulation compositions are listed in Table 3.1. The solution was then allowed to stir 
for a further 3 hours. Lecithin, the selected formulation excipient was prepared by dissolving 
lyophilized soybean lecithin in deionized water. The desired quantity of the lecithin solution (1%v/v) 
was added to the crosslinked s-IPN xerogel while undergoing continuous stirring (da Fonseca et 
al., 2008).  
Table 3.2: Compositions of pilot study formulations. 
 
PRELIMANRY FORMULATION COMPOSITIONS 
PF 1: 1%w/v GG, 2%w/v PEO, 0.4%v/v EPI 
PF 2: 1% w/v GG, 2.5% w/v PEO, 0.8% v/v EPI 
PF 3: 0.5% w/v GG, 2% w/v PEO, 0.4% v/v EPI 
PF 4: 0.5% w/v GG, 2.5% w/v PEO, 0.8% v/v EPI 
PF 5: 1% w/v GG, 1% w/v PEO, 0.8% v/v EPI 
PF 6: 1% w/v GG, 1% w/v PEO, 0.4% v/v EPI 
 
3.2.3. Fabrication of xerogel polymer matrix system 
The homogenous s-IPN xerogel was then allowed to stir at a high speed on a magnetic stirrer, to 
allow for the crosslinked s-IPN xerogel to sufficiently blend with the lecithin. After which it was 
removed and precipitated in a small volume of acetone for approximately 10 minutes. The 
precipitated xerogel was then placed on a glass petri dish and dried in laboratory fumehood at 
room temperature overnight. The dried xerogel was then crushed into a powder using a mortar 
and pestle. The xerogel powder was then mixed with surfactant (1.5mg magnesium stearate), 
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which allows for the stabilization of the polymer particles (Bassett and Hamilec, 2009), 
carboxymethylcellulose sodium a tablet filler, and sulpiride the model drug to form the porous 
xerogel-polymer drug loaded matrix. The porous xerogel matrix system was then compressed into 
an oral dosage form (tablet) using a Carver Tablet Compressor (model 3851-0), the tablets were 
0.9×0.9cm in size. 
3.2.4. Determining the upper and lower limit variables of the formulation required for input 
into the Central Composite Design 
Following the identification of the most appropriate polymer combination to be utilized in the 
fabrication of the s-IPN xerogel matrix drug delivery system, upper and lower limits of the 
formulation variables were determined for input into a Central Composite Factorial Design. 
Determination of the variables involved combining the polymers in various ratios with 
corresponding variances in crosslinker concentration followed by tablet compression as detailed 
in Chapter 3, Section 3.2.1 and 3.2.2., and thereafter assessing whether the formulations satisfied 
the following criteria:  
- Demonstrated physical properties that could withstand and undergo tableting. 
- Demonstrated good physiomechanical characteristics appropriate for oral dosing.  
- Displayed morphological structure conducive to sustained drug delivery. 
- Polymers were successfully crosslinked to form the s-IPN xerogel. 
- Controlled drug release over the desired period of time (24 hours).  
3.2.5. Validation and determination of chemical transitions upon crosslinking  
The FTIR spectra of PEO, GG and the crosslinked s-IPN xerogel were recorded using an FTIR 
Spectrophotometer (Perkin Elmer Spectrum 100, FT-IR Spectrometer) fitted with a universal ATR 
Polarization Accessory (Perkin Elmer Ltd., Beconfield UK). Wavelengths were recorded between 
4000 and 650cm-1 and FTIR spectrums of absorbance and % transmittance against distance was 
obtained. 
3.2.6. Identification of optimization variables for degree of swelling and erosion 
Evaluation of the degree of swelling and erosion of the s-IPN xerogel was conducted. Respective 
pre-formulation samples were weighed and placed in 250mL beakers containing 200mL 
potassium phosphate buffer (pH 6.8; 37˚C) and allowed to swell over a 24 hour period. At 
predetermined time intervals tablets were removed from the buffer and weighed after removing 
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surface water with absorbent tissue paper on a calibrated electronic scale. The mean % swelling 
and erosion were calculated.  
3.2.7. Surface morphological analysis 
SEM was employed in determining the surface morphology of crude PEO and GG, as well as 
evidence of the synthesis of an s- IPN xerogel within the crosslinked formulations with the aid of 
the generated microscopic images. It further assisted in identifying the differences in physical 
morphology and characteristics of the crude polymers as compared to the crosslinked xerogel.  
Dried xerogel samples before tableting and native polymers were placed on steel studs and 
sputter coated with carbon and gold palladium shadowing using the Phenom™ G2 Pro SEM (FEI 
Company, and Hillsboro, Oregon, USA) by employing various magnifications. 
3.2.8. Determination of the physiomechanical properties of the s-IPN xerogel matrix system 
via textural analysis 
The Brinell hardness test was employed to determine the strength of tablets where a load of 5kg 
was applied to the surface of the tablets via a steel indenter of 3.175mm in diameter. Thus the 
diameters of the resultant indentation on the surface of the tablets were measured and the Brinells 
Hardness Number (BHN) was calculated using the following equation:  
 
𝐵𝑟𝑖𝑛𝑒𝑙𝑙 𝐻𝑎𝑟𝑑𝑛𝑒𝑠𝑠 𝑁𝑢𝑚𝑏𝑒𝑟 = 2𝐹/(𝜋𝐷(𝐷 − (𝐷2 − 𝑑2) 
 Equation 3.1 
Where, F=load on the indenting tool (force generated in kg), D=diameter of the spherical probe 
indenter (3.175mm), and d=diameter at the rim of the impression made (depth 0.5mm) (Choonara 
et al., 2006). 
By plotting a force vs. time graph resilience was calculated when a strain of 10% is applied with 
the use of the following equation:  
𝑅𝑒𝑠𝑖𝑙𝑖𝑒𝑛𝑐𝑒 = (
𝐴𝑟𝑒𝑎 2: 3
𝐴𝑟𝑒𝑎 1: 2
) × 100 
Equation 3.2 
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3.2.9. Construction of calibration curve for the determination of sulpiride release from the 
s-IPN xerogel matrix 
Employing Ultraviolet (UV) spectroscopy and a sequence of known concentrations (0.2-1mg/mL) 
of sulpiride in Phosphate Buffered Saline (PBS) (pH 6.8; 37˚C), a calibration curve was 
constructed. The linear curve was plotted with use of the detected absorbance of sulpiride as the 
dependent variable and the concentration of sulpiride as the independent variable. A statistical 
illustration of the degree at which the function relates the set of values (R2 value) was calculated 
for the curve.  
3.2.10. Identification of optimization variables via in vitro drug release studies 
Dissolution studies were carried out utilizing a USP type II apparatus (Caleva, model 7ST) at 
50rpm and 37˚C in 900mL of potassium phosphate buffer (pH 6.8) with the addition of a stainless 
steel mesh ring, which fits under the paddle into the lower part of the standard dissolution vessel. 
5mL of dissolution medium  was withdrawn manually at predetermined time intervals during the 
24 hour study and replaced with an equal volume of fresh dissolution medium to ensure sink 
conditions were maintained. The samples were then analyzed for drug release via ultraviolet 
spectrometry (WinAspect Spectro-analytical software, Analytik Jena AG), at a wavelength of 
291nm employing a calibration curve obtained for the drug (Strübing et al., 2008).  
3.3. Results and Discussion  
3.3.1. Analysis of chemical transitions upon crosslinking 
Pilot Fourier Transform Infrared Spectroscopy (FTIR) studies were conducted to determine the 
success of crosslinking poly (ethyleneoxide) (PEO) with gellan gum (GG), a novel concept. Thus 
a preliminary experiment was conducted by formulating a 1% PEO solution and a 1% GG solution, 
these were then combined and crosslinked using epichlorohydrin as described in Chapter 3, 
Section 3.2.2.  FTIR is defined as being the absorption of electromagnetic radiation through a 
sample and the vibrations observed due to specific chemical bonds present. As new bonds are 
formed there is the appearance of new bands or shifts in bands that suggest chemical bonds are 
being formed or broken. FTIR is useful in that it can provide information about the chemical 
bonding and change in chemical nature of a formulation due to crosslinking reactions. 
Based on visual observation it can be seen that the system is stable and homogenous allowing 
for a well-structured gel system. FTIR has shown that GG and PEO have similar bands; however 
gellan lacks the aromatic C-H bond which is still present in the crosslinked gel, the shift in bands 
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of saturation also shows that bonds have been broken and new bonds created between GG and 
PEO.  
FTIR was then conducted on both crude polymer solutions and on the crosslinked formulation to 
determine the success of the crosslinking procedure. The FT-IR spectra depicted in Figure 3.2d 
of PEO displayed functional groups present, such as that of O-H functional groups characteristic 
of alcohols in a range of 3200-3600cm-1, and C≡C stretching depicted at wavenumber range of 
2100- 2260cm-1. A broad band at 2850-2960cm-1 relating to C-H stretching in alkane groups is 
observed as a characteristic functional group of GG, seen in Figure 3.2a, in addition, all preliminary 
formulations display this band (Coates, 2000). 
Results in Figure 3.2 below depicted that there were shifts in the peaks relating to double C꞊C 
bonds (alkenes) at 1640- 1680cm-1 and the addition of an aromatic ring corresponding to C-H 
group at 675- 870 cm-1 (aromatic ring/ alkenes 675-1000cm-1), thus the shifts in peaks and the 
additional aromatic structure prove that crosslinking was successful and the PEO and GG did form 
new bonds.  
The introduction of amine groups was found in formulations that consisted of a higher percentage 
crosslinker, at a wavelength of 3360.17cm-1 (Coates, 2000). Preliminary formulations also showed 
C=C stretch at a wavelength of 1500cm-1 (Coates, 2000), which corresponds to a conjugational 
asymmetrical stretch, occurring when the ratio of polymers is 1:2 and crosslinker is at an 
intermediate density. 
The results that were received has shown that the crosslinking process has been successful with 
the appearance of new bonds that were clearly depicted by the bands displayed in FTIR, this 
provides a novel approach and will allow for the enhanced bioavailability of sulpiride by combining 
the effects of polymers. 
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Figure 3.2: FTIR spectra of a) gellan gum, b) PF 5, c) PF 1 and d) PEO. 
 
3.3.2. Pre-formulation evaluation of the swelling and erosion characteristics of the s-IPN 
xerogel 
The mean percentage swelling and erosion of the preliminary s-IPN xerogel samples were 
investigated by observing the variation in sample weight over a predetermined time interval; Figure 
3.3 shows the mean percentage swelling and erosion respectively. All formulations displayed 
appreciable swelling and erosion, it was noted that preliminary formulations with increased 
polymer concentrations had a corresponding rise in swelling and erosion. On the other hand, a 
lower concentration of crosslinking agent led to an increase in percentage swelling. It has been 
indicated that swelling is controlled by the rate of hydration when in contact with aqueous medium. 
Therefore, the degree of swelling and erosion affect drug release kinetics, due to drug release 
being delayed with an increase in swelling of the delivery system (Sriamornsak et al., 2007).  
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Figure 3.3: Illustration of the % swelling and erosion for all preliminary formulations.  
 
3.3.3. Assessment of surface morphological characteristics 
The surface morphology of PEO, GG, and preliminary formulations are shown with the use of 
scanning electron microscopy (SEM) imagery in Figure 3.4. The SEM micrograph of pure PEO 
(Figure 3.4a) shows distinct tightly clumped polymer particles with an uneven surface structure 
and absence of pores, conversely SEM images of GG (Figure 3.4b) indicate clear polymer 
“ribbons” with smooth surfaces apart from the occasional occurrence of slight ridges. 
Comparatively, SEM micrographs of preliminary crosslinked s-IPN xerogel formulations (Figure 
3.4c/d) display a definite modification in surface structure. They exhibit a vastly porous surface 
morphology, which proves the crosslinking reaction to be effective and the subsequent formation 
of an s-IPN xerogel. s-IPN crosslinking of the respective polymer in effect forms the porous 
structure, in addition to this the drying procedure allows for the fabrication of the xerogel aspect 
which also involves the formation of air filled pores. The overall porosity of the resultant s-IPN 
xerogel formulations permits sustained release of bioactive from within the pores of the polymer 
network.  
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Figure 3.4: SEM micrographs of a) PEO, b) GG, c) PF 5 and d) PF 1. 
 
3.3.4. Evaluation of textural analysis studies  
Textural analysis data graphs were utilized to evaluate the physiomechanical characteristics of 
the preliminary crosslinked s-IPN xerogel matrix tablets when a uniaxial force of compression is 
applied. From the graphs of force vs. distance obtained it was observed that the resultant curves 
displayed sharp peaks which indicate that the s-IPN xerogel matrix offers a greater degree of 
resistance to the force applied.  
The mechanical strength of the s-IPN xerogel matrix was further illustrated via assessment of the 
brinells hardness number as seen in Figure 3.5. It was observed that the brinells hardness number 
is proportional to the density of crosslinking and polymer ratios, thus the strength of the matrix 
was increased with a corresponding increase in crosslinker concentration and a higher overall 
polymer concentration.  
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Figure 3.5: Graphical illustration of Brinell hardness numbers and respective standard deviations 
for preliminary formulations.  
 
Furthermore, the physiomechanical properties of the preliminary formulations were evaluated with 
the use of the percentage resilience derived from the force vs. time textural analysis graphs as 
shown in Figure 3.6. Percentage resilience is yet another parameter employed to determine the 
mechanical strength of polymer systems, it has been indicated that the percentage resilience of 
the s-IPN xerogel matrix is directly proportional to the polymer concentration ratio and the degree 
of crosslinking. It can thus be seen that preliminary formulations with a greater polymer ratio and 
crosslinking density displayed a corresponding increase in matrix resilience; this may be 
accredited to the greater network formation, leading to a highly structured interpenetrating polymer 
system. Therefore, in conclusion all preliminary formulations displayed satisfactory 
physiomechanical strength; however those with higher polymer and crosslinker concentrations 
were marginally enhanced.  
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Figure 3.6: Percentage resilience and respective standard deviations of the respective pilot study 
formulations.  
 
3.3.5. Construction of a calibration curve for the ultraviolet spectrophotometric 
determination of sulpiride  
Utilizing UV spectroscopy, it was established that sulpiride exhibits a maximum wavelength at λ300, 
consistent with published literature on the absorption peak of sulpiride being at 300nm (Parikh et 
al., 2010; Phapale et al., 2010). Using a series of known concentrations (0.2-1mg/mL) of sulpiride 
in PBS, a calibration curve at λ300was conducted (Figure 3.7). The linear curve was plotted with 
the observed absorbance of sulpiride as the dependent variable and the concentration of sulpiride 
as the independent variable (Figure 3.7). The obtained R2 value of the calibration curve was 0.99 
(Figure 3.7), indicating a perfect correlation.  
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Figure 3.7: Calibration curve of sulpiride in PBS at λ300.  
 
3.3.6. Assessment of in vitro drug release  
So as to determine the release of drug from the crosslinked s-IPN xerogel matrix, dissolution 
studies were conducted in simulated intestinal conditions as described in Chapter 3, Section 
3.2.10. The fractional release vs. time graphs for the preliminary s-IPN xerogel matrix formulations 
are shown in Figure 3.8.  
y= 1.599x+0.000238 
R2= 0.99 
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Figure 3.8: Fractional release profiles of preliminary formulations. 
 
From the drug release profiles it can be seen that all preliminary formulations provided sustained 
drug release over the predetermined 24 hour test duration, it can clearly be seen that variations 
on polymer ratios and crosslinker density have an effect on the resultant drug release profiles. In 
particular, PF 6 displays an initial lag phase which may be attributed to the possible free 
uncrosslinked polymer chains, which swell extensively and uncontrollably leading to a delay in 
drug release as drug becomes entrapped within the matrix due to a thick outer gel layer. All 
remaining formulations display slight variances in drug release pattern; however they all perform 
effectively in prolonging drug release over the desired period due to their porous structure, 
allowing for entrapment of drug within these polymer network pores and thus controlling drug 
release.  
3.3.7. Determining the upper and lower limits of the formulation variables required for input 
into the Central Composite Design 
Subsequent to identification of the polymer combinations for the s-IPN xerogel matrix, the upper 
and lower limit variables of the formulations was determined. The resultant variables are illustrated 
in Table 3.2. The limits were determined via ensuring that the formulated tablets met the criteria 
identified in Chapter 3, Section 3.2.4.  
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Table 3.3: The identified variables and their corresponding upper and lower limits for input into 
the Central Composite Design.  
Polymer  Lower Limit (%w/v) Upper Limit (%w/v) 
GG 0.5% - Anything <0.5% did not 
form a sufficiently viscous gel 
and thus could not be used in 
the formation of a xerogel.  
1% - Formulations comprised 
of ˃1% formed viscous 
solutions that resulted in a 
solid mass.  
PEO 1% - solutions of <1% were 
viscous but not of an 
appropriate consistency to be 
crosslinked to form a xerogel 
and could not be precipitated.  
2.5% - Formulations 
containing ˃ 2.5% was difficult 
to dissolve and resulted in 
solutions that presented with 
hydrated clumps and were too 
sticky to work with.  
               Crosslinker 
EPI 0.4% - crosslinking with  
< 0.4% was not successful.  
When precipitated, PEO 
would dissolve out of xerogel 
into acetone.  
0.8% - formulations 
comprising ˃0.8% formed 
highly brittle xerogels that did 
not withstand the tableting 
process.  
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3.4. Concluding Remarks 
Preliminary studies led to the rational identification of the formulation variables that were most 
appropriate for the development and further optimization of the s-IPN xerogel matrix component 
of the ODLS. Due to their ability to control drug release and novelty in regard to the crosslinking 
reaction, GG and PEO were chosen as the crude polymers to undergo crosslinking for the 
formation an s-IPN xerogel.  
An essential outcome of this chapter was to ensure that the fabricated s-IPN xerogel was 
successfully crosslinked by the use of epichlorohydrin, that controlled drug release was achieved 
in a sustained manner, and that good mechanical properties were provided for oral administration. 
This chapter functioned to identify the candidate formulation range which resulted in the 
identification of 3 variables, with their corresponding upper and lower limits, for input into a Central 
Composite Design. The Central Composite Design, which is detailed in Chapter 4, was conducted 
with the purpose of further optimization of the s-IPN xerogel matrix component of the ODLS.  
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CHAPTER 4 
FABRICATION AND STATISTICAL OPTIMIZATION OF THE NOVEL 
EPICHLOROHYDRIN-CROSSLINKED semi-INTERPENETRATING GG-PEO 
XEROGEL NETWORK MATRIX TABLET 
 
4.1. Introduction  
Formulation optimization based on statistical approaches, utilizing a systematic Design of 
Experiments (DoE), is broadly practiced to enhance the outcomes of formulation design in the 
development of Drug Delivery Systems, due to it being an effective and cost efficient tool that is 
able to afford the most optimal formulation in response to the most desired formulation 
characteristics (Singh et al., 2004; Singh et al., 2005). So as to ensure the efficacious 
implementation of an experimental design, the experimental objectives and the parameters to be 
investigated need to be clearly defined. By means of preliminary studies, detailed in Chapter 3, a 
prototype formulation led to the identification of independent variables (i.e. polymer and crosslinker 
concentration) which influenced the measured responses (i.e. drug release, mean % swelling and 
mean % erosion).  
To achieve the desired characteristics and advantages of a Drug Delivery System, it is necessary 
to determine whether factors involved in the formulation process will impact characteristics of the 
resulting formulation. In the course of the preliminary studies, one or more procedural formulation 
process variables or factors were intentionally varied to determine the effect the variance may 
have on the measured responses (Singh et al., 2004; Singh et al., 2005). Outcomes indicated that 
varying the components, specifically, the polymer and crosslinker concentration of the system 
resulted in alterations that would influence drug release properties of the system. However, 
employing this methodology in formulation design is a costly and time-consuming process and 
obtaining an optimized formulation is not a certainty.  In order to overcome this limitation of 
formulation design, the use of a statistically sound experimental Central Composite Design may 
be employed; which is an optimization strategy that exploits lesser experimental runs, has a 
reduced level of time–consumption and produces an accurate optimized formulation via 
systematic and methodical approach.  
The Response Surface Methodology (RSM) was elected in implementation of the design strategy 
as factors affecting formulation characteristics were identified in Chapter 3, thereby facilitating the 
optimization procedure. The ultimate objective of utilizing the RSM was to enable the identification 
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of the most appropriate combination of formulation components that would accomplish an optimal 
formulation for the s-IPN xerogel matrix component of the ODLS.  
RSM is frequently used in Central Composite Designs to aid researchers in the identification of 
optimal framework of experimental factors which provide the maximum or minimum value of the 
measured response. Fundamentally RSM is an assemblage of both mathematical and statistical 
strategies for empirical prototype assembly grounded on literal experiments or experimental 
derived observations (He et al., 2005; Raissi and Farsani, 2009).  
Based on the preliminary results obtained from Chapter 3, the formulation component (input 
variables) that influenced the drug release characteristics, degree of crosslinking, and 
physiomechanical properties of the formulation (measured responses) were identified in 
conjunction with their upper and lower limits. Factors with their corresponding factor levels were 
selected for the s-IPN xerogel matrix component of the ODLS so that a mathematical model was 
generated. Polymers, crosslinking agent, and the model drug employed in the system design are 
outlined below:  
Gellan gum (GG), a natural polysaccharide with low toxicity, was employed as one of the polymer 
components of the crosslinked s-IPN xerogel matrix. It is a high molecular weight hydrophilic 
anionic deacetylated polysaccharide which is produced by the fermentation of Shingomonas 
Elodea; the organism is aerobic, gram negative, and non-pathogenic. Its chemical structure 
consists of four linked monosaccharides, one molecule of rhamnose, one molecule of glucuronic 
acid, and two glucose molecules (Singh et al., 2011). GG functions as a gelling agent in many 
foods and pharmaceutical products. The hydrophilic nature of GG has been exploited in the 
present study to ensure sustained drug release via means of water penetration, dissolution, 
polymer swelling and erosion. Hydrophilic polymers have been extensively employed in controlled 
drug delivery (Du¨rig and Fassihi, 2002). The concentration range selected for optimization of the 
s-IPN xerogel component of the ODLS was based on preliminary studies detailed in Chapter 3 
and was determined to be 0.5-1g.  
Poly (ethyleneoxide) (PEO), a non-ionic water soluble polymer, was employed as the other 
polymer components of the crosslinked s-IPN xerogel matrix. Research has shown it is capable 
of retarding the release of drugs and thus its use in controlled release formulations is widespread. 
The mechanism of drug release from poly (ethyleneoxide) based delivery systems are centered 
on swelling and erosion of the polymer. The chemical structure consists of an epoxide ring, two 
corners of the molecule have –CH2- links, with the third corner having oxygen. These poly 
(ethyleneoxide) water soluble polymers may be crosslinked to form gels with great water retention 
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properties. Poly (ethyleneoxide) is non- toxic and biodegradable and thus well suited for use within 
the pharmaceutical scope of drug delivery systems (Cappello et al., 2006). Its use in controlling 
drug delivery has been exploited in the present study to ensure sustained release of the selected 
bioactive over a 24 hour period.  
Epichlorohydrin (EPI), an epoxide agent, was used as a crosslinking agent for the formation of an 
s-IPN between GG and PEO. It is colorless sweet chloroform smelling liquid at room temperature. 
It is used in the production of many synthetic materials as well as in the crosslinking of starch and 
in the production of pharmaceutical products (National Toxicology Program, 2011; Kittipongpatana 
and Kittipongpatana, 2013). 
Sulpiride (5- (aminosulfonyl)-N- f1-ethyl-2-pyrrolidinylgmethyl-2-methoxybenzamide) is a known 
selective dopamine D2 antagonist, with both antipsychotic and antidepressant action, it displays 
poor aqueous solubility (Chiba et al., 2011; Sigma Aldrich, MDS (±) Sulpiride, Germany).   
4.2. Materials and Methods  
4.2.1. Materials 
Gellan gum (GG) (Gelzan™CM), poly(ethyleneoxide) (PEO)  (Polyox™, WSR303), (±) sulpiride, 
epichlorohydrin (EPI) 99%, carboxymethylcellulose sodium (CMC) and magnesium stearate were 
purchased from Sigma Aldrich (Steinham, Germany), while acetone (Analytical grade) and sodium 
hydroxide (assay min. 97%) were purchased from Merck (Darmstadt, Germany). All other 
reagents employed were of analytical grade and used without further purification. 
4.2.2. Construction of a Randomized Central Composite Design for the optimization of the 
s-IPN xerogel matrix component of the ODLS 
A model independent approach (Minitab® V15, Minitab Inc. PA, USA) was employed for 
optimization of the s-IPN xerogel. The input factors or independent variables were the 
concentration of GG: PEO and concentration of the crosslinking agent EPI. These were studied 
at three levels each, and the DoE generated 15 experimental runs (formulations). Statistical 
optimization was employed to ascertain the ideal combination of polymers and crosslinker required 
to achieve the desired drug release profile, swelling, erosion and matrix resilience efficacies. Table 
4.1 summarizes the derived factor combinations of the 15 experimental runs studied and their 
conversion of the coded levels to the experimental units utilized during the study. The coded 
variables chosen for the statistical design were; total Mean Dissolution Time (MDT), mean % 
swelling and mean % erosion. Whereas, parameters for the design were set as the concentrations 
of PEO %w/v, epichlorohydrin (mL), GG (g).  
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Table 4.1: Box-Behnken design template for the statistically derived 15 s-IPN xerogel formulations 
and their respective chemical compositions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.3. Synthesis of crosslinked s-IPN xerogel 
s-IPN xerogels were synthesized in accordance with the Box-Behnken statistical experimental 
design shown in Table 4.1. Polymeric solutions of PEO of varying concentrations in distilled water 
were prepared ranging from 1-2.5%w/v; once a homogenous solution was achieved, GG ranging 
between 0.5-1g was added to the above mentioned solutions and allowed to further homogenize 
and form a viscous polymer blend.  
F# 
PEO 
Concentration  
(%w/v) 
GG (g) 
EPI-
Crosslinker 
Volume 
(mL) 
 
F1 
 
2.5 
 
1 
 
0.6 
F2 2.5 0.75 0.8 
F3 1.75 0.75 0.6 
F4 1.75 0.75 0.6 
F5 1 0.75 0.8 
F6 1 1 0.6 
F7 1.75 1 0.4 
F8 1 0.5 0.6 
F9 1.75 1 0.8 
F10 1.75 0.5 0.8 
F11 1 0.75 0.4 
F12 1.75 0.75 0.6 
F13 2.5 0.5 0.6 
F14 1.75 0.5 0.4 
F15 
 
2.5 
 
0.75 
 
0.4 
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Once GG was appropriately dissolved, epichlorohydrin (EPI) was added drop-wise allowing for a 
period of stirring between each drop, within a range of 0.4-0.8mL followed by further stirring with 
a magnetic stirrer for 30 minutes to allow for effective crosslinking to occur. The resulting viscous, 
slightly opaque gel was poured into a beaker of acetone (50mL), and allowed to precipitate for 
approximately 3 hours. Thereafter the precipitated gel was drained of all the excess acetone using 
a laboratory strain and placed in a petri dish, and air dried under the influence of a fumehood for 
a further 24 hours. The resultant s-IPN xerogel is then crushed into a uniform powder using a 
mortar and pestle and electrical grinder for formulation of sustained release s-IPN xerogel matrix 
tablets as depicted in Figure 4.1. 
 
 
 
 
 
 
 
 
 
Figure 4.1:  (a) Digital images of s-IPN xerogel after precipitation in acetone at 3 hours and (b) s-
IPN xerogel polymer matrix tablets compressed employing the Carver Press 3851-0.  
 
4.2.4. Preparation of the s-IPN xerogel matrix tablets 
s-IPN xerogel matrix tablets were prepared consisting of a 50mg sulpiride to 100mg s-IPN xerogel 
using the direct compression method. All tablet excipients including the xerogel with the exception 
of magnesium stearate were mixed with equal concentrations initially after which the concentration 
of each excipient gradually increased until all weighed out excipients were added.  Magnesium 
stearate was added and mixed for a further 2 minutes. The dry blend of powdered excipients was 
directly compressed using a hand operated Carver Press (Model 3851-0, S/N 43000-904, 
Wabash, IN, USA) at a pressure of 5 tons. 
                           (a)                                                           (b) 
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4.2.5. Physiomechanical evaluation of fabricated s-IPN xerogel matrix tablets 
The matrix tablets of PEO-GG xerogel, crude GG, and crude PEO were evaluated by textural 
analysis studies to determine the physiomechanical properties of the tablets. Parameters such as 
hardness, deformation, rigidity, and matrix resilience were obtained. PEO-GG xerogel, GG, and 
PEO tablets, 5mm in thickness respectively were evaluated  from (force vs. distance) and (force 
vs. time) profiles generated on a TA.XTplus Texture Analyzer (Stable Microsystems, Surrey, UK) 
equipped with a 2mm flat cylindrical probe,5kg load cell and Texture Exponent (V3.2) software for 
processing of data. Matrix tablets were secured on a raised platform fitted with a 5mm diameter 
central hole. A central probe with a weight of 5kg was lowered on to the surface of the tablet 
(Covielloa et al., 2005), in accordance with the test parameters listed in Table 4.2.  
Table 4.2:  Test parameters used during Texture Analysis as per standard protocol for solid 
dosage forms 
 
 
 
 
 
 
 
 
 
 
 
4.2.5.1. Brinell hardness number, deformation, rigidity, and resilience determination 
The Brinell hardness test was employed to determine the hardness of tablets where a load of 5kg 
was applied to the surface of the tablets via a steel indenter of 3.175mm in diameter. Thus the 
Parameters Test Settings 
 
Test mode Compression 
Pre-Test 1mm 
Test 0.5mm 
Post-Test 1mm 
Target 
Mode:  
Distance - 
Strain 0.5mm- 10% 
Trigger 
Force 
 
 
0.05N 
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diameters of the resultant indentation on the surface of the tablets were measured and the Brinell 
Hardness Number (BHN) was calculated using Equation 4.1. 
 
𝐵𝑟𝑖𝑛𝑒𝑙𝑙 𝐻𝑎𝑟𝑑𝑛𝑒𝑠𝑠 𝑁𝑢𝑚𝑏𝑒𝑟 = 2𝐹/(𝜋𝐷(𝐷 − (𝐷2 − 𝑑2) 
Equation 4.1 
 
Where, F=load on the indenting tool (force generated in kg), D=diameter of the spherical probe 
indenter (3.175mm), and d=diameter at the rim of the impression made (depth 0.5mm) (Choonara 
et al., 2006).  
Deformation and rigidity was determined from evaluating the area under the curve (AUC) as well 
as the gradient from the force vs. distance graph. By plotting a force vs. time graph the values for 
1:2 and 2:3 (values for the peak anchors) were obtained, thereby resilience was then calculated 
when a strain of 10% is applied with the use of Equation 4.2. 
 
𝑅𝑒𝑠𝑖𝑙𝑖𝑒𝑛𝑐𝑒 = (
2: 3
1: 2
) × 100 
Equation 4.2 
 
4.2.6. Surface morphological analysis 
Scanning Electron Microscopy (SEM) was employed to determine the surface morphology of 
crude PEO and GG, as well as provide evidence of the synthesis of an s-IPN within the crosslinked 
xerogel formulations with the aid of the generated microscopic images. It further assisted in 
identifying the differences in physical morphology and characteristics of the crude polymers as 
compared to the crosslinked xerogel. Dried xerogel samples before tableting and native polymers 
were placed on steel studs and sputter coated with carbon and gold palladium shadowing using 
the Phenom™ G2 Pro SEM (FEI Company, and Hillsboro, Oregon, USA) by employing various 
magnifications. 
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4.2.7. Chemical composition analysis 
The FTIR spectra of PEO, GG and the crosslinked s-IPN xerogels were recorded using an FTIR 
Spectrophotometer (Perkin Elmer Spectrum 100, FT-IR Spectrometer) fitted with a universal ATR 
Polarization Accessory (Perkin Elmer Ltd., Beconfield UK). Wavelengths were recorded between 
4000 and 650cm-1 and FTIR spectrums of absorbance and % transmittance against distance was 
obtained. 
4.2.8. Thermal transition examination  
DSC analysis was conducted for PEO, GG and the s- IPN- xerogels using a Mettler Toledo, DSC 
1 , STARE System (Schwerzenback, Switzerland) at a heating rate of 10˚C/min from 25-300˚C 
under the constant flow of nitrogen gas. Accurately weighed samples of each formulation (±10mg) 
were placed into aluminum sample holders covered and a central pin hole made. Indium metal 
(99.99%) was used to calibrate the DSC with regards to temperature and enthalpy (Kreye et al., 
2012). 
4.2.9. Response surface analysis of the employed responses 
Minitab® statistical software (V15, Minitab Inc., PA, USA) was utilized to perform the response 
surface analysis of the various response variables. The results were demonstrated employing 
response surface and contour plots which were derived for the measured responses (drug release 
and degree of swelling and erosion), based on the experimental model.  
4.2.10. Water content determination employing Karl- Fischer Analysis (KF) 
KF analysis was conducted for all formulations within the study using the Mettler Toledo V30 
Volumetric KF Titrator, with methanol as the moisture standard. Accurately weighed out xerogel 
samples of 0.01g were placed within the solvent bath after a baseline drift of zero was achieved, 
under continuous vigorous stirring with a magnetic stirrer until the titration end point is reached. 
All samples were tested to determine water content with results obtained in % water content per 
sample (Scaccia, 2005).  
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4.2.11. Powder flow characterization studies 
4.2.11.1. Angle of repose 
The angle of repose is the angle formed between the horizontal bench surface and the cone-
shaped mass of powdered xerogel. A glass funnel, 5cm in height from the base to the orifice was 
employed. The funnel was secured 4cm above the bench surface. Thereafter, the powdered 
xerogel was poured through the funnel orifice, a cone shaped mass of xerogel formed. The height 
(h) and radius(r) of the cone-shaped mass were recorded. The angle of repose was thus 
calculated as per Equation 4.3 below (Shah et al., 2008):  
 
 
Ɵ= tan -1 (h/r) 
Equation 4.3  
 
4.2.11.2. Carr’s Compressibility Index and Hausner ratio  
Bulk (ρbulk) and tapped (ρtap) densities were recorded employing methods as described in the 
USP. Samples were poured into a 10mL graduated measuring cylinder. The bulk density was 
measured after tapping the cylinder twice on a flat bench top surface. Thereafter the tapped 
volume was recorded after tapping in increments of 10, 15, 20, 30, 50, and 100 taps (Shah et al., 
2008) 
The recorded bulk and tapped densities were utilized to calculate the Carr’s compressibility index 
(Equation 4.4) and Hausner ratio (Equation 4.5) respectively.  
𝐶𝐼 =  
𝜌𝑡𝑎𝑝 −  𝜌𝑏𝑢𝑙𝑘
𝜌𝑡𝑎𝑝
× 100 
Equation 4.4 
 
𝐻𝑅 =
𝜌𝑡𝑎𝑝
𝜌𝑏𝑢𝑙𝑘
 
Equation 4.5 
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4.2.12. Swelling and erosion studies  
A study to evaluate the swelling, erosion and water uptake characteristics of the tablets was 
conducted. Whereby the respective tablets were weighed and placed in 250mL beakers containing 
200mL potassium phosphate buffer pH 6.8 at room temperature and allowed to swell over a 24 
hour period. Tablets were at predetermined time intervals removed from the buffer and weighed 
after removing surface water with absorbent paper on a calibrated electronic scale. The swelling 
ratios, erosion and water uptake % was calculated using Equations 4.6-4.10 (Özerogluand Birdal, 
2009).  
 
 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 =
𝑊𝑡
𝑊𝑜
 
Equation 4.6 
Where, Wt. =weight of the tablet at time t, and WO=initial weight of the tablet. 
 
𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 (𝑆) =
𝑊𝑡 − 𝑊𝑜
𝑊𝑜
 
Equation 4.7 
Where, Wt. =weight at time t, and WO=initial weight of the tablet. 
 
𝑊𝑎𝑡𝑒𝑟 𝑈𝑝𝑡𝑎𝑘𝑒 % =
𝑊𝑠 − 𝑊𝑜
𝑊𝑜
× 100 
Equation 4.8 
Where, Ws=weight of the swollen tablet, and WO=weight of the initial tablet. 
 
% 𝐸𝑟𝑜𝑠𝑖𝑜𝑛 =
𝑊𝑜 − 𝑊𝑒
𝑊𝑒 
 × 100 
Equation 4.9 
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Where, WO=initial weight of the tablet, and we=weight of the test after the erosion test (Reddy et 
al., 2012). 
𝐸𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 𝑊𝑎𝑡𝑒𝑟 𝐶𝑜𝑛𝑡𝑒𝑛𝑡(𝐸𝑊𝐶%) =
𝑊𝑒𝑞 − 𝑊𝑜
𝑊𝑒𝑞
 × 100 
Equation 4.10 
Where, Weq=weight at equilibrium, and WO=weight of the initial tablet (Murthy et al., 2006; Reddy 
et al, 2012).  
4.2.13. In vitro drug release studies 
Dissolution studies were carried out utilizing a USP type II apparatus (Caleva, model 7ST) at 
50rpm and 37˚C in 900mL of potassium phosphate buffer (pH 6.8) with the addition of a stainless 
steel mesh ring, which fits under the paddle into the lower part of the standard dissolution vessel.  
5mL of dissolution medium  was withdrawn manually at predetermined time intervals during the 
24 hour study and replaced with an equal volume of fresh dissolution medium to ensure sink 
conditions were maintained. The samples were then analyzed for drug release via Ultraviolet 
spectrometry (WinAspect Spectro-analytical software, Analytik Jena AG), at a wavelength of 
291nm employing a calibration curve obtained for the drug (Strübing et al., 2008). The Mean 
Dissolution Time (MDT) was calculated for all samples, the concept of MDT relates to the average 
time required for dissolution of a drug delivery system. MDT can be arithmetically calculated from 
experimental dissolution data using Equation 4.11:  
𝑀𝐷𝑇 =  
𝐴𝐵𝐶
𝑊∞
 
Equation 4.11 
Where W∞ is the asymptote of dissolved amount of drug and ABC is the area between the 
cumulative dissolution curve and W∞ (Rinaki et al., 2003). 
4.3. Results and Discussion  
4.3.1. Assessment of the physiomechanical properties of the s-IPN xerogel matrix 
component of the ODLS 
Textural analysis data profiles were employed to study the mechanical properties of the 
crosslinked s-IPN xerogel matrix tablets in comparison to the PEO-GG blend tablets alone when 
a uniaxial compression force was applied to the tablets. The work of deformation energy which is 
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calculated as the area under the curve (AUC) of the force-distance curve points to the deformation 
and rigidity of the tablets. The force-distance curves obtained is a measure of the force of 
resistance encountered by the probe infiltration as a function of the travelled distance into the 
tablet. A low resistance is depicted by a low slope which further illustrates that the strength of the 
tablet is low, while a sharp increase in force, a higher slope as the test probe penetrates deeper 
into the tablet corresponds to a greater strength (Pillay and Fassihi, 2000). From the profiles of 
force-distance obtained there was a display of both a high and sharp curve as well as short curve, 
s-IPN xerogel matrix tablets had a greater resistance to the force applied than to the comparative; 
namely; PEO-GG blend tablets. This may be further highlighted by calculating the gradients of the 
various force-displacement curves as indicated in Table 4.3, whereby the gradient shows the 
rigidity of the tablets tested, data indicates that the crosslinked PEO-GG xerogel tablets have an 
greater rigidity than the PEO-GG blend as a consequence of the new formed polymer chain 
strength, with Formulation 10 (F10) displaying the highest rigidity. 
Table 4.3: Comprehensive table of data obtained from textural analysis describing the mechanical 
properties of the s-IPN xerogel matrix tablets. 
Formulation 
Code 
Force (N) BHN 
No. 
Deformation 
(AUC) 
Rigidity 
(N.mm) 
Resilience 
% 
 
F1 
46.67 236.00 0.011 96.412 145.00 
F2 41.43 209.69 0.008 88.945 54.62 
F3 40.38 204.40 0.008 84.674 143.80 
F4 39.38 199.00 0.008 83.754 141.78 
F5 42.67 215.96 0.009 89.565 155.81 
F6 44.64 225.90 0.010 93.264 44.60 
F7 48.00 242.94 0.011 101.104 45.66 
F8 39.41 199.50 0.008 83.607 54.92 
F9 44.64 225.90 0.010 93.625 54.80 
F10 48.21 244.00 0.011 101.332 45.63 
F11 42.86 216.90 0.009 91.720 56.17 
F12 39.38 199.00 0.008 83.754 141.65 
F13 42.07 212.93 0.009 87.998 55.00 
F14 39.68 200.80 0.008 81.759 42.39 
F15 47.14 
 
238.59 
 
0.011 
 
98.587 
 
54.99 
 
 
 
The same applied for deformation, the crosslinked xerogel tablet showed a lower level of deformity 
whereas the PEO -GG blend tablet showed the highest value of deformation due to the high 
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binding properties and loose bonds between polymer molecules. The Brinell hardness and 
resilience of design formulations are represented graphically in Figures 4.2 and 4.3, respectively.  
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Figure 4.2: Diagrammatic representation of Brinells Hardness Number for Box Behnken Statistical 
formulations depicting the effect of polymer concentration and crosslinking density on the 
hardness and mechanical strength of formulations 
 
To determine the resilience of the tablets a strain of 10% was applied to the tablets whereby a 
textural analysis profile was generated of Force (N) - Time (sec) to the 1:2 and 2:3 ratios, after 
which the resilience was calculated as depicted in Table 4.3 above.  
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Figure 4.3: Illustration of the difference of Resilience between all statistical Box-Behnken design 
formulations with variances in chemical composition. 
 
From the results obtained it can be seen that the s-IPN xerogel matrix formulation F5 has the 
greatest % resilience than its comparatives, which may be attributed to the greater mechanical 
strength of the crosslinked xerogel due to a greater concentration of crosslinker being used. The 
strain applied as well as the deformation of the xerogel was directly proportional to the 
compression force applied. In addition, the applied stress and deformation was inversely 
proportional to the radius and diameter of the indenter probe. This can be confirmed theoretically, 
from the principles of Young’s modulus (E) and Equations 4.12-4.15 (Ruvalcaba et al., 2009). 
 
ô = −𝐸(ë − 1) 
Equation 4.12 
Where, ô is the applied stress, and  ë is the deformation (Khalid et al., 2002) 
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𝐸2/3 =
𝐾𝐹2/3
𝑅1/3𝑑
 
Equation 4.13 
Where, R is the indenter radius, d is the displacement of the indenter, and F is the compression     
force. Equating 4.12 and 4.13, the relations shown in Equations 4.14 and 4.15 can be deduced. 
 
ô 𝑎𝑛𝑑 ë ∝ 𝐹 
Equation 4.14 
ô 𝑎𝑛𝑑 ë ∝ 1/𝑅 
Equation 4.15 
 
4.3.2. Assessment of the surface morphology of the s-IPN xerogels as per design 
Scanning electron micrograms displayed in Figure 4.4 displays the surface morphology of pure 
PEO, GG, and crosslinked s-IPN xerogel formulations F1, F7 and F9 that showed distinct 
alterations after precipitation in acetone and drying under the influence of a fumehood. The SEM 
micrographs show that the s-IPN xerogel formulations are highly porous as compared to the pure 
PEO and GG. The average particle size ranged from approximately 240-486μm. The drastic 
change in surface morphology between the native polymers and crosslinked s-IPN xerogels shows 
that the modification of these polymers was successful. The resultant porous nature of the s-IPN 
xerogel furthermore allows for the sustained release of the active from within the interpenetrating 
network formed. Formulations with a greater degree of crosslinking display a reduced free volume 
of polymer matrix, which thus delays the passage of drug through the matrix (Kulkarni et al., 2011 
(1); Kulkarni et al., 2011 (2).  
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Figure 4.4: SEM Micrographs of PEO (A), GG (B), F1(C), F7 (D), and xerogel F9 (E). 
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4.3.3. Chemical compositional assessment of the s-IPN xerogels 
FT-IR may be used as a ‘fingerprint’ tool to determine which molecules can differentiate between 
the xerogel formulations and its precursors such as GG and PEO by using comparisons of known 
compound consistency. Figure 4.5 below represents the FTIR spectrum obtained for PEO, GG, 
xerogel F1, F7 and F9 as a function of % transmittance against wavelength. 
 
Figure 4.5: FTIR Spectra of crosslinked s-IPN xerogel F1 (f), F7(c), F9 (d), as well as pure PEO 
(b) and GG (a) depicting the change within chemical structure via the identification of specific 
functional groups within the spectra obtained. Pink and green spectra correspond to PEO and GG 
respectively with black, red and blue representing formulations 1, 7 and 9 respectively. 
 
Modifications in chemical structure of the s-IPN xerogel formulations were analyzed employing 
FT-IR spectroscopy, which assists in identifying interactions of parent polymers upon chemical 
reactions such as crosslinking. The current observation of crosslinking was optically detected by 
noted change in solution viscosity as well as opacity on completion of the crosslinking reaction. 
The FT-IR spectra of PEO depicted the functional groups present within the chemical compound 
by determining characteristic bands such as that of O-H functional groups characteristic of 
alcohols in a range of 3200-3600cm-1, and C≡C stretching depicted at wavenumber range of 2100- 
2260cm-1. Furthermore the spectrum for crude GG depicts an important peak at a range of 2850-
2960cm -1 which corresponds to C-H stretching band (Coates, 2000), and is found in all design  
formulations as a characteristic GG absorption. On experimental evaluation of the FT-IR data set 
it has been inferred that changes in the polymer ratios and crosslinking density have an effect on 
the vibrational frequencies observed. A broad band in the range of 2850-2960cm-1 relating to C-H 
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stretching (Coates, 2000) in alkane functional groups is observed in all s-IPN xerogel formulations, 
characteristic of GG. 
Due to the presence of NaOH within the crosslinking reaction, it leads to the breakdown of O-H 
bonds (Adel et al., 2010) thus causing these hydrogen and oxygen molecules to interact with other 
molecules, forming new functional groups. This chemical phenomenon leads to the addition of 
alkene groups with C-H stretching at higher wavelengths of 3276cm-1(Coates, 2000), as depicted 
by the highlighted peak in Figure 4.5 of F7. This confers a greater degree of conjugation thereby 
improving stability and as an extension the physiomechanical properties of the polymer network 
synthesized. In addition a strong band relating to the O-H bonding groups within the range of   
3200-3600cm-1 (Coates, 2000), is observed in s-IPN xerogels that had an intermediate ratio of 
polymers relating to the presence of alcohols or phenols. There also exist shifts in the spectrum 
with the varying crosslinking density. The introduction of N-H amine groups is found in F1, 2, 3, 5, 
and 10, at a wavelength of 3360.17cm-1 (Coates, 2000) this is due to the increase in crosslinker 
density, therefore promoting bond formation, the absence of the amino groups within the 
remaining formulations indicates the absence of amino groups for bonding reactions, this 
occurrence could be due to the reduced concentration of GG and increased density of EPI within 
these formulations which thereby creates steric hindrance. 
F9 showed C=C stretch at a wavelength of 1500cm-1 (Coates, 2000), highlighted in the FT-IR 
spectra in Figure 4.5, which corresponds to a conjugational asymmetrical stretch, occurring when 
the ratio of polymers is 1:2.5 and crosslinker is at an intermediate density. C-H stretching within 
the aromatic ring structure which is derived from the structure of pure GG, was observed with all 
formulations with the resulting incorporation of a C-O functional group within the aromatic structure 
at a wavelength of 1080cm-1 (Coates, 2000). Furthermore methyl and methylene functional groups 
were introduced within formulations with a higher concentration of crosslinker due to the 
introduction of RCH=CH2 bridges extending from the aromatic ring backbone. Aliphatic ethers 
represented by wavelengths occurring at 1060-1150cm-1 were observed in s-IPN xerogels that 
consisted of PEO at a concentration of 1.75%w/v. C-N stretching occurred between 1560-1650cm-
1 in formulations that had crosslinking density of 0.6mL, these peaks tend to occur at higher 
vibrational frequencies and are known to be associated with the degree of crosslinking (Adel et 
al.,2010) and polymer network formation resulting in a change within the structural configuration 
of the molecules, thus formulations with higher degrees of crosslinking was found to have 
wavelengths shifting to the greater end of the spectrum. From the data obtained from the FT-IR 
spectra of all compounds tested it can be seen that there are distinct changes within the chemical 
structure with the addition and removal of certain functional groups. Shifting of the aromatic ether 
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occurs in F1, 3, 4, 8 and 11 which all have a crosslinking concentration of 4.4%v/v. There is a 
disappearance of the C-H in plane bending from xerogel formulations consisting of a polymer ratio 
of 0.75: 1.75%w/v thus describing an effect of polymer concentrations of the C-H bonding. 
Furthermore individual formulations show characteristically new bands, such as the addition of an 
alkyne and amine group in F1 as well as methyl groups in F7 and F9. 
Chemical crosslinking entails the use of a crosslinking agent to allow a linkage between two 
polymer chains. The actual crosslinking reaction of both synthetic and natural polymers is 
accomplished via the reaction between their functional groups with crosslinkers such as 
epichlorohydrin. Chemical crosslinking largely implicates the introduction of new functional groups 
and molecules between the polymeric chains to thereby produce crosslinked chains (Syed et al., 
2011). This theoretical explanation thus accounts for the additional functional groups and chemical 
orientation seen in the FT-IR spectra of the crosslinked s-IPN xerogel formulations as compared 
to the spectra of PEO and GG. All of the observations help to conclude that polymer concentration 
as well as crosslinking density has an effect on the formation of semi Interpenetrating networks 
as observed by peaks within the FT-IR spectra. 
4.3.4. Thermal analysis of the crosslinked s-IPN xerogel 
Differential Scanning Calorimetry (DSC) is employed to determine the well as the crystallization 
temperature of the crude polymers, pure Gelzan™ CM, GG and pure PEO WSR303 as compared 
to crosslinked s-IPN xerogel. The procedure follows a thermal analytical method that maintains all 
test samples at a constant temperature throughout the experimental procedure, whereas the 
sample temperature holder increases in a linear manner. The DSC thermogram of pure PEO 
shown in Figure 4.6, displays a pronounced endothermic peak at 73.86˚C which corresponds to 
the crystalline melting (Tm) temperature of crude PEO (Ibrahim and Johan, 2012).Glass transition 
of pure PEO occurs at approximately 65.72˚C. An exothermic peak at 190.51˚C depicts melting of 
stable modification.  Figure 4.6 also depicts the thermogram of GG (Gelzan™ CM), shows an 
endothermic peak at 62.98˚C which is due to endothermic peaks only appearing at GG 
concentrations of w and lower with these peaks disappearing at concentrations greater than 8% 
(Izumi et al., 1999).  
 
The glass transition temperature (Tg) is directly proportional to the crosslinking density, thus as 
seen in the DSC curves for design formulations it is clearly visible that there is an increase in the 
Tg with a corresponding increase in the crosslinker concentration ranging between 64.95-
65.92˚C.Melting peaks for all design formulations remained within a stable, constant range 
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between 106-107˚C; however there was a slight reduction noted in the melting temperature when 
the ratio of polymers was reduced , this phenomenon has been described earlier by the Sanchez-
Eby theory which states that a reduction in melting temperature is due to a reduction in the heat 
of fusion present within the reaction,  this results because with lower concentrations of polymers 
there is a greater degree of non-crystallizable units (Zo-li, 2005).  
The melting peaks observed were broad due to the partial crystalline nature of the polymers, this 
occurs due to the size distribution of crystallites. Melting is then followed by a broad exothermic 
crystallization peak, the surface of the xerogel which after melting forms a rigid envelope leads to 
crystallization which involves the transition of the polymeric material from a liquid to a crystalline 
solid, with repeated units forming rigid structure crystallization (Mettler Toledo, 2000). It was found 
that the temperature of crystallization was shifted to higher temperatures with a corresponding 
increase in crosslinker and polymer concentrations with broad peaks depicting that with an 
increase in crosslinking the crosslinks appear within the amorphous regions, thus allowing a 
greater crystalline peak (Reis and Pruitt, 2005). A prominent crosslinking peak is also noted within 
the crosslinked s-IPN xerogel formulations, thus proving the crosslinking reaction of GG-PEO 
employing epichlorohydrin. This peak is representative of the crosslinking reaction that occurs 
upon heating of the sample called curing. These crosslinking peaks are observed with formulations 
with a higher concentration of crosslinking agent, but absent from those with a reduced crosslinker 
concentration, most prominent around the temperature of 215˚C. 
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Figure 4.6: DSC Thermograms of s- IPN xerogel Formulations F1(c), F7 (d), F9 (e), as well as 
PEO (b) and GG (a) at a heating rate of 10˚C/ min from 10- 300˚C under nitrogen atmosphere. 
 
4.3.5. Response surface analysis of the Box-Behnken design 
With the purpose of determining the relationship between the response variables and predictor 
variables, a complete ANOVA analysis was performed of the measured formulation responses 
(Figure 4.7, Table 4.4), drug release, swelling and erosion. The aptness of the multiple regression 
models are accessed via residual analysis. Residual plots for drug release (total MDT), mean % 
swelling and mean % erosion are depicted in Figure 4.7. The hypotheses of a multiple linear 
regression model is that the response variables are independent and ordinarily distributed, 
arbitrary variables with constant variance and means depending linearly on the explanatory 
variables (Larsen and McCleary, 1972; Huynh, 2000). Resilient linear relationships were observed 
for all response variables as indicated by the confined clustering of the partial residuals. The 
scatter plot of the residual, in which the residuals were plotted against the model predictions, is 
objectively uniform and radiate in the vicinity of zero. They generally displayed irregular scatter 
i.e. no specific trends, indicating none of the underlying hypotheses of the multiple regression 
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analysis were obviously breached; some deviations (outlying points) and some widely spread 
points were observed indicative of a degree of non-constant variance (du Toit et al., 2013).  The 
normal probability plots of the residuals fell on a straight line demonstrating the data to be normally 
distributed with no affirmation of unidentified variables. Definite patterning was not observed in 
any of the variable plots, indicating non-contravention of the assumptions of zero means and 
constant variance of the regression model notwithstanding the presence of a few outlying points 
in these plots. Deviations could have resulted from experimental error. The histograms for drug 
release and erosion were largely symmetrical thus supporting the probability plots of constant and 
uniform distribution. The attained histogram for swelling depicted an absence of symmetry 
suggestive of a random error of the data set. The scatter plot, which is the residual vs. observation 
order, depicts the performance of the model. Scatter plots stayed within constant scale indicating 
non-arbitrary error. A full ANOVA was conducted and shown in Table 4.4.  
Table 4.4: ANOVA analysis for the measured responses. 
Response Variables  p-values 
 
Drug Release             % Swelling                      % Erosion 
[GG] 0.152 0.025 0.055 
[PEO] 0.734 0.148 0.112 
[EPI] 0.618 0.814 0.872 
 
The complete regression equations generated for drug release, mean % swelling and mean % 
erosion are indicated below;  
𝑀𝑒𝑎𝑛 % 𝐸𝑟𝑜𝑠𝑖𝑜𝑛 = 102.194 − 41.5[𝐺𝐺] − 9.424[𝑃𝐸𝑂] + 3.521[𝐸𝑃𝐼] 
Equation 4.16 
𝐷𝑟𝑢𝑔 𝑅𝑒𝑙𝑒𝑎𝑠𝑒 (𝑇𝑜𝑡𝑎𝑙 𝑀𝐷𝑇) =  −18.968 + 99.504[𝐺𝐺] + 6.250[𝑃𝐸𝑂] − 39.221[𝐸𝑃𝐼] 
Equation 4.17 
𝑀𝑒𝑎𝑛 % 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 = 1017.20 − 1020.11[𝐺𝐺] − 161.85[𝑃𝐸𝑂] + 99.63[𝐸𝑃𝐼] 
Equation 4.18 
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Figure 4.7: Residual plots for the responses a) mean % erosion b) drug release (MDT) c) mean 
% swelling.  
 
Matrix erosion, drug release and polymer swelling are vital parameters influencing the resultant 
drug release profile from the s-IPN xerogel matrices. The integration of swelling, erosion and 
diffusion assists in achieving the desired zero-order drug release profile. Data plots were utilized 
to illustrate the purposeful relationship between the experimental variables and achieved 
responses. The effects of the GG, PEO and EPI on erosion are depicted in Figure 4.8 GG: PEO 
ratio of 1g: 0.8%w/v displayed lower percentage erosion, whereas a GG: PEO ratio of 
approximately 0.5g:2.5%w/v displayed an increase in matrix erosion. Higher concentrations of EPI 
of ˃ 0.6mL enhanced the erosion capability with both polymers employed in the system design.  
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Figure 4.8: Response surface and contour plots depicting the effects of gellan gum (GG), poly 
(ethyleneoxide) (PEO) and epichlorohydrin (EPI) on mean % matrix erosion.  
 
GG at a concentration of 0.5g and PEO at 1.5 % w/v show desirable MDT as seen in Figure 4.9. 
The ratio of 0.8mL EPI to 1g GG derived an anticipated MDT of 12.5. It was observed that an 
increase in concentration of GG and PEO resulted in a corresponding increase in MDT. An 
increase in the concentration and volume of the respective polymers and crosslinker leads to an 
increase in the bulk volume of the xerogel matrix thus causing a reduction in drug release as drug 
has to pass through a greater bulk of s-IPN xerogel polymer network. Thus the concentration of 
GG had a significant interaction on the desired system responses.  
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Figure 4.9: Response surface and contour plots depicting the effects of gellan gum (GG), poly 
(ethyleneoxide) (PEO) and epichlorohydrin (EPI) on drug release (total MDT).  
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An observed ratio of 2.4 %w/v PEO and 1g GG greatly raises the mean % swelling. Furthermore, 
a reduction in concentration of the respective polymers results in a corresponding decrease in 
swelling. The reduction in swelling could be attributed to the reduced polymer chain entanglement 
leading to rigidity of the s-IPN xerogel matrix. Conversely, an increase in volume of crosslinker 
employed ˃0.6 mL results in an intermediate to low percentage of mean swelling.  An approximate 
mean % swelling of ≥ 200% is considered appropriate to attain the desired prolonged release 
profile. A greater degree of swelling provides a matrix barrier to drug release thus sustaining drug 
release over 24 hours.  
4.3.6. Influence of water content as determined via titrimetric analysis  
The percentage water content was obtained for all Box-Behnken design formulations employing 
a sample size of 0.01g. Results obtained ranged between 3.149-11.454% water content using 
Equation 4.19. 
 
% 𝑊𝑎𝑡𝑒𝑟 𝐶𝑜𝑛𝑡𝑒𝑛𝑡 =
𝑉𝑜𝑙𝑢𝑚𝑒 𝑎𝑡 𝐸𝑞𝑢𝑙𝑖𝑏𝑟𝑖𝑢𝑚 (𝑚𝑙)×𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑖𝑛 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 (𝑚𝑒𝑡ℎ𝑎𝑛𝑜𝑙)𝑚𝑔/𝑚𝑙
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑚𝑔)
 × 100% 
Equation 4.19 
 
Formulations depicted varying degrees of water capacity based on the ratio of polymer and 
crosslinker content. Formulations with an a higher concentration of polymer and crosslinker in 
overall showed a higher percentage of water content whereas; formulations with lower polymer 
and crosslinker concentrations depicted a reduction in water content. This is possibly due to the 
greatly hydrophilic nature of PEO and GG, as well as the high degree of water content found in 
EPI. Ideally water contact of a solid dosage form should be kept to a minimum due to adverse 
effects it may have on the physical and chemical characteristics of the pharmaceutical product 
(Szakonyi and Zelkó, 2012).) However, in the current study it can be seen that although the water 
content is on the greater spectrum it’s mostly due to the hydrophilic nature of the parent polymers 
and the crosslinking agent used. The water content for design formulations are shown in Figure 
4.10. 
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Figure 4.10: % water content obtained for 15 design formulations employing Karl-Fischer 
analysis. 
 
4.3.7. Flow properties of powdered-drug loaded xerogel 
The angle of repose, Carr’s compressibility index and Hausner ratio were measured for all design 
formulations and the results are illustrated in Figure 4.11. The angle of repose calculated for all 
design formulations ranged from 20.48 to 34.4˚, with majority of the formulations falling within the 
20˚ range. The angle of repose, which is a customary characterization tool used to determine 
pharmaceutical powder flow. Flowability is based on the angle of repose obtained via the 
calculation. A value of <30˚ specifies excellent flow, while values ˃56˚ indicates poor flow 
properties (Shah et al., 2008). Based on the results obtained, formulations were rated as having 
excellent to good flow characteristics.  
In contrast, the Carr’s compressibility (CCI) index and Hausner ratio (HR) were also calculated 
based on equations 4.4 and 4.5 outlined in Chapter 4, Section 4.2.11. The CCI and HR were found 
to range from 9-31 and 1.1-1.45 respectively. CCI is a measure of powder bridge strength and HR 
is a degree of interparticulate friction. In theory, lower values for CCI and HR respectively dictate 
better flow properties. A CCI value of <10 or HR <1.1 is indicated as excellent flow, whereas CCI 
˃38 and HR ˃1.6 is considered poor flow (Schnaare et al., 2005). Therefore, based on the data 
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obtained, flow of the powdered drug loaded xerogel was rated as excellent to good established by 
CCI and HR.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: a) Graphical illustration of calculated angle of repose and Carr’s compressibility index 
b) Graphical illustration of Hausner ratio.  
 
4.3.8. Analysis of the swelling behavior 
In this study the dynamic swelling, in terms of water uptake and erosion of the s-IPN xerogel and 
PEO-GG blend tablets, were analyzed by monitoring the change in weight over a pre-determined 
a) 
 
 
 
 
 
 
 
 
 
b) 
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period of time. Figure 4.12 indicates the percentage of water uptake and thus swelling over a 
period of time for the varying crosslinked s-IPN xerogel formulations as well as the PEO-GG blend 
tablets. The porosity of the polymeric material in question such as GG is a predominant feature 
that determines its swelling ability. In theory an increase in porosity leads to greater initial rates of 
water uptake and a greater level of equilibrium swelling (Ferrero et al., 2010). Porosity affects the 
rate of dissolution, when a porous polymeric delivery system is placed in direct contact with 
dissolution medium, release of the drug must be headed by the penetration of dissolution medium 
into the pores. Pores close to the surface of the polymer matrix become filled with dissolution 
medium, thus the initial drug diffusion is controlled by the dissolution of drug within the pores 
(Ahuja and Pathak, 2009). Therefore, the formation of pores within the xerogel system involves 
the initial penetration of dissolution medium into the pores followed by swelling of the xerogel-pore 
boundaries thereby further prolonging release of drug. 
Swelling also depends largely on the extent of crosslinking. As seen from Figure 4.12, xerogel 
formulations F1, F7 and F9 have similar swelling characteristics with a uniform delayed swelling 
behavior ranging between 450-500%. Whereas PEO-GG blend shows a constant exponential 
increase in water uptake and swelling up to and beyond the 24 hour test period. Thus the following 
observation was made based on swelling test results, the greater the amount of water uptake the 
greater the degree of erosion due mostly to gellan gum as seen in Figure 4.13. Therefore tablets 
having a high degree of water uptake were found to erode at a faster rate and thus undergo 
complete disintegration at an accelerated rate, although water uptake also encouraged the degree 
of swelling which mostly relied on the properties of PEO and related to a delayed dissolution and 
disintegration process. 
Previous studies have shown that the amount of water uptake is directly proportional to the degree 
of polymeric erosion; and swelling is controlled by the rate of hydration within dissolution medium. 
Therefore, extent of matrix swelling and erosion determines drug release kinetics (Sriamornsak et 
al., 2007). Visual observations showed that xerogel matrices swell in contact with dissolution 
medium to form a viscous gel barrier around the core of the tablet. Drug release occurred via this 
hydrophilic gel barrier; therefore the rate of release from the matrix is dependent on the viscosity, 
swelling rate and erosion of the gel layer.  It was also noted within the study that the swelling of 
the s-IPN xerogel was increased with a corresponding increase in crosslinker concentration, due 
to the formation of polymer networks between PEO and GG. Therefore the Equation 4.19 
substantiates this theory. 
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𝐶𝑐 =
1
𝑆𝑤
 
Equation 4.20 
Where, Sw is the percentage swelling and Cc is the concentration of crosslinker. 
 
Hence by extension a reduction in crosslinker concentration leads to the formation of looser 
polymer networks or IPNs which thus entails the existence of greater hydrodynamic free volume 
allowing for the absorption of a greater amount of solvent in turn creating a greater swelling 
capacity (Kulkarni et al., 2011 (1); Kulkarni et al., 2011 (2). In theory, from the equation of Fick’s 
law of diffusion and the equation for dynamic swelling we can deduce the relationships shown in 
Equations 4.21-4.23 (Kulkarni et al., 2011 (1).  
 
𝑀𝑡
𝑀∞
= 𝐾𝑡𝑛 
Equation 4.21 
Where 
𝑀𝑡
𝑀∞
=fraction of drug released per unit time, k=release constant and n=release index. 
𝐷𝑡
𝐷∞
= 𝐾𝑡𝑛 
Equation 4.22 
Where 
𝐷𝑡
𝐷∞
=dynamic swelling, k=release constant and n=release index (Rokhade et al., 2006). By 
equating Equations 4.20 and 4.21, we find that, 
 
𝑀𝑡
𝑀∞
∝
𝐷𝑡
𝐷∞
 
Equation 4.23 
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Therefore, it can be further deduced that the amount of drug released has a strong correlation 
with the extent of swelling. The amount of drug released at time t is inversely proportional to the 
overall swelling; hence with an increase in swelling the drug release at time t, will be reduced, 
because the drug molecule has to traverse the gel layer before coming into contact with the 
dissolution medium 
 
Figure 4.12: Graphical representation of Swelling characteristics (a and b)  of crosslinked xerogel 
formulations vs. a non-crosslinked blend to assist in identification of the influence of polymer ratio 
as well as crosslinker density on the swelling and erosion capabilities of formulations based on 
chemical variations on exposure to an aqueous environment (pH 6.8).  
 
4.3.9. In vitro drug release analysis 
In order to determine the release profiles of the drug from the hydrophilic matrix tablets, dissolution 
experiments were performed in accordance with simulated intestinal parameters. The plots of 
Fractional Drug Release vs. Time for the crosslinked s-IPN xerogel matrix tablet F1-15 as well as 
the PEO-GG blend are depicted in Figure 4.13 a, b respectively. 
(a)                                                                                     (b) 
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In the case of the crosslinked s-IPN xerogel formulations, drug release was sustained over a 
period of 24 hours, the variation in concentration of polymers and crosslinker did generate a 
noticeable deviation in drug release, however all crosslinked xerogel formulations showed a 
sustained release over the 24 hour study period. Drug delivery from hydrophilic matrix based 
systems is controlled by surface erosion of the polymers as well as diffusion of the drug out of the 
porous matrix network. Furthermore, erosion is based on factors such as water uptake and 
polymer chain lengths (Toti and Aminabhavi, 2004).   
 
Figure 4.13: Graphical illustration of the in vitro fractional drug release vs. time of sustained 
release s-IPN xerogel matrix tablets in comparison to release profiles of PEO-GG blend 
formulations. 
 
Polymers forming hydrophilic matrices that come into contact with water are known to undergo 
prompt ‘gelification’ which is due to the increased size of polymer molecules. There are mainly 
two mechanisms by which drug release occurs within hydrophilic matrix systems; namely, release 
by ‘controlled swelling’, whereby drug undergoes the process of diffusion through the gel layer 
which is formed as stated above by the swelling or increase in size if polymer chains owing to 
entry of water, and secondly release by ‘controlled dissolution’ in which the water gains entry into 
the system thereby causing ‘gelification’ of the polymer chains that it comes into contact with, on 
the other hand; in addition to the conversion of polymer chains to a gel it also causes the polymer 
to be dissolved, this involves dissolution or erosion of the polymer. 
(a)                                                                                 (b) 
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PEO-GG blends showed drug release behavior with characteristics of both the above mentioned 
mechanisms, GG was subject to controlled dissolution and thus together with swelling it showed 
an increase tendency to disintegrate and dissolve thus leading to the initial burst effect in drug 
release, whereas the following controlled release behavior was mainly based on the properties of 
PEO which follows controlled swelling mechanisms of drug release, in that polymer chains 
undergo swelling on contact with aqueous phase due to the vitreous-elastic transition of the 
polymer been activated, thus the gel layer becomes thicker therefore making the drug release 
slower, because the drug molecule has to now pass through the thickened gel layer formed by 
swelling of polymer chains which is at a  greater distance from the surface of the dosage form, 
this creates a greater resistance to the diffusion of drug out of the gel layer (Maderuelo et al., 
2011). Thus drug release from the PEO-GG blend indicated an initial burst effect followed by a 
rhythmic sustained release above the desired study period of 24 hours. 
Crosslinked PEO-GG s-IPN xerogels F1-F15 displayed constant sustained release during the 24 
hour period with 100% drug being released by the end of 24 hours, with slight variations in release 
rate due to the fact that the swelling and erosion properties of both PEO and GG where modified 
via the crosslinking reaction, thus these formulations showed a combined mechanism of drug 
release in terms of ‘controlled erosion’ and ‘controlled dissolution’. From these results it can be 
deduced that the higher the crosslinker concentration the greater the modification in drug release, 
as can be seen in F1 and F9 where a concentration of crosslinker between 0.6-0.8mLis correlated 
to a greater extent of sustained release, whereas F7, 11, 14, and 15 which has a lower 
concentration of crosslinker depicts irregular drug release kinetics. It can be proven that the 
boundary layer thickness is directly proportional to the diffusion of the drug; in addition the 
tortuosity of the matrix is inversely proportional to the boundary layer thickness. In theory, this can 
be explicated according to the Levenberg Marquardt method and Equations 4.24-4.27 (Siepmann 
et al., 1999). 
 
𝐺 =
𝐿 × ℎ
𝐷
 
Equation 4.24 
Where, G=‘Sherwood number’, D=diffusion coefficient of the drug, h=coefficient of the boundary 
layer and L=thickness of delivery system. 
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𝐷′ = (
𝐷
ô
) 
Equation 4.25 
Where, D=diffusion coefficient of the drug, ô=tortuosity of the diffusion matrix and D’=effective 
diffusion coefficient (Siepmann and Peppas, 2012).). By equating Equations 4.24 and 4.25 the 
relations shown in Equations 4.25 and 4.27 can be deduced. 
 
ℎ ∝
1
𝐷′
 
Equation 4.26 
 
1
ô
∝ ℎ 
Equation 4.27 
 
To determine the mechanism of drug release from the xerogel matrix tablet formulations, the data 
obtained from in vitro release studies were applied to the zero-order ( cumulative amount of drug 
released vs. time) (Shoaib et al., 2006) and Higuchi’s (cumulative % of drug released vs. square 
root of time) (Shah et al., 2008) equation patterns. Release kinetic data for both equations can be 
seen in Table 4.5. 
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Table 4.5: Design formulations and their corresponding R2 values fitted into the zero-order and 
higuchi model equations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zero order equation, Q= k0t, Higuchi equation, Q= kHt
1/2 
 
Data plotted in accordance with the zero-order equation showed linearity, with corresponding 
regression values ranging between 0.9902-0.9879. Release of drug from the matrix system 
comprising hydrophilic polymers encompasses dynamics of diffusion. Diffusion is responsible for 
drug passage from the matrix of the system to the dissolution medium subject to a concentration 
gradient. As the gradient fluctuates, drug is released and the distance for diffusion is increased.  
 
Formulation Code Zero-order Kinetics  
 
Regression Coefficient 
(R2) 
Higuchi Model Kinetics 
 
Regression Coefficient 
(R2) 
Formulation 1 0.9879 0.9955 
Formulation 2 0.9924 0.989 
Formulation 3 0.9927 0.9928 
Formulation 4 0.9964 0.9887 
Formulation 5 0.9943 0.9952 
Formulation 6 0.9969 0.9981 
Formulation 7 0.9902 0.9977 
Formulation 8 0.9918 0.9991 
Formulation 9 0.9965 0.9901 
Formulation 10 0.9946 0.9918 
Formulation 11 0.9971 0.9953 
Formulation 12 0.9953 0.9963 
Formulation 13 0.9902 0.9905 
Formulation 14 0.9927 0.9973 
Formulation 15 0.9957 0.9904 
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Therefore, drug will diffuse at a reduced rate as the distance for diffusion increases, which is 
denoted as Higuchi kinetics (Reddy et al., 2003).  
Within the context of the current study, in vitro profiles of drug release can be elucidated by Higuchi 
kinetics, as plots showed a great degree of linearity R2 = 0.9887-0.9991. However, the comparative 
complexity of the formulation and its respective constituents may imply that drug release is 
controlled via more than one kinetic process. 
4.3.10. Response optimization of s-IPN xerogel matrix  
Response optimization procedure (MINITAB®, V15, Minitab, USA) was employed to attain the 
desired levels of the chosen formulation components. An optimal formulation was fabricated 
subsequent to concurrent constrained optimization of matrix erosion, drug release, and swelling 
properties. Minimization of matrix erosion, minimization to an intermediate MDT (Mean Dissolution 
Time) for drug release and maximization of swelling were utilized for response optimization. The 
optimized levels of the independent variables and their respective predicted responses were 
determined. The optimal levels of the independent variables as well as the constraint setting used 
which would accomplish the preferred erosion, drug release and swelling characteristics are listed 
in Table 4.6. The optimized levels of the independent variables, the aim for the response, the 
predicted response (y), at the present factor settings, and the individual and composite desirability 
scores are shown in Figure 4.16 
 
Table 4.6: Formulation constraints employed for response optimization 
                       Responses                                                              Parameters 
Mean % Erosion                                                                                 Minimize 
Drug Release (Total MDT)                                                              Minimize (±13) 
Mean % Swelling                                                                                Maximize 
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Figure 4.16: Desirability plots representing the levels of GG, PEO and EPI required to synthesize 
the optimized formulation.  
 
4.4. Concluding Remarks  
This chapter detailed the use of a crosslinked PEO: GG polymer solution to formulate an s-IPN 
xerogel matrix for sustained drug delivery. Results were exhibited employing 3 variables, namely 
amount of GG, concentration of PEO, and amount of EPI (crosslinker), derived for the measured 
responses i.e. drug release and degree of swelling and erosion. A ratio of GG: PEO of 0.5g: 
1.5%w/v showed desirable drug release in the form of total MDT. A ratio of crosslinker to GG of 0.8 
mL: 1g obtained an efficient MDT of 12.5. The concentration of polymers and the ratio of 
crosslinker influenced drug release, swelling and erosion capabilities of the s-IPN xerogel. Textural 
profile analysis of the various s-IPN xerogel matrices showed that the crosslinked xerogels were 
significantly resilient and physically stable. Swelling, erosion and water content studies were 
consistent with the predicted results from the response surface analyses.  
Subsequent to formulation optimization described in the current chapter, additional 
characterization of the s-IPN xerogel component of the ODLS via physiochemical and 
physiomechanical characterization studies are described in Chapter 5 so as to evaluate the 
efficacy of the design and development of the s-IPN xerogel for ensuing in vivo studies.  
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CHAPTER 5 
CHARACTERIZATION AND FURTHER EVALUATION OF THE OPTIMIZED ORAL S-
IPN XEROGEL MATRIX FORMULATION 
 
5.1. Introduction  
An ultimate dosing regimen in drug therapy of any disease state is one which instantaneously 
achieves the desired therapeutic concentration of drug in system circulation and maintains a 
constant plasma concentration for the complete duration of treatment. Comprehensive research 
efforts have been concentrated on administering drug delivery systems targeted to the site of 
action for optimum drug bioavailability and minimization of dose related side effects (Bhardwaj et 
al., 2012). 
For drugs administered as a conventional dosage form, such as a tablet, the dosing interval is 
usually considerably shorter than the half-life of the drug, resulting in restrictions such as poor 
patient compliance, peak-valley plasma concentration-time profiles, and fluctuations in drug 
concentration which may lead to the occurrence of adverse effects. So as to overcome these 
limitations controlled release drug delivery systems are designed and developed (Bhardwaj, et al., 
2012).  
Sustained release systems include any drug delivery system that achieves slow release of drug 
over an extended period of time. If the system is successful in maintaining constant drug levels in 
plasma or target tissue it is considered a sustained release system (Chen et al., 2013; Pundir et 
al., 2013). Sustained release of drug molecules employing polymers is a deep-rooted proficiency, 
wherein polymers are rationally selected to encapsulate drug, modify and control its release from 
the delivery system in a calculated and controllable manner (Angadi et al., 2010). Controlled 
release formulations can be used to lessen the amount of drug required to illicit the same 
therapeutic effect. The ease of fewer and more effective doses improves compliance (Huang and 
Brazel, 2001).  
Among the various approaches investigated for attaining sustained release delivery systems, 
matrix tablets, predominantly those formulated via direct compression methods, are most efficient 
and remarkable from both the economic and process development perspectives (Marinich et al., 
2012). Hydrophilic matrices in particular are been increasingly experimented for controlled drug 
delivery due to their biocompatibility. Drug release from hydrophilic matrix tablets is governed by 
the formation of a hydrated viscous polymer layer at the outer boundary of the tablet which acts 
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as a barrier to drug release by preventing and opposing infiltration of dissolution medium into the 
tablet and the flow of dissolved solutes out of the matrix tablet (Sriamornsak et al., 2007; Akhgari 
et al., 2011). The chief drawback to conventional drug delivery systems is their inaptitude to 
maintain therapeutic concentrations of drugs at the target site. Overcoming this disadvantage by 
the design and development of sustained release drug delivery systems may offer a great degree 
of benefit. Sustained release s-IPN xerogel matrices are one example of such drug delivery 
systems.  
An obstacle to the successful treatment of schizophrenia with sulpiride is the reduced patient 
compliance due to high dosages and therefore, high pill burden; and secondly the low 
bioavailability observed. A sustained release formulation that would preserve plasma drug levels 
for 10-12 hours might prove efficient for once-daily dosing of sulpiride. Furthermore, the low 
bioavailability may be addressed with the incorporation of a P-glycoprotein efflux pump substrate 
such as lecithin as a formulation excipient, formulation of an s-IPN xerogel matrix system for the 
delivery of sulpiride, in order to achieve a greater bioavailability; and controlled release will reduce 
the need for multiple administrations and thus improve patient compliance. 
So as to gain insight into the physiomechanical and physiochemical properties of the optimized s-
IPN xerogel matrix various studies were conducted. Swelling and erosion were assessed in 
simulated intestinal conditions; in addition fronts movement studies were performed to evaluate 
the mechanism of drug release in terms of diffusion and erosion. Fourier Transform Infrared 
Spectroscopy and Differential Scanning Calorimetry studies were undertaken to assess the 
chemical composition and thermal characteristics respectively. Porosity analysis, Magnetic 
Resonance Imaging and Scanning Electron Microscopy were performed to evaluate the surface 
morphology and physical structure of the matrix system. In vitro pharmacokinetic analysis was 
conducted to decipher the release profile.  
5.2. Materials and Methods 
5.2.1. Materials 
Gellan gum (Gelzan™ CM,1.000kg/mol), poly (ethyleneoxide)  (POLYOX™, WSR 303, Average 
Mv ~ 300.000), (±) sulpiride, epichlorohydrin 99%, carboxymethyl cellulose (disintegrate) , sodium 
salt, and magnesium stearate (lubricant), were all purchased from Sigma Aldrich (Steinham, 
Germany), while acetone (Assay 58.08), and sodium hydroxide pearls (Assay min. 97%) were 
purchased from Merck (Darmstadt, Germany).  
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5.2.2. Fabrication of optimized s-IPN Gellan Gum- Poly (ethylene) oxide xerogel matrix 
For the crosslinked sustained release xerogel, a 1.8578%w/v PEO- 5M sodium hydroxide solution 
was prepared, in which GG was dissolved subsequently. Thereafter, EPI was added drop wise to 
facilitate IPN formation by crosslinking of GG. The fabricated gel solution was then placed in 
acetone for approximately 3 hours to assist solvent removal and pore formation. EPI crosslinking 
of polysaccharides involves the formation of links via the carbon atoms present, these chemical 
modifications to the structure of GG allows for characteristic alterations in its mechanical strength, 
degree of swelling and thus rate of drug release (Gonçalves et al., 2005; Sahin et al., 2011). On 
the other hand, the presence of PEO during the crosslinking reaction of EPI and GG results in the 
partial interaction of PEO with the crosslinking agent thus resulting in bonds formed between the 
ethylene oxide and EPI, resulting in a copolymer (EO-co-EP) (Sanchez et al., 2002). 
Subsequently, xerogel samples were allowed to dry under ambient conditions, drug was 
appropriately weighed and added to the powdered xerogel samples (1000mg max. drug loading 
capacity), and tableted using a hand operated Carver Press tableting press (Model 3851-0, S/N 
43000-904, Wabash, IN, USA) employing a compression force of 5 tons. 
5.2.3. Characterization of vibrational transitions of optimized s-IPN xerogel 
Fourier Transform Infrared Spectroscopy (FTIR) employing a spectrum 100 FTIR spectrometer 
(Perkin- Elmer, Beaconsfield, BUCKS, UK) was utilized to detect the vibrational individualities of 
chemical functional groups in the optimized xerogel samples. FTIR analysis was conducted on 
native polymers incorporated in the xerogel as well as on the optimized s-IPN xerogel as a means 
of validating the successful crosslinking reaction performed. Samples were placed on a diamond 
crystal and processed by the universal ATR polarization accessory software for the FTIR spectrum 
series at a wave number range of 650-4000 cm-1.  
5.2.4. Characterization of thermal transitions of the optimized s-IPN xerogel by Differential 
Scanning Calorimetry and Thermogavimetric Analysis 
Differential Scanning Calorimetry (DSC) curves were recorded on a Mettler Toledo, DSC 1, STARe 
System (Schwerzenback, Switzerland). The instrument was calibrated with the use of Indium 
metal (99.99%) with regards to temperature and enthalpy (Kreye et al., 2013). Accurately weighed 
samples of each (±10mg) were placed into aluminum sample holders covered and a central pin 
hole made. Samples of crude polymers PEO and GG as well as the optimized s-IPN xerogel were 
heated in sealed aluminum pans between a temperature range of 25-300˚C under the constant 
flow of nitrogen gas at a heating rate of 10˚C/minute. Thermogavimetric analysis (TGA) 
measurements were conducted with a Perkin- Elmer TGA 7 apparatus. Samples of crude PEO 
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and GG and of  optimized s-IPN xerogel, all with an approximate weight of 10mg, were heated in 
a dynamic nitrogen atmosphere from 30- 700˚C at a heating rate of 10˚C/ min, this was done in 
order to determine their respective thermal degradation properties.  
5.2.5. In vitro drug release studies 
A calibration curve for sulpiride was constructed as detailed in Chapter 3, Section 3.3.5. 
Dissolution and drug release studies were conducted employing a USP type II apparatus (Caleva, 
model 7ST, UK) at a rate of 50 rpm and temperature of 37˚C maintained by a thermometer in 
900mL of potassium phosphate buffer (pH 6.8) in triplicate. A stainless mesh ring was immersed 
in to the dissolution bath, secured below the paddle to ensure minimal floating of the sample. 5ml 
of dissolution medium was withdrawn manually at pre-defined time points during a 24 hour 
experimental study and an equal volume of drug free dissolution medium was replaced to as to 
ensure the maintenance of sink conditions. Samples withdrawn were analyzed for drug content 
by utilizing Ultraviolet Spectrometry at a wavelength of 300nm and drug release profiles were 
thereby plotted with the use of the generated calibration curve for sulpiride (soluble in phosphate 
buffer pH 6.8). The conventional system was not tested within this experimental set up due to its 
rapid dissolution characteristics.  
5.2.6. Morphological and surface structure analysis 
Scanning Electron Microscopy (SEM) was utilized in determining the surface morphology of crude 
PEO and GG, as well as providing evidence of the synthesis of s-IPN within the optimized 
crosslinked xerogel formulation. Samples of native PEO and GG as well as optimized s-IPN 
xerogel were mounted on steel stubs using double sided adhesive tape and sputter coated with 
carbon and gold palladium shadowing to ensure increased conduction of the sample employing a 
sputter coater. The coated samples were observed employing the Phenom G2 Pro SEM 
(Germany) by utilizing various magnifications at room temperature. 
5.2.7. Porositometric analysis 
Porosity evaluation was conducted employing the Brunauer- Emmet- Teller (BET) isotherm of 
nitrogen as a tool to investigate the presence and size of pores within the networked structure of 
the optimized s-IPN (n=3). An ASAP 2020 Porositometer (Micromeritics Instrument Company 
(Pty) Ltd., Norcross, GA, USA) equipped with research grade ASAP 2020 V3.01 software was 
utilized in the determination of the optimized s-IPN xerogel porous structure, such as pore surface 
area, pore diameter, total pore volume, as well as bulk and absolute densities. Samples were 
treated with a heat gradient and then evacuated with nitrogen gas (N2) for the removal of surface 
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moisture and gas particles preceding analysis. Table 5.1 below lists the parameters and settings 
used under standard conditions of temperature and pressure (STP: 0˚C and 760 torr). The 
optimized s-IPN xerogel samples were weighed to (100mg ± 10mg) and placed in a cylindrical 
sample tube. In order to reduce the total free space and thereby allow for timely degassing, a 
glass filler rod was inserted within the sample tube. The samples were then covered in an 
isothermal jacket and degassed for approximately 20 hours. The degassed samples were then 
transferred to the analysis port and immersed in liquid nitrogen preceding the analysis. The 
Barrett, Joyner and Halenda (BJH) as well as Brunauer- Emmett- Teller (BET) adsorption and 
desorption associations were generated. 
Table 5.1: Parameters utilized for the evacuation and heating phases in degassing of the 
optimized s-IPN 
Parameter Rate/Target 
  
Heating Phase   
Temperature ramp rate  10˚C/min  
Hold Temperature  30˚C 
Hold Time  1320 min  
Evacuation Phase   
Temperature ramp rate  10˚C/min  
Evacuation rate  50.0mmHg/s 
Target Temperature  40 ˚C 
Unrestricted Evacuation from 30mmHg 
Vacuum set point  500μmHg 
Evacuation Time  60 min 
 
5.2.8. Assessment of degree of mucoadhesion of the optimized xerogel matrix 
Mucoadhesion studies were performed on the optimized matrix tablet to deduce the effect of 
polymer ratios on the amount of mucoadhesion of the system (n=3). For this study a 0.1%w/v mucin 
solution prepared in USP intestinal fluid (pH 6.8) was incubated; the optimized xerogel tablet was 
placed in an orbital shaker maintained at 37˚C and 50 rpm. Concentration of free mucin in the 
solution, after a 6 hour duration, was determined by a UV spectrophotometer, at wavelength 201 
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nm(IMPLEN NanophotometerTM, Implen GmbH, München Germany),using a 10 times dilution 
factor of path-length 0.1 mm. The difference in the concentration of the mucin solution before and 
after incubation was the indication of the amount crosslinked with the xerogel tablet as seen in 
Equation 5.1 below, indicating the interaction between particles and mucin (Ping et al., 1998).  
𝑀𝑢𝑐𝑜𝑎𝑑ℎ𝑠𝑖𝑜𝑛 % =
[𝑀𝑢𝑐𝑖𝑛 𝑏𝑒𝑓𝑜𝑟𝑒] − [𝑀𝑢𝑐𝑖𝑛 𝑎𝑓𝑡𝑒𝑟]
[𝑀𝑢𝑐𝑖𝑛 𝑏𝑒𝑓𝑜𝑟𝑒]
× 100 
Equation 5.1 
 
5.2.9. Elucidation of the pertinent rheological properties of the optimized s-IPN xerogel 
The rheological properties of the optimized s-IPN xerogel were evaluated with the use of a Haake 
Modular Advanced Rheometer System (ThermoFisher, Scientific, Karlsruhe, Germany). Viscosity 
affects the rate and extent of swelling of polymer agents, thereby imparting vital insight into the 
drug release behavior within a xerogel based matrix system. Optimized s-IPN samples were 
analyzed by placing the xerogel solution on the sample stage and then immersing the C35/1˚ 
titanium rotor on to the xerogel solution while the temperature was maintained at 34˚C, while the 
shear rate was maintained at 100s-1 for 360s with viscosity readings being quantified (n=3).  
5.2.10. Textural characterization of the optimized s-IPN xerogel matrix tablet 
Optimized s-IPN xerogel matrix tablet was analyzed for its physiomechanical properties by 
performing textural analysis studies (n=3). Results based on hardness, deformation, resilience, 
and matrix rigidity were obtained from the data generated. Matrix tablets of 3mm thickness were 
subjected to analysis with the generation of force vs. time and force vs. distance profiles on a 
TX.XT plus texture analyzer (stable Microsystems, Surrey, UK) equipped with a  2mm flat head 
cylindrical probe, a 5 kg load cell and texture component V3.2 software for processing data. 
Tablets were secured on to a raised platform fitted with a central probe with a 5mm diameter 
central hole. The central probe with a 5kg weight load was lowered on to the tablet surface and 
measurement conducted. Parameters employed for textural analysis were as follows; test mode 
was compression, pre-test speed 1mm, test speed 0.5mm, post-test speed 1mm, and the target 
mode was set as; Distance (0.5mm), Strain( 10%), and a trigger force of 0.05N. 
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5.2.11. Gravimetric swelling and erosion studies 
Equilibrium water uptake and swelling studies of the s-IPN xerogel matrix tablets (n=3) loaded 
with drug was conducted by measuring the extent of swelling of the matrix in Phosphate buffered 
saline (PBS) (pH 6.8;37˚C). Samples were placed in 20ml  PBS and allowed to swell. At pre-
determined time intervals over a 24 hour test period, samples were removed from the buffer, 
surface water was removed with blotting paper and samples weighed. Equations such as, dynamic 
swelling ratio, equilibrium water content, water uptake and % erosion were employed in 
characterization of the swelling behavior of the xerogel matrix tablets (Murthy et al., 2006; Reddy 
et al., 2012). 
 
𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 𝑅𝑎𝑡𝑖𝑜 (𝑆) =
𝑊𝑡 − 𝑊𝑜
𝑊𝑜
 
Equation 5.2 
Where Wt. is the weight at time t, and Wo is the initial weight of the tablet. 
 
𝐸𝑞𝑢𝑖𝑙𝑖𝑏𝑟𝑖𝑢𝑚 𝑊𝑎𝑡𝑒𝑟 𝐶𝑜𝑛𝑡𝑒𝑛𝑡(𝐸𝑊𝐶%) =
𝑊𝑒𝑞 − 𝑊𝑜
𝑊𝑒𝑞
 × 100 
Equation 5.3 
Where Weq is the weight at equilibrium, and Wo is the weight of the initial tablet. 
 
𝑊𝑎𝑡𝑒𝑟 𝑈𝑝𝑡𝑎𝑘𝑒 % =
𝑊𝑠 − 𝑊𝑜
𝑊𝑜
× 100 
Equation 5.4 
 
Where Ws is the weight of the swollen tablet, and Wo is the weight of the initial tablet 
 
% 𝐸𝑟𝑜𝑠𝑖𝑜𝑛 =
𝑊𝑜 − 𝑊𝑒
𝑊𝑒 
 × 100 
118 
 
Equation 5.5 
Where Wo is the initial weight of the tablet, and We is the weight of the test after the erosion test. 
 
5.2.12. Determination of the diffusion, swelling and erosion fronts  
The experiment was conducted on the s-IPN xerogel, GG and PEO tablets respectively (n=3) to 
observe the radial swelling behavior and overall swelling capacity of each. In order to improve the 
visual detection of the swelling fronts, dyes were added to the PBS buffer (pH 6.8; 20ml). At pre–
defined time points, over a 24 hour period the hydrated fronts were measured using a digital caliper 
and pictures were taken using a camera with a 10X digital zoom. The focal distance was kept 
constant throughout the study, with the interface between the matrix and the dissolution medium 
at the start of the study been labeled the initial diameter, with inward movement denoted as 
negative and outward movement denoted as positive.  
5.2.13. Magnetic Resonance Image (MRI) analysis of the swelling behavior of the optimized 
xerogel matrix tablets 
s-IPN xerogel matrix tablets were imaged in phosphate buffered saline of pH 6.8 at 37˚C utilizing 
a 0.5T open – configuration Magnetic Resonance Imaging (MRI)  system ( Signa SP,General 
Electric Medical Systems, Milwaukee, WI, USA). Imaging of samples tested was obtained at 30 
minute intervals over a 24 hour test period to evaluate the extent of swelling and erosion over 
time.   
5.3. Results and Discussion 
5.3.1. Inter and intra- polymeric interaction validation of the optimized crosslinked xerogel  
FTIR spectra of the native polymers employed in the synthesis of the crosslinked s-IPN xerogel 
were analyzed in relation to the spectrum attained for the optimized formulation, to determine 
whether any components within the formulation interacted as a result of the polymer crosslinking. 
GG (Figure 5.1a) demonstrates a characteristic peak at 2850-2960cm-1 which corresponds to C-
H stretching of alkane functional groups (Krishnaraj et al., 2012; Coates, 2000); this is observed 
within the optimized formulation as a characteristic GG absorption band. The FTIR spectra of 
crude PEO depicted the functional groups present within its chemical structure, with characteristic 
bands being the O-H functional groups characteristic of alcohols in the range of 3200-3600cm-1 
and C≡C stretching depicted at a wavelength range of 2100-2260cm-1 ( Figure 5.1c) (Krishnaraj 
et al., 2012;Coates, 2000).  
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Due to the existence of NaOH within the crosslinking reaction, there is a breakdown of the O-H 
bonds, thereby leading to an interaction of the hydrogen and oxygen molecules respectively with 
other molecules, thus forming new functional groups (Durig and Fassihi, 2002).This chemical 
occurrence causes the addition of alkene groups with characteristic C-H stretching at 
wavenumbers of approximately 3276cm-1 as shown by the highlighted peak in Figure 5.1b. This 
particular phenomenon relates to a higher level of conjugation and improved stability of the 
polymer network (Coates, 2000; Krishnaraj et al., 2012). In addition, the strong O-H band at 3200-
3600cm-1 is observed within the optimized xerogel relating to the presence of alcohols or phenols 
(Coates, 2000; Krishnaraj et al., 2012).  
 
 
Figure 5.1: FTIR spectra of (a) crude GG; (b) optimized s-IPN xerogel and (c) PEO. 
 
C-N amine stretching occurred at 1560-1650cm-1 shown in Figure 5.1b, these peaks tend to occur 
at higher vibrational frequencies and are known to be associated with the degree of crosslinking 
and polymer network formation resulting in a change within the structural configuration of 
molecules (Durig and Fassihi, 2002).The prominent peak at 1606.88cm-1 is characteristic of 
aromatic ring conjugation, thus confirming the presence of an aromatic ring structure within the 
 
 
 
(a) 
 
 
(b) 
 
 
(c) 
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optimized formulation. C-H stretching at 2886.96cm-1 in Figure 5.1b within the aromatic ring 
structure, is derived from the chemical structure of crude GG, resulting in the incorporation of C-
O functional group within the aromatic structure at 1080-1300cm-1 (Coates, 2000; Krishnaraj et 
al., 2012). 
Furthermore, methyl and methylene groups at 1430-1470cm-1 were introduced within the structure 
of the optimized xerogel with the addition of RCH꞊CH2 bridges extending from the aromatic ring 
backbone. A shifting of the aromatic ether occurs at 1240cm-1 as compared to 1200cm-1 in the 
spectrum of GG. In addition, the optimized xerogel displays characteristically new bands, such as 
the addition of a methyl and methylene group at 1430-1470cm-1, alkyl ethers at 1060-1150cm-1 
and C-H out of plane bending at 800-1000cm-1. Based on the FTIR spectra the optimized xerogel 
may be characterized as an organic compound due to the presence of C-H stretch and the 
presence of aromatic bands. In addition the broad O-H alcoholic band is characteristic of the 
crystalline structure of the xerogel (Coates, 2000).  
Chemical crosslinking reactions are associated with the addition of new functional groups and 
molecular interactions between polymer chains thereby resulting in crosslinked chains (Adel et al., 
2010). This theoretical description explains the additional functional groups observed within the 
chemical structure of the optimized xerogel as compared to the crude polymers utilized.  
5.3.2. Thermal analysis of the optimized crosslinked PEO-GG based xerogel by Differential 
Scanning Calorimetry and Thermogavimetric Analysis 
Thermal characterization was conducted to identify any irregularities or damaging alterations to 
the sample after the crosslinking reaction as well as to determine the thermal stability of the 
potential drug delivery system. In crosslinked systems, the glass transition temperature (Tg) is 
dependent on the degree of crosslinking. The relationship between Tg and crosslinking is a 
proportional one, with an increase in crosslinking degree there is a corresponding increase in the 
Tg temperature (Mettler Toledo, 2001).  Differential Scanning Calorimetry (DSC) results shown in 
Figure 5.2a depict that the Tg for the optimized formulation was 67.74˚C with a crosslinking 
concentration of 4%v/v. Furthermore, DSC data for the optimized formulation showed an 
endothermic melting peak at a temperature of 101.65˚C thus indicating the melting temperature 
of the crosslinked polymer. The optimized xerogel displays a larger relaxation peak when 
compared to the crude polymers as seen in Figure 5.2a. This is defined by the lower integral value 
of PEO the crude polymer compared to the higher  -274.90mJ of the optimal xerogel thus indicating 
that more energy was required from the heating system (for the optimized) to allow for melting to 
occur. An additional exothermic peak at a temperature of 224.59˚C is identified within the DSC 
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results, corresponding to crystallization on decomposition. This represents the phase change of 
the sample from a melted (liquid) state to a solid crystalline solid.  
 
Figure 5.2: DSC Thermograms of a) Gellan Gum b) Optimized s-IPN xerogel c) Polyethylene 
Oxide  
 
Thus DSC shows that the crosslinking reaction does affect the thermal properties of the optimized 
formulation yet maintains its stability. Tg is defined as the temperature at which a large variety of 
coordinated molecular motions occur. Therefore below 67.74˚C the amorphous polymer chains 
are stationary with only vibrational motion and short range rotations occurring. As the temperature 
increases to 67.74˚C and above the polymer chains gain mobility and relaxation. At 67.74˚C the 
sample begins to soften and is described as the melting of the amorphous region of a semi-
crystalline sample. As the temperature reaches 101.65˚C the sample undergoes melting and then 
proceeds to crystallization of the polymer at 224.59˚C.  
 
 
 
 
(a) 
 
 
(b) 
 
 
(c) 
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Thermogavimetric analysis (TGA) was employed to further assist in the interpretation of thermal 
properties of the optimized xerogel sample by utilizing heat and stoichiometric ratios to determine 
the percentage by mass of solute. The optimized xerogel displayed weight loss in the region 
showing an extrapolated onset of 250˚C and an endset of 350˚C which is described as the 
decomposition temperature (Figure 5.3). The first derivative on a TGA curve (Figure 5.3) 
designates the point of highest rate change in weight loss (inflection point). The inflection point 
within the optimized s-IPN xerogel sample was observed at a temperature of 240.33˚C. The 
observed inflection point may be attributed to chemical reactions such as decomposition, 
crystallization or physical transitions due to reactions such as evaporation desorption or drying.  
Figure 5.3: TGA thermogram of optimized s-IPN xerogel. 
The resulting TGA curve illustrates a multistep decomposition process with two distinct weight loss 
steps. The first weight loss step occurs at an onset temperature of 219.67˚C (Figure 5.3) due to 
drying of residual moisture within the sample. The second weight loss step is at an onset 
temperature of 414.87˚C indicating decomposition of the sample on melting (Figure 5.3). On 
removal of the sample after TGA testing the sample presented black in color, this change in 
sample appearance can be explained by the pyrolysis of organic samples under the influence of 
nitrogen.  Polymers present within the sample turns a carbon black upon pyrolysis and when 
exposed to an air environment it burns (Mettler Toledo, 2001). 
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5.3.3. Construction of calibration curve for ultraviolet spectrophotometric determination of 
bioactive release from optimized s-IPN xerogel matrix 
A calibration curve for sulpiride was constructed in PBS (pH6.8; 37˚C) using a known series of 
concentrations of sulpiride as detailed in Chapter 3, Section 3.2.9 and 3.3.5.  
5.3.4. In vitro drug release determination of optimized s-IPN xerogel matrix tablets 
Drug release from hydrophilic based matrix systems is considered a multifaceted interaction 
between dissolution, diffusion, and erosion. Generally, drug release from controlled release matrix 
tablets encompassing a bioactive and hydrophilic polymer, as is the case in the current research; 
release ought to ideally follow three steps.  i) Dissolution medium penetration into the tablet matrix. 
ii) Swelling in conjunction with dissolution or erosion of the matrix. iii) Passage of the dissolved 
bioactive agent, either via the hydrated matrix or from the eroded fragments of the tablet, into the 
dissolution medium (Shoaib et al., 2006).  
In order to investigate the in vitro drug release various kinetic models were employed to describe 
the mechanism of release kinetics. Therefore, to investigate the mechanism of drug release, 
release data obtained via in vitro dissolution studies were analyzed utilizing zero order, first order, 
Higuchi, Korsmeyer, and Hixson-Crowell mathematical models. The following plots were made: 
cumulative % drug release vs. time (zero order); log cumulative % drug remaining vs. time (first 
order); cumulative % drug release vs. square root time (higuchi); log cumulative % drug release 
vs. log time (Korsmeyer- Peppas) and cube root of % drug remaining vs. time (hixson-crowell) as 
seen in Figure 5.4.  
For analytical completion of drug release, release data of sulpiride obtained via dissolution studies 
was plotted as fractional release vs. time. The resulting straight line specifies zero order release 
kinetics in accord with the zero order equation (Q=Q0+k0t). Linear regression analysis of the data 
produces the equation; c = 0.1136t and an R2 value of 0.9956. Thus, the rate of dissolution is k0= 
0.115 mgL-1 h-1. 
Table 5.2: Zero-order kinetic data.  
 
 
 
Linear regression analysis of zero-
order release plot (Q=Q0+k0t) 
c = 0.1136t 
R2= 0.9956. 
k0= 0.115 mgL
-1 h-1 
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Figure 5.4: Plots of drug release based on the respective mathematical models (n=3). 
Hence, the optimized formulation allows for steady sustained release of the bioactive with the drug 
release rate being independent of concentration, from within the gel matrix. Sulpiride diffuses 
(a) 
(b) 
(c) 
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through the outer gel layer, which in turn undergoes erosion permitting additional dissolution 
medium penetration into the matrix core. Within the zero order and first order plots, the obtained 
R2 value was 0.99 and 0.64 respectively, thereby confirming drug release as zero order, 
independent of drug concentration. The Higuchi equation plot was linear with an R2 value of 0.996 
(Figure 5.4) demonstrating the release of bioactive from the matrix as a square root of time. The 
dissolution data was also plotted into the Hixson-Crowell cube root law equation applicability of 
the data (R2 0.9703) which indicates an alteration in surface area and diameter of the matrix tablets 
via the progressive dissolution as a function of time.  
By means of integrating release data into the Korsmeyer equation the mechanism of release can 
be obtained, where n is the release exponent, indicative of mechanism of drug release. For the 
Korsmeyer equation an R2 value of 0.9943 and the value of the release exponent in sulpiride 
sustained release obtained as 0.85 which follows anomalous transport (0.45<n<0.89). However, 
the power law can only provide restricted understanding into the precise release mechanism of 
the bioactive (Dash et al., 2010; Sharma, et al., 2014).  
5.3.5. Assessment of the surface morphology of the optimized crosslinked xerogel 
Scanning Electron Microscopy (SEM) was employed to evaluate the surface morphology of the 
optimized xerogel formulation. This evaluation was utilized to assess the difference in porosity and 
surface morphology of the optimal xerogel before and after swelling in phosphate buffered saline 
of pH 6.8. SEM images for the optimized xerogel (Figure 5.5) revealed a consistently porous 
crystalline surface morphology with noticeable crevices cracks and pores.  
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Figure 5.5: SEM images of A) optimized xerogel before swelling B) optimized xerogel after 
swelling C) pure polyethylene oxide D) pure gellan gum. 
 
The results obtained from SEM imagery showed, as expected, a semi- porous solid matrix. The 
matrix appeared to have a solid surface with interconnecting networks as well as the presence of 
interspersed pores (Figure 5.5b). The observed pores are generally circular or asymmetrical 
through the matrix surface area. Entry of aqueous medium into these pores allowed for the 
swelling of the polymer chains and thus entrapment of drug within the porous structures.   
 
SEM imagery of the optimized xerogel post swelling show a prominent increase in pore size and 
a visible increase in the polymer density. The xerogel forms structured pores surrounded by thin 
folds of polymer. This further ascertains the effect of swelling and pore formation on the resulting 
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s-IPN xerogel for controlled release of drug from the system. The comprehensive crosslinking of 
the crude polymers indicated by the lack of excess polymeric residue indicates a high degree of 
inter-polymeric structure and thus suggests a compact structural integrity.  
5.3.6. Determination of xerogel porosity  
Porosity analysis was conducted in order to determine the volume of distribution of pores present 
within the optimized xerogel as observed in surface morphology evaluation studies. Pore size was 
also investigated. It was determined that pores contained in the s-IPN xerogel were essentially 
microporous. Pores ranged between the sizes of 67.448 - 70.390Å in diameter. The total pore 
volume extended between 3.368 - 3.5402m2/g indicating an increased pore volume which was 
anticipated. As discussed above, the presence of pores within the matrix system allows for 
entrapment of drug within the porous structures upon swelling. Therefore, the presence of 
microporous sized pores is beneficial so as to permit controlled drug release behavior. Table 5.3 
summarizes derived porosity data.  
Table 5.3: Summary of porosity data obtained for the optimized xerogel.  
Measured Characteristic Optimized s-IPN xerogel formulation 
Single Point Surface area 1.9952 m2/g 
BJH: Cumulative surface area of pores Adsorption: 3.368 m2/g  
Desorption: 3.5402 m2/g 
BJH: Cumulative volume of pores Adsorption: 0.005926 cm2/g  
Desorption: 0.005970 cm2/g 
BJH Adsorption average pore diameter (4V/A) Adsorption: 70.390 Å 
Desorption: 67.448 Å 
 
5.3.7. Determination of degree of mucoadhesion 
Mucoadhesive drug delivery structures employ the attractive forces present between mucus and 
polymeric drug molecule carriers. Mucoadhesive structures allow for localization of the drug 
delivery system within a specified target site thereby prolonging residence time. This particular 
mechanism greatly enhances the bioavailability of drugs. Hence, understanding the interactions 
between mucin and respective polymers within the physiological environment is vital for the 
rational design and development of mucoadhesive delivery systems (Peppas and Huang, 2004).  
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Mucoadhesive experimentation of the optimized tablet displayed a mucoadhesion of 74.2%. The 
observed degree of mucoadhesion may be attributed to the excipients utilized during the 
formulation process. GG and PEO are known for their excellent mucoadhesive characteristics 
(Gaikwad and Bhatia, 2012).Thus the resulting mucoadhesion can be attributed to the additive 
mucoadhesive properties of each of the above mentioned polymers.  
5.3.8. Rheological characterization of non-drug loaded xerogel polymeric solution 
employed in matrix formation 
Rheological characteristics, in particular the viscosity of polymeric solutions regulates whether the 
formulated solution may undergo precipitation, in addition it influences the quality and degree of 
swelling once formulated into a solid matrix system.  The solution parameters for the non-drug 
loaded formulation was 0.5%w/v GG, 1.858%w/v PEO, and 0.4mL EPI, the drug loaded formulation 
comprised of the same solution parameters with 50mg sulpiride included. The resulting viscosity 
at shear rate of 100/s (mPas) standard derivative was 2938.1 and 1815 respectively. As observed 
the addition of drug into the xerogel solution results in an increased viscosity. 
The shear rate (γ) is directly related to the applied stress (σ), the resulting proportionality is the 
coefficient of dynamic viscosity (η).  With a high degree of viscosity and a corresponding low flow 
rate a thick boundary layer is formed which becomes thinner as the viscosity drops and the flow 
rate increases (Schnaare et al., 2005). The resulting rheological data indicates non-Newtonian 
behavior of the s-IPN xerogel solution. This deduction was made on the basis that the xerogel 
begins to flow as soon as the shear stress is applied, with the slope progressively decreasing with 
a consistent increase in shear rate. A degree of thixotropy is also observed, after the xerogel is 
exposed to a particular shear rate, the shear stress and viscosity will decrease with time. When 
the applied shear stress is removed, even if the structure has been disrupted it is reversible; as 
thixotropy is defined as a reversible time-dependent decrease in apparent viscosity.  
Samples that depict thixotropic behavior are commonly composed of asymmetric macromolecules 
capable of interacting by numerous secondary bonds so as to produce a loosely linked three-
dimensional structure. Thus the sample is gel- like when un-sheared. Upon shearing these bonds 
become disrupted, so flowing elements align and the viscosity decreases (Schnaare et al., 2005). 
5.3.9. Mechanical evaluation and validation of structural integrity of the optimized xerogel 
matrix 
Mechanical evaluation of the matrix system, PEO-GG blend was conducted. For all formulations, 
a typical force-distance and force-time profile was generated to evaluate deformation energy, 
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rigidity, resilience, Brinell hardness number (BHN). The force vs time profiles for the optimized 
xerogel matrix tablet and the PEO-GG blend tablet are depicted in Figures 5.6 and 5.7 
respectively. In the textural analysis profile, the gradient represents the matrix flexibility (rigidity), 
while the area under the curve depicts the deformation energy. Data obtained suggests that the 
optimized formulation has superior mechanical properties.  
Values of resilience and deformation for the optimized tablet and the PEO-GG blend tablet were 
found to be 46.78%, 54.16%, 0.008J, and 0.013J respectively. Notably both formulations allowed 
for very high matrix resilience. This is due to the high degree of saturated ionic bonding present 
in both. The matrix rigidity values obtained varied greatly. The PEO-GG blend tablet displayed a 
rigidity of 83.119 N.mm as compared to the 104.730N.mm of the optimized matrix tablet. This 
phenomenon is attributed to the crosslinking present within the optimized formulation thus allowing 
for greater inter-polymeric bonding thereby forming a greater polymeric network. The resulting 
BHN showed that the optimized formulation is characterized by a more rigid and solid structural 
integrity.  
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Figure 5.6: (a) Textural analysis Force vs. Time profile for the optimized xerogel matrix tablet and 
(b) Textural analysis Force vs. Time profile for the PEO-GG blend tablet.   
 
5.3.10. Gravimetric swelling and erosion analysis  
Hydrophilic matrix systems are being progressively investigated for their utility within controlled 
release drug delivery systems. Hypothetically, drug release from hydrophilic matrix tablets were 
controlled by the formation of a hydrated viscous barrier layer around the tablet which acts by 
opposing penetration of aqueous medium into the tablet as well as limiting the transport of 
dissolved solutes out of the matrix. The characteristic hydration of the polymer and the ensuing 
physical properties of the hydrated gel layer may significantly impact drug release (Sriamornsak 
et al., 2007). Swelling data obtained for the optimized xerogel matrix tablet via gravimetric analysis 
indicated the rate at which the formulation absorbed water from the surrounding dissolution media 
and the degree to which swelling occurred (Figure 5.7). Alterations in weight and an increase in 
the degree of swelling began when the sample was placed in the dissolution media and continued 
up to eight hours into the experiment. The percentage of remaining matrices reflects the amount  
(a)                                                                                            (b) 
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of polymer dissolved and the erosion of the polymer matrix within dissolution medium during the 
course of dissolution testing. Weight loss from the matrix tablets increased gradually with the 
swelling time, as depicted by the percentage remaining tablet mass.  
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Figure 5.7: (a) % water uptake vs. time and (b) % erosion vs. time of the optimized xerogel matrix 
tablet.  
 
 
(a)  
 
 
 
 
 
 
 
 
 
 
(b) 
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Swelling ranged between 346.85 - 685.76% over the 24 hour experimental time period. Erosion 
of the matrix was observed to range from 77.62 - 87.27%; both swelling and erosion displayed 
paralleled patterns over the test period, with an increase in percentage swelling and erosion 
observed for the first 8 hours followed by a gradual reduction in both up until 24 hours. By means 
of visual observation it was found that the matrices appeared to swell immediately, once in contact 
with the dissolution medium. A viscous gel layer was formed when they were placed in the reaction 
vessel in direct contact with dissolution medium. The hydrated surface layer formed a viscous 
transparent gel as it underwent swelling and disintegrated into large particles of gel upon erosion, 
in contrast the core of the matrix still untouched by aqueous medium remained intact and non- 
hydrated (Sriamornsak et al., 2007).  
Resulting from research investigation on the swelling and dissolution behavior of polymeric matrix 
systems, it has been established that the thickness of the continuously forming hydrated viscous 
barrier layer upon water penetration was proportional to the square root of time, where the swelling 
front was faster than the eroding front. The constant thickness of the hydrated gel layer and zero 
order drug release kinetics could be achieved when the swelling and erosion fronts synchronized 
their movements as observed based on data obtained from the gravimetric analysis of the 
optimized PEO-GG crosslinked xerogel matrix tablet (Yin et al., 2013).   
5.3.11. Evaluation of the diffusion, swelling and erosion fronts of the matrix system 
Dissolution medium penetration into a swellable matrix system creates defined boundaries (fronts) 
which isolate various phases of the matrix upon swelling. Lee and Peppas (Lee and Peppas, 1987) 
have labelled these boundaries as the dissolution/erosion fronts (Escudero et al., 2010). Front 
movement studies were conducted with the purpose of obtaining useful information in order to 
gain a better understanding of the drug release mechanism from the optimized s-IPN xerogel 
matrix. According to Kiil and Dam-Johansen (Kiil and Dam-Johansen, 2003), for swellable 
matrices there are three proposed fronts observed during front movement studies. They are i) 
Swelling front, located between the immobile glassy polymer and its rubbery gel layer, ii) Diffusion 
front, between the undissolved drug and the dissolved drug within the gel layer, and iii) Erosion 
front, which is located between the matrix and the dissolution medium as depicted in Figure 5.8 
below (Escudero et al., 2010). 
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Figure 5.8: The theoretical fronts observed for s-IPN xerogel matrix systems and the respective 
digital images obtained during the front movement study conducted for the optimized matrix tablet. 
 
 
 
 
 
 
 
 
 
Figure 5.9: Graphical representation of the fronts present and their positions over a 24 hour test 
period.  
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Dissolution medium penetration through pores with a greater size regulates the position of the 
water uptake (swelling) front. As the matrix becomes involved in water uptake; a saturated layer 
of dye forms.  This phenomenon is due to dye diffusion toward the core of the tablet. The 
crosslinked xerogel present in zone 1 is in its crystalline form since water has not yet infiltrated 
and plasticised the matrix. The movement of macromolecules within zone 1 is very slow thus 
leading to a reduction in diffusion rates of dissolution medium. As dissolution medium penetrates 
the solid matrix (Figure 5.8), it attaches itself between the hydrogen bonds of adjacent polymer 
chains. As additional dissolution medium becomes inserted between the polymer chains, 
intermolecular forces weaken. The chains initially begin to inhabit more space, thus resulting in 
swelling of the polymer. As the dissolution medium penetrates into the matrix it fills voids between 
the polymer chains and thereby diffuses into denser regions of the polymer matrix (Escudero et 
al., 2010). 
However, the movement of polymer chains in regard to swelling in zones 2 and 3 respectively are 
greatly increased as compared to zone 1, therefore resulting in higher diffusion rates of dissolution 
medium into the matrix. The diffusion front is described as the boundary between the undissolved 
and dissolved drug, along which drug diffusion occurs. Therefore, drug dissolution occurs at the 
diffusion front allowing dissolved drug to successively diffuse in a radial direction towards the 
erosion front. A plot of front position against time in hours for the optimized s-IPN xerogel tablet 
was made. The plot in Figure 5.9 shows the progressive position of the respective fronts over a 
24 hour period.  
The mobile erosion front is also accurately estimated by the model up to the point at which the 
swelling front has reached the middle of the matrix which is up to approximately 8 hours of 
experimentation. The location of the erosion front is a function of the position of the swelling front, 
as the swelling front disappears; the erosion front becomes immobile and constant. It is clearly 
evident from the observed experimental data in Figure 5.9 that although the erosion front seems 
to be immobile once the swelling front disappears, it does continue in a constant fashion to allow 
for further expansion of the matrix. Once the swelling front reaches the center of the matrix the 
dissolution medium concentration at all points in the matrix is greater than the threshold 
concentration for swelling. Therefore, the extended expansion of the matrix is due to polymer 
chains swelling within the gel layer, most likely due to additional dissolution medium absorption.  
Resulting data showed an outward movement of the diffusion front thus indicating the occurrence 
of the swelling front overcoming drug diffusion. In conclusion, the existence of the distinct swelling 
and erosion fronts indicate that the optimized matrix can be described as a swellable matrix tablet. 
Furthermore drug release could be a function of swelling and diffusion mechanisms. 
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5.3.12. Magnetic Resonance Imaging of the optimized s-IPN xerogel matrix tablet 
Magnetic resonance imaging (MRI) has been employed in the study of internal mechanisms 
underlying in vitro drug release behavior in solid dosage forms, so as to observe the events 
involved in pharmaceutical processes. Hydration of a system reinforces the performance of 
various solid dosage forms, many studies have utilized MRI to detect the internal events occurring 
as a result of solvent penetration.  
Figure 5.10: MRI imagery of xerogel matrix tablets over 24 hours. 
 
Following ingestion of a solid dosage form surface polymers hydrate and swell to form a viscous 
gel layer. It is this gel layer that acts as a barrier to bioactive efflux and solvent influx into and out 
of the solid dosage form, thereby preventing matrix disintegration and prolonging the rate of drug 
release. Water soluble bioactives seem to endure a diffusion controlled release via the gel layer,  
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Whereas insoluble bioactive agents are released from the outer surface of the gel layer via surface 
erosion.  MRI may be utilized to evaluate the extent and rate of polymer swelling thus providing 
evidence of the functionality of hydrophilic matrices (Richardson et al., 2005). It was possible to 
visually determine the extent of swelling and gel layer thickness of the optimized xerogel matrix 
tablet. Figure 5.10 shows that upon hydration, the matrix expanded predominantly. This observed 
phenomenon can be attributed to the release of the tablet compression forces employed during 
the formulation process.  
Based on MRI images, three distinct regions of the matrix system can be observed. These are i) 
the peripheral region observed as a white hazy area (Figure 5.10i) comprising of freely mobile 
polymer chains which are undergoing dissolution and diffusing into the bulk dissolution medium ii) 
the gel layer in which the polymer chain’s mobility is reduced attributable to inter-polymeric 
cohesive forces observed as the grey shaded region (Figure 5.10h), and iii) the core region, within 
which the mobility of polymer chains is restricted so that it appears to be solid which is seen as 
the black shaded region (Figure 5.10a).  
Determination of the resulting gel structure and the evaluation of the individual constituents are 
considered vital information due to dissolution medium penetration and polymer swelling directly 
affects the mechanism and kinetics of drug release. Specifically, the parting of the swollen glassy 
layer from the gel layer is a critical factor attributing to the understanding of drug release. This is 
due to polymer chains relaxing within dissolution medium and thereby forming larger voids to allow 
for drug to diffuse through, thus the drug release rate is directly proportional to the extent and 
thickness of the swollen gel layer.  
As seen in Figure 5.8 the optimized xerogel matrix displayed the formation of a thick gel layer thus 
creating a barrier to drug release. As time progressed the gel layer became thicker and results in 
erosion of the surface polymer chains, as this occurs it allows for the penetration of more 
dissolution medium into the matrix, therefore allowing for dissolution medium to fill the voids and 
aid in drug diffusion and finally dissolution within the bulk of the dissolution medium. An important 
observation made from MRI is the presence of air bubbles, seen as minute white spheres with a 
slightly darker core; this is a characteristic feature of xerogels as they are composed of pores.  
It can be deduced that drug release is based on a complex interplay of swelling, erosion and 
diffusion from the matrix system. Within the context of the current system the bioactive release is 
sustained due to the fact that the formation of the gel layer acts as a rate limiting step and a barrier 
to the diffusion and dissolution of the drug in the dissolution medium. 
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5.4. Concluding Remarks  
The use of matrix based systems has been explored and is proven to have the most benefits due 
to its ease of administration and improved compliance. Modification via crosslinking of hydrophilic 
polymers to form an s-IPN xerogel matrix is a novel approach; the resulting system displayed 
desirable release kinetics and physiomechanical properties.  The derived optimized formulation 
showed an admirable swelling capability which is vital to the observed drug release kinetics; in 
addition, when in vitro drug release data was fitted into the various mathematical models the 
system conformed to zero-order release. Overall, the system has proven to be efficient in 
prolonging the drug delivery of sulpiride, in addition it displays good physiomechanical 
characteristics which is vital to maintain the integrity of the system post oral administration.  
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CHAPTER 6 
PRELIMINARY DESIGN OF THE MULTI-LAYERED BIOADHESIVE POLYMERIC 
INTESTINAL PATCH FOR PULSATILE DRUG DELIVERY (IPRPS) 
 
6.1. Introduction  
As previously outlined schizophrenia often presents as schizoaffective disorder which requires the 
concomitant treatment with antipsychotic and mood stabilizing agents. Valproic acid a well-known 
mood stabilizing agent also used in the treatment of epilepsy, in particular has been shown to 
improve behavioral and cognitive performance, suppress neurodegeneration and 
neuroinflammation (Chiu et al., 2013).  
In a study conducted by Suzuki and co-workers atypical antipsychotics were augmented with 
valproic acid in severely compromised Japanese patients presenting with chronic schizophrenia. 
The mechanism of valproic acid augmentation of atypical antipsychotics includes the known action 
on GABAergic neurons, thus potentiating inhibitory neurons and reducing agitation and 
aggression. Additional mechanisms may be linked to the synergistic increase in dopamine or 
acetylcholine release in the prefrontal cortex (Suzuki et al., 2009).  
Overall the study displayed significant improvement in clinical outcomes, valproic acid 
augmentation was generally well tolerated, however the few serious side effects observed were 
thrombocytopenia, anemia, and sedation (Suzuki et al., 2009).  
The precipitation of adverse effects in valproic acid augmentation of antipsychotics may lead to a 
reduction in compliance to therapy and hence treatment resistance and poor clinical outcomes 
(Belcastro et al., 2013), this may be related to multiple daily administrations required and thus 
prolonged exposure to the drug.  
Efficacy and tolerability of drug therapies could be conspicuously enhanced by the design and 
development of delivery systems envisioned to timely release drug post administration; thus 
providing pharmacological protection when necessary while avoiding unnecessary prolonged 
patient exposure to the bioactive. In addition, when multiple dosing regimens are required 
repeated pulsatile drug delivery patterns may assist in improving patient compliance when the 
bioactive agent is not suited for sustained release formulations, one such example would be due 
to the development of tolerance (Gazzaniga et al., 2008), as is the case with valproic acid.  
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For this reason pharmaceutical scientists have focused on drug delivery systems that allow for the 
desired amount of drug to be made available at a predetermined time at the site of action (Gupta 
et al., 2002). This may be referred to as pulsatile release, generally pulsatile release is meant as 
the timed release of drugs following programmed lag phases, in this case only system design 
based mechanisms are operating which is independent of the environmental variables (Gazzaniga 
et al., 2008).  
The current study details a novel drug delivery system that offers numerous advantages. One of 
the proposed strategies for achieving greater levels of site specific drug absorption at the intestinal 
epithelium is the use of multilayered intestinal patches. Once the patch is in contact with the 
mucus; surface drug flows unidirectionally through the intestinal wall into the bloodstream at a rate 
that is controlled by the rate controlling layer (Tao and Desai, 2005). 
For pulsatile delivery of valproic acid in the treatment of schizoaffective disorder, the second 
component of the ODLS delivery system will be formulated as bioadhesive multilayered intestinal 
patches. A schematic representation of the proposed patch is shown in Figure 6.1.  
 
Figure 6.1: Assembly of the bioadhesive multilayered intestinal patches 
 
The current system consists of layers; a backing layer composed of an impermeable ethycellulose 
polymer; a drug loaded layer comprised of sodium alginate and Poly(ethyl acrylate-co-methyl 
methacrylate-co-trimethylammonioethyl methacrylate chloride (Eudragit® RS 100); a 
mucoadhesive layer encompassing chitosan and hypromellose amalgamated with soybean lectin 
and a mucus cleaving layer comprising an N-acetyl cysteine (NAC): gellan gum: chitosan blend.  
Backing Layer 
Drug Loaded Layer 
Mucoadhesive Layer 
Mucus Cleaving Layer 
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Film formation from polymeric solutions is a reasonably forthright procedure as the selected 
polymer/s is already dissolved as shown in Figure 6.2. The polymeric solution spreads over the 
film casting surface, and as the solvent evaporates, polymer chains interpenetrate, passing from 
a gel state to then forming a film with additional drying. Polymer chain interpenetration arises at a 
particular concentration which is the reciprocal of the intrinsic viscosity of the polymeric solution. 
Intrinsic viscosity is the rise in viscosity precipitated by the dissolved polymer and thus is an 
indication of hydrodynamic interaction between the polymer/s and solvent. The rate at which 
solvent evaporates is vital in the film formation process (Felton, 2013).  
If a solvent evaporates too slowly the film casting surface becomes over wetted resulting in the 
film being unable to be removed easily; conversely, if solvent evaporates too quick the polymer 
solution begins to dry before impacting onto the casting surface thereby leading to an uneven film 
being formed with a tendency to form cracks.  
 
Figure 6.2: Mechanism of polymeric film formation by the film casting method.  
 
6.1.1. Selection of independent variables for input into a Central Composite Design 
Based on the preliminary results conducted, the formulation component (input variables) for the 
bioadhesive layer that influenced the mucoadhesion, swelling and membrane strength of the 
formulation (measured responses) were identified in conjunction with their upper and lower limits. 
The same was done for the drug loaded layer with the measured response being drug release 
kinetics. Factors with their corresponding factor levels were selected for the bioadhesive 
multilayered intestinal patch component of the ODLS so that a mathematical model was 
generated. Polymers, crosslinking agents, active formulation excipients and the model drug 
employed in the respective layers of the system design are outlined below:  
Spreading 
Solvent Evaporation  
Film Casting Surface/ Mold 
Film Forming Polymeric Solution  
Polymeric 
particles Contact Film Formation 
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Sodium alginate is a water soluble polymer which may be easily crosslinked with the use of other 
multivalent cations such as calcium. It is the major structural polysaccharide found in brown 
seaweed. In its crude state alginate exists as calcium, magnesium and sodium salts of alginic acid 
which provides flexibility and strength to the seaweed.  Alginate is a linear copolymer of –d-
mannuronic acid and –I-guluronic acid linked residues arranged in homopolymer blocks, alginate 
is commonly employed in bioencapsulation (Himadri and Samit, 2014; Sellimi et al., 2015). 
Poly (ethylacrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride 
(Eudragit® RS 100), is a copolymer synthesized from acrylic and methacrylic acid esters, 
consisting of a low degree of quaternary ammonium groups. RS100 has a lower consistency of 
charged groups and is considered less permeable to water. It is capable of swelling and hence 
controlled drug delivery (Pignatello et al., 2001; Barzegar-Jalali et al., 2012).  
Chitosan, derived from crab and shrimp shells has been employed in food and pharmaceutical 
fields due to its outstanding antimicrobial properties, biocompatibility, and biodegradability (Zhang 
and Zhao, 2015). It is derived from chitin a non-starch based material, which is similar in structure 
to cellulose. It’s the second most abundant biopolymer in nature; the partial alkaline deacetylation 
of chitin produces the cationic polysaccharide, chitosan. Chitosan is soluble in organic solvents 
such as formic and citric acid. The linear biopolymer is made up of two monosaccharides, namely 
N-acetyl-glucosamine and D-glucosamine, which are linked by glycosidic bonds (Yang et al., 
2015).  
Hypromellose, or hydroxypropyl methylcellulose (HPMC) are water soluble cellulose ethers which 
are synthesized by substituting the hydroxyl group of anhydroglucose with methoxy/ 
hydroxypropyl groups. The resulting cellulose ethers may undergo thermos reversible sol-gel 
transitions (Almeida et al., 2014). Hypromellose is a commonly utilized pharmaceutical excipient 
with low toxicity, easily accessible and cheap.   
Soybean Lectin (agglutinin), is a carbohydrate–binding protein, it belongs to a heterogeneous 
group of proteins that reversibly bind specific mono or oligosaccharides. Lectins have been 
isolated from various plants, animals and bacteria. They are classified into 5 subgroups based on 
their respective origins (Guo et al., 2013). Soybean lectin is a legume derived lectin isolated from 
seeds of soybeans. Soybean lectin displays specificity to N-acetyl-D-galactosamine and D-
galactose, it is one of the best characterized lectins, which consists of four 30 kDa sub-units with 
two polysaccharide binding sites per 120 kDa (Panda et al., 2014).  
The focus of this Chapter lies in the development and optimization of the bioadhesive and drug 
loaded layers of the intestinal patch component of the ODLS through a systematic approach of 
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experiments, employing a two level, face-centered, randomized Central Composite Design. The 
optimized formulation will provide the most ideal drug release profile and mucoadhesion.  
Subsequent to identification of the polymer combinations for the respective mucoadhesive and 
drug loaded layers, the upper and lower limit variables of the formulations was determined. The 
resultant variables are illustrated in Table 6.1. The limits were determined via ensuring that the 
fabricated formulations met the criteria required for appropriate mucoadhesion and drug release 
respectively.  
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Table 6.1: The identified variables and their corresponding upper and lower limits for input into 
the Central Composite Design. 
Polymer 
employed 
Lower Limit (%w/v) Upper Limit (%w/v) 
Mucoadhesive Layer 
Chitosan 0.05g - Anything <0.05g did not 
demonstrate satisfactory film 
forming properties. These 
formulations tended to stick to 
the mold surface and could not 
be peeled off. There was also an 
observed reduction in 
mucoadhesion.  
0.25g- Formulations containing ˃0.25g resulted in 
solutions that were too viscous for appropriate film-
casting and films formed were not uniform and 
consistent in surface structure.  
Hypromellose 0.05g- Formulations containing 
<0.05g demonstrate poor 
mucoadhesion properties and 
not form good films, films 
formed were too thin and prone 
to tearing.  
0.15g- Formulations containing ˃ 0.15gdid not form 
viable films, the resulting polymeric solution was too 
viscous and stick to work with.  
Citric Acid 0.15g- Formulations containing 
<0.15g did not dissolve the 
chitosan sufficiently. Solutions 
remained murky  
0.3g- Formulations containing ˃0.3g resulted in 
solutions that had a residue of citric acid and chitosan.  
Drug Loaded Layer 
Eudragit® RS100 0.1g- Formulations 
with <0.1g did not 
form viscous 
solutions and were 
unable to form films 
and thus could not 
allow for the 
required drug 
release.  
1g - Formulations comprising ˃1gformed relatively 
viscous solutions that were capable of film-casting, 
however, they formed brittle films that were prone to 
cracking and breakage.  
Calcium Chloride 0.01g- Formulations 
containing <0.01g 
did not sufficiently 
crosslink the sodium 
alginate: Eudragit 
RS100 blend and 
thus could not 
control drug release. 
0.1g- Formulations of ˃0.1g crosslinked the blend 
successfully, however the resulting solution was far too 
viscous and could not undergo film-casting 
methodology.  
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6.2. Materials and Methods 
6.2.1. Materials  
Chitosan  (deacetylated chitin) medium molecular weight, Citric acid ACS reagent ≥ 99.5 %Mw 
192.12 g/mol, sodium valproate ≥ 98% Mw 166.19 g/mol, hypromellose (hydroxypropyl)methyl 
cellulose 2910, sodium alginate, glycerin Mw 92.09g/mol, potassium phosphate monobasic Mw 
136.09 g/mol, Mucin, from porcine stomach were all procured from Sigma-Aldrich® (St. Louis, 
USA). Lectins (Bio-Research products (Cherry St. North Liberty, USA), Methacrylic acid 
copolymer (Eudragit RS 100) (Degussa, Röhm GMbH, Pharma Polymers, Germany) and calcium 
chloride dihydrate 99% was purchased from Rochelle Chemicals (Johannesburg, South Africa) . 
All other reagents were of analytical grade and are used as received.  
6.2.2. Construction of a Randomized Central Composite Design for optimization of the 
bioadhesive multilayered intestinal patch component of the ODLS 
A model independent approach (Minitab® V15, Minitab Inc. PA, USA) was employed for 
optimization of the intestinal patches. The input factors or independent variables were the 
concentration of chitosan, citric acid and hypromellose for the mucoadhesive layer and the 
concentration of Eudragit®RS100 and calcium chloride for the drug loaded layer. These were 
studied at two levels each, and the DoE generated twenty and thirteen experimental runs 
(formulations) for the mucoadhesive and drug loaded layers respectively. Statistical optimization 
was employed to ascertain the ideal combination of polymers and crosslinker required to achieve 
the desired drug release profile, swelling, and mucoadhesive efficacies amongst others. Tables 
6.2 and 6.3 summarize the derived factor combinations for the mucoadhesive and drug loaded 
layer respectively of the experimental runs studied and their conversion of the coded levels to the 
experimental units utilized during the study. The coded variables chosen for the statistical design 
were; total mean dissolution time (MDT), mean % swelling, Young’s Modulus and % 
mucoadhesion. Whereas, parameters for the design were set as the concentrations of 
hypromellose (g), citric acid (g) and chitosan (g) for the mucoadhesive layer and concentrations 
of Eudragit® RS100 (g) and calcium chloride (g) for the drug loaded layer.  
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Table 6.2: Mucoadhesive layer Central Composite statistical design.  
Mucoadhesive 
Film  
[Chitosan] 
(g) 
[Hypromellose] 
(g) 
[Citric Acid] 
(g) 
F1 0.15 0.1 0.225 
F2 0.15 0.1 0.225 
F3 0.15 0.05 0.225 
F4 0.15 0.1 0.225 
F5 0.15 0.1 0.225 
F6 0.05 0.05 0.15 
F7 0.05 0.05 0.3 
F8 0.15 0.1 0.225 
F9 0.05 0.15 0.15 
F10 0.25 0.1 0.225 
F11 0.25 0.15 0.15 
F12 0.15 0.15 0.225 
F13 0.05 0.15 0.3 
F14 0.05 0.1 0.225 
F15 0.25 0.05 0.3 
F16 0.25 0.15 0.3 
F17 0.15 0.1 0.15 
F18 0.25 0.05 0.15 
F19 0.15 0.1 0.3 
F20 0.15 0.1 0.225 
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Table 6.3: Drug loaded layer Central Composite statistical design. 
Drug 
Loaded 
Film  
[Eudragit® RS 100] 
 (g) 
[Calcium Chloride] 
(g) 
F1 0.55 0.055 
F2 0.55 0.1 
F3  0.1 0.055 
F4 1 0.1 
F5 1 0.055 
F6 1 0.01 
F7 0.55 0.055 
F8 0.55 0.01 
F9 0.55 0.055 
F10 0.55 0.055 
F11 0.55 0.055 
F12 0.1 0.1 
F13 0.1 0.01 
 
 
6.2.3. Fabrication of mucoadhesive lectin fused hypromellose-chitosan blend and drug 
loaded layer 
Bioadhesive multilayered intestinal patch layers were prepared by solvent casting method 
(Gungor et al., 2008). A chitosan aqueous solution was prepared by dissolving the chitosan 
powder into distilled water containing varying concentrations of citric acid until the chitosan was 
completely dissolved and a clear solution was formed. Subsequently, the chitosan solution was 
added into aqueous solutions of varying concentrations of hypromellose. Once the blend formed 
a homogenous solution soybean lectin (0.25mg/mL) was added and allowed to undergo 
amalgamation for 2 hours. 
Eudragit® RS100 in varying concentrations was dissolved in a 60:40 %w/v isopropyl alcohol, 
acetone mixture. A 2%w/v sodium alginate solution was added to the above mentioned solution 
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until homogenous. Thereafter, varying concentrations of calcium chloride solution was added to 
the blend and allowed to crosslink for 3 hours.  
Glycerin (1mL) was added to both film forming solutions as a plasticizer, the use of a plasticizer 
aims to i) providing easily removable films from the casting surface (mechanical stability and drug 
permeability, and ii) ensuring the polymer particles coalesce during film formation (Siepmann and 
Siepmann, 2013). A thin layer of the respective polymer solutions were casted onto individual 
molds and allowed to dry under the influence of a fumehood at room temperature for 24 hours. 
The resulting polymeric films were then carefully lifted off the mold surface and layered into the 
final intestinal patch with the assistance of compression employing the Carver Press tableting 
press (Model 3851-0, S/N 43000-904, Wabash, IN, USA) employing a pressure of 5 tons. 
PART I: Preliminary Mucoadhesive Layer Characterization 
6.3. Physiomechanical and Physiochemical Characterization of the Mucoadhesive Layer   
6.3.1. Chemical transitional characterization of the lectin amalgamated mucoadhesive layer 
of the intestinal patches 
Fourier Transform Infrared Spectroscopy (FTIR) employing a spectrum 100 FTIR spectrometer 
(Perkin- Elmer, Beaconsfield, BUCKS, UK) was utilized to detect the vibrational frequencies of 
chemical functional groups in the design formulations. FTIR analysis was conducted on native 
polymers incorporated in the mucoadhesive layer as a means of validating the successful lectin 
amalgamation. Samples were placed on a diamond crystal and processed by the universal ATR 
polarization accessory software for the FTIR spectrum series at a wave number range of 650-
4000cm-1.  
6.3.2. Thermal analysis of polymeric material employed in the formulation of the 
mucoadhesive layer of the intestinal patch 
Differential Scanning Calorimetry (DSC) was conducted on the mucoadhesive layers. Obtained 
DSC thermograms provided information regarding the thermal stability of the formulations. With 
the further intention of ascertaining the melting points, phase transitions and glass transitions (Tg) 
of the formulated lectin amalgamated hypromellose, DSC studies employing a Temperature 
Modulated DSC (Mettler Toledo DSC- 1 STARe System , Schwerzenback, ZH, Switzerland) was 
conducted. 
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6.3.3. Mucoadhesive analysis of the mucoadhesive layer  
Mucoadhesion studies were performed on all Box–Behnken design mucoadhesive layer 
formulations to deduce the effect of the change in variable concentration on the amount of 
mucoadhesion of the polymeric film. For this study a 0.1%w/v mucin solution prepared in USP 
intestinal fluid (pH 6.8) was used to incubate mucoadhesive films in an orbital shaker maintained 
at 37˚C and 50 rpm. Concentration of free mucin in the solution, after 6h duration, was determined 
by a UV spectrophotometer, at 201nm (IMPLEN NanophotometerTM, Implen GmbH, München 
Germany), using a 10 times dilution factor of path-length 0.1 mm. The difference in the 
concentration of the mucin solution before and after incubation was the indication of the amount 
crosslinked with the mucoadhesive films as seen in Equation 6.1, indicating the interaction 
between particles and mucin (He et al., 1998).  
 
𝑀𝑢𝑐𝑜𝑎𝑑ℎ𝑒𝑠𝑖𝑜𝑛 % =
[𝑀𝑢𝑐𝑖𝑛 𝑏𝑒𝑓𝑜𝑟𝑒] − [𝑀𝑢𝑐𝑖𝑛 𝑎𝑓𝑡𝑒𝑟]
[𝑀𝑢𝑐𝑖𝑛 𝑏𝑒𝑓𝑜𝑟𝑒]
× 100 
Equation 6.1 
6.3.4. Evaluation of the swelling behavior of the mucoadhesive layer  
Mucoadhesive films were analyzed for water content and swelling by gravimetric analysis utilizing 
the weight of the sample. Gravimetric analysis was performed as follows: the film sample was 
weighed before submersion in 20 ml PBS (pH 6.8, 37˚C) and then again after 24 hours. The film 
was then removed and surface water removed by blotching on dry laboratory paper, followed by 
the determination of the equilibrium swelling ratio by use of the following Equation 6.2 (Murthy et 
al., 2006; Reddy et al., 2012):  
 
ESR=W1-W0 )/W0 
Equation 6.2 
Where W0 is the initial weight of the film and W1 is the weight after the 24 hour swelling time. 
6.3.5. Textural analysis of formulated mucoadhesive film layer 
Mechanical properties of the mucoadhesive layers were evaluated via textural analysis using the 
TX.XTplus Texture Analyzer. Films were cut into approximately 0.55× 2.55 mm2 strips and 
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secured within the grips, textural analysis was conducted with a pre-test and test speed of 0.5, 
post-test speed of 5, with the target mode being distance, and the force applied being 5N. The 
Young’s Modulus or ratio of stress over strain of the mucoadhesive film was determined by the 
Equation 6.3 via utilization of data obtained from textural analysis;   
E=
Tensile stress
Extensional strain
=
FL0
A0∆L
 
Equation 6.3 
Where; 
E is the Young's modulus  
F is the force exerted on an object under tension; 
A0 is the original cross-sectional area through which the force is applied; 
ΔL is the amount by which the length of the object changes; 
L0 is the original length of the object. 
 
6.3.5.1. Determination of the tensile properties and Young’s modulus of the intestinal 
mucoadhesive films via NanoTensile analysis 
The tensile characteristics and Young’s modulus were determined further employing the 
NanoTensile® 5000 (Hysitron Inc. Nanomechanical Test Instrument, Minneapolis, MN, USA). 
NanoTensile (NT) system was calibrated prior to sample testing to ensure accurate analysis. 
Samples cut into approximately 0.55 x 2.55 mm2 strips were mounted on the specially designed 
mounting brackets. Brackets were held together with a rigid cardboard frame, enabling ease of 
sample alignment, samples were attached to the brackets using double sided adhesive tape, thus 
keeping the sample in place during evaluation. Accurate measurements of the sample width, 
thickness and length were recorded utilizing a digital caliper. Thereafter, the upper sample bracket 
was attached to the upper sample holder of the NT head and the mass recorded. The NT head 
was then lowered and aligned to the lower NT stage; the lower sample bracket was then secured 
to the lower sample holder on the NT stage. Sample mounting brackets were pulled apart at a 
constant rate of displacement; 100μm/s-1 whereby tensile characteristics of the mucoadhesive 
formulation sample was measured and recorded. 
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6.3.6. Elucidation of the pertinent rheological properties 
Using a Modular Advanced Rheometer system (ThermoHaake MARS Rheometer, Thermo 
Fischer Scientific, Karlsuhe, Germany) equipped with a T-type spindle sensor (C35/1˚Ti) set at a 
sample gap of 1mm and Thermo controller (UTC-MARS II) utilized for viscosity measurements.  
Viscosity is a vital parameter in the formation of polymeric films or membranes. For this reason 
viscosity measurements were carried out on the mucoadhesive layer polymeric solution.  
6.3.7. Response surface analysis of the employed responses 
Minitab® statistical software (V15, Minitab Inc., PA, USA) was utilized to perform the response 
surface analysis of the various response variables. The results were demonstrated employing 
response surface and contour plots which were derived for the measured responses (Young’s 
Modulus, and % mucoadhesion), based on the experimental model.  
6.4. Results and Discussion 
6.4.1. Chemical composition elucidation of the mucoadhesive layer of the intestinal 
patches 
Analysis of all design formulations (Figure 6.3) revealed that all characteristic peaks present within 
the FTIR spectra of the native polymers were altered proving that covalent interactions between 
polymers occurred, thereby resulting in improved mucoadhesion. Fourier Transform Infrared 
Spectroscopy (FTIR) of the native excipients employed in the formulation of the mucoadhesive 
layer displayed characteristic functional groups; chitosan displayed a peak at 3493cm-1 (Figure 
6.3a) relating to a normal O-H polymeric stretch (Krishnaraj et al., 2012), a second distinct peak 
is observed at 1697.14cm-1 illustrative of a C=O carboxylic acid group, a third distinct peak is seen 
at 1388.02cm-1 representative of C-H alkanes, a peak at approximately 1140cm-1 is depictive of 
C-O phenol functional groups, and a peak at 771.69cm-1 is descriptive of an o-substituted C-H 
functional group (Figure 6.3a).  
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Hypromellose FTIR spectra showed peaks at 3497cm-1 relating to a normal O-H polymeric stretch, 
3354cm-1 N-H amine groups, 2911cm-1 depictive of a O-H carbon, 1670cm-1 C=O aldehyde, 
1138cm-1 is related to C-O phenol functional groups, and a peak at 780.56cm-1 characteristic of 
substituted aromatic C-H bending (Figure 6.3b). Citric acid displayed FTIR peaks at 2635.93cm-1 
related to carboxylic acid functional group, 766.94cm-1 depictive of a C-H alkene (Figure 6.3c). 
Lectin FTIR spectra exhibited peaks at 3253.65cm-1 hydrogen bonded alcohol O-H, 1639.46cm-1 
representative of C=C alkyl stretch, a peak at 1518.09cm-1 related to NO2 nitro functional groups, 
1237.22cm-1 aryl/vinyl ethers (Figure 6.3d).  
 
Figure 6.3: FTIR spectra of native polymers a) chitosan, b) hypromellose, c) citric acid and d) 
lectin employed in the fabrication of the mucoadhesive films and e) a representative design 
formulation. 
 
Spectra of the mucoadhesive design formulations exhibited peaks in the range of 3200-3600cm1 
relating to a broad hydrogen bonded alcohol which is also known as a normal polymeric O-H 
stretch observed within all native polymer FTIR spectra, a peak in a range of 3200-3570cm-1 linked 
to C-H stretching for diagonal carbon alkyls displaying a shift in peak intensity of the polymeric O-
H stretch which is attributed to the formation of intermolecular and intra-molecular hydrogen bonds 
(Wang et al., 2014), an additional peak in the region of 2100-2260cm-1 was observed which 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
(e) 
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represents C≡C terminal alkyne, an additional peak in the range of 1590-1650cm-1corresponding 
to C=C aromatic double bond was noted (Figure 6.3e).The presence of a peak at ±1730cm-1 
corresponds to ester C=O stretching (Krishnaraj et al., 2012). In addition, it was observed that a 
reduction in hypromellose and an increase in citric acid concentration within formulations led to a 
shift into the lower region of the FTIR spectra, whereas an increase in chitosan concentration led 
to a corresponding shift of the spectra to higher frequencies. The manifestation of two additional 
peaks demonstrates the successful lectin amalgamation to the chitosan: hypromellose blend. In 
addition, the known amine groups on the chitosan molecule provide polycationic electrolytes when 
dissolved in acid solutions, such as citric acid. These electrolytes are able to bind with other 
hydrophilic compounds, in this case the hydroxyl group of hypromellose.   
6.4.2. Thermal appraisal of polymeric components of the mucoadhesive film layer 
DSC thermal analysis of native polymers utilized in the formulation process of the mucoadhesive 
layer displayed the following thermal events: chitosan presented with a Tg of 26.21˚C, an 
endothermic peak at 65.42˚C related to solid-solid phase interactions, an exothermic peak at 
211.56˚C representative of crystallinity, and an exothermic peak at 275.34˚C illustrative of 
decomposition (Figure 6.4a). Citric acid exhibited a Tg of 26.24˚C, an endothermic event at 
128.19˚C relating to sublimation or solid-solid transitions, an endothermic peak at 212.97˚C 
representing melting with decomposition followed by an exothermic peak at 259.31˚C illustrating 
melting along with eutectic impurities present (Figure 6.4b). Hypromellose revealed a Tg of 
26.12˚C, an endothermic thermal event at 77.36˚C representing solid-solid phase sample 
transitions, followed by an endothermic peak at 261.98˚C descriptive of melting along with 
decomposition (Figure 6.4c). Thermogram of lectin WGA displayed a Tg of 25.71˚C, an exothermic 
peak at 238.57˚C illustrating crystallinity, and an endothermic peak at 255.48˚C signifying melting 
upon stable modification ( Figure 6.4d) (Mettler Toledo, 2001).  
Mucoadhesive layer design formulations showed four characteristic thermal peaks. The first event 
representing the Tg occurred in a range within 83.99˚C- 138.72˚C, it was noted that with an 
increase in crosslinker density, the Tg was shifted to higher values. The second thermal peak 
ranges between 139.03˚C- 178.95˚C relating to crystallinity and solid-solid transitional peaks 
(Figure 6.4e). The third observed thermal event constituted an endothermic peak representative 
of the beginning of the melting phase. The fourth thermal event was an exothermic peak 
associated with decomposition.  
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Figure 6.4: DSC thermograms of the native polymers a) chitosan, b) citric acid, c) hypromellose 
and d) lectin employed in the fabrication of the mucoadhesive layer and e) a representative design 
formulation.  
 
6.4.3. Clarification of the mucoadhesive properties of the mucoadhesive layer 
Mucoadhesive properties of the statistically derived mucoadhesive film formulations were 
evaluated to screen their ability to adhere to the intestinal surface lining, to increase the retention 
time and enhance absorption of the drug through the mucosal lining of the small intestine. Figure 
6.5 summarizes the mucoadhesion results for the mucoadhesive film design layers via mucin 
cleavage, yielding the average percentage crosslinking values of the mucus solution.  
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Figure 6.5: Percentage adhesion of mucoadhesive films to mucus for all 20 design formulations. 
 
Formulations displayed mucoadhesion in the range of 61.2 to 88.1%, it was observed that % 
mucoadhesion increased with a corresponding increase in polymer concentration (HPMC and 
CHT) thus allowing for greater interaction between the polymeric chains and mucus. Lectin, a 
highly heterogeneous group of proteins and glycoproteins of non-immune origin that bind to 
carbohydrates in biological tissue specifically and non-covalently (Gavrovic-Jankulovic and 
Prodanovic, 2011) was amalgamated to the solutions forming polymeric films at a constant 
concentration, thus resulting in the high level of mucoadhesion observed in all formulations. 
However, it was also noted that an increase in citric acid concentration (0.3%) lead to a reduction 
in the percentage mucoadhesion possibly due to a reduced amount of polymer chains available 
for crosslinking to the mucin.  Generally, all formulations exhibited satisfactory mucoadhesive 
abilities and thus would function efficiently in prolonging residence time and thus improving drug 
absorption through the intestinal mucosal surface.  
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6.4.4. Assessment of the gravimetric swelling characteristics of the mucoadhesive layer 
Through gravimetrical analysis it was shown that with an increased exposure to simulated 
intestinal conditions design formulations of the mucoadhesive layer tended to swell, resulting in a 
corresponding increase in weight. The hydrated and thus expanded nature of the polymeric 
network allows for mutual interpenetration between the mucoadhesive layer with mucin molecules, 
subsequently forming stabilized interactions and thereby strengthening the mucoadhesive 
characteristics of the formulations (Salamat-Miller et al., 2005; Roy et al., 2009).  
 
Figure 6.6: Percentage swelling of mucoadhesive layer design formulations over 24 hours.  
 
With exposure of the surface layer of the mucoadhesive films to simulated intestinal conditions, 
polymeric chains present on the surface, underwent swelling, thus promoting both mucoadhesion 
and weight gain. Upon continuous exposure the surface layer ultimately disintegrates and erodes 
out of the film, resulting in a decrease in both the swelling (weight gain) and mucoadhesion. The 
underlying polymeric chains consequently become exposed to the surrounding fluid and undergo 
swelling, and hence mucoadhesion. As a result, a fluctuating degree of swelling was observed at 
differing time points, leading to the resultant variations in mucoadhesion among design 
formulations. Formulations 6, 7, 13 and 14 of the mucoadhesive layer design (Figure 6.6) were 
excluded from the gravimetrical swelling study as they were shown to disintegrate before the 0.5 
hour time interval. This is attributed to the reduced concentration of chitosan among these 
formulations, with a corresponding low concentration of hypromellose. The high percentage of 
157 
 
swelling observed within the range of design formulations could be attributed to the high 
polydispersity index and solubility parameter of hypromellose and chitosan. The degree of swelling 
is also affected by citric acid content, with a higher ratio of citric acid to chitosan the percentage 
swelling was lower, and this is attributed to the ester bonds formed between citric acid and the 
polysaccharide, thus producing a dense structure (Azeredo et al., 2015).  
6.4.5. Mechanical strength appraisal of the mucoadhesive film layer 
Tensile properties determine the mechanical response and flexibility of the produced films to 
forces it may be subjected to. Young’s Modulus and other tensile properties of the design 
mucoadhesive layer were determined utilizing the NanoTensile® 5000 and Texture Analyzer as 
described in Chapter 6, Sections 6.3.5 and 6.3.5.1 respectively. The stress-strain relationship of 
a material is greatly reliant on the flexibility of the polymer chains and the strength of the material. 
When a small degree of stress is requisite to produce a large degree of strain, the test material is 
considered to be flexible and the Young’s Modulus, which is the slope of the linear portion of the 
stress-strain curve will be comparatively small (Leung and Ko, 2011). Tensile properties were 
determined as the mucoadhesive layer would eventually be compressed to form an intestinal 
patch which would further be incorporated into a layered tablet to ease oral administration.  
The average experimental values of Young’s Modulus (E), yield stress (QY) (extent of stress on 
the stress-strain curve at which considerable deformation occurs without any considerable 
increase in stress), ultimate strength (QU) (the maximum stress a material can withstand), ultimate 
strain (ɛu) and toughness (Uf) are outlined in Table 6.4 . 
Table 6.4: Experimental average values obtained from NanoTensile (NT) and Textural analysis 
(TA) of mucoadhesive layer design formulations. 
Formulation E(MPa) 
NT 
E(MPa) 
TA 
QY (MPa) QU(MPa) ɛu Uf(J/cm-3) 
Mucoadhesive 
Layer 
0.48 0.15 0.09 0.1 0.53 0.002 
 
The observed Young’s Modulus values were relatively low indicating that the films demonstrated 
good elasticity. The mucoadhesive films, containing chitosan and hypromellose, displayed high 
elasticity values (a low Young’s Modulus). The films demonstrated suitable strength and 
toughness to be able to withstand compression and incorporation into tablets. 
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6.4.6. Assessment of Rheological characteristics of the mucoadhesive polymeric solutions 
of the multi-layered intestinal patch 
The rheological characteristics, and in particular the viscosity, of polymeric solutions determines 
whether the solution can satisfactorily form a polymeric film, and further influences the casted 
film’s surface morphology and quality. A low viscosity polymer solution leads to the formation of 
thin films that easily undergo tearing, on the other hand a polymer solution with a high viscosity 
leads to the formation of casted films which are brittle and display a reduced quality of surface 
morphology. The respective viscosities, determined through rheological analysis of the 
mucoadhesive layer polymeric solutions, are listed in Table 6.5. As illustrated in the table, an 
increase in % concentration of polymeric material increases the viscosity of the solutions. 
Table 6.5: Effect of polymer concentration on viscosity for the mucoadhesive layers.  
Intestinal Patch 
Layer 
Solution Parameters Viscosity at shear rate of 
100 m/s (mPas) 
 
Mucoadhesive 
Layer 
 
5%w/vCHT+2% w/vHPMC+0.225%w/v CA 1071.3 
5% w/v CHT+3% w/v HPMC+0.15%w/v CA 2597.5 
5% w/v CHT+3% w/v HPMC+0.3% w/v CA 4974.6 
 CHT (Chitosan), HPMC (Hypromellose), CA (Citric Acid). 
As shown in the Table 6.5, for the mucoadhesive layer polymeric solution there is evidence that 
an increase in hypromellose and citric acid concentrations leads to a corresponding rise in solution 
viscosity. Mucoadhesive film solutions with a viscosity in the range of 1071.3 to 2253 mPas formed 
satisfactory polymeric films that had a durable structure with good surface morphology and tensile 
strength. However, as the concentration of polymers increased so did the viscosity which resulted 
in the formation of polymeric films with a greater film thickness and brittleness with a related 
reduction in tensile strength; solution viscosity also influences droplet spreading, thus with more 
viscous solutions they are not able to readily spread across the film casting surface before solvent 
evaporation occurs (Felton, 2013). The thickening capacity of some formulations is greater than 
others, which may be attributed to the significant differences in their polymer chain arrangement 
(Xuaet al., 2015).  
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6.4.7. Response surface analysis of the Central Composite design 
With the purpose of determining the relationship between the response variables and predictor 
variables, a complete ANOVA analysis was performed of the measured formulation responses 
(Figure 6.7, Table 6.6), mucoadhesion and Young’s Modulus. The aptness of the multiple 
regression models are accessed via residual analysis. Residual plots for mucoadhesion (%) and 
Young’s Modulus are depicted in Figure 6.7. The hypotheses of a multiple linear regression model 
is that the response variables are independent and ordinarily distributed, arbitrary variables with 
constant variance and means depending linearly on the explanatory variables (Larsen and 
McCleary, 1972; Huynh, 2000). Resilient linear relationships were observed for all response 
variables as indicated by the restrained grouping of the partial residuals. The scatter plot of the 
residual, in which the residuals were plotted against the model predictions, is empirically uniform 
and radiate around zero.  
The exhibited asymmetrical scatter demonstrated that none of the fundamental hypotheses of the 
multiple regression analysis were visibly breached; some deviations and some broadly spread 
points were observed revealing of a degree of non-constant variance (du Toit et al., 2013).  The 
normal probability plots of the residuals fell on a straight line signifying the data to be ordinarily 
distributed with no assertion of unknown variables. Deviations could have resulted from 
experimental error. The histograms for Young’s Modulus were largely symmetrical thus supporting 
the probability plots of constant and uniform distribution. The attained histogram for % 
mucoadhesion depicted an absence of symmetry suggestive of a random error of the data set. 
The scatter plot, which is the residual vs. observation order, depicts the performance of the model. 
Scatter plots stayed within constant scale indicating non-arbitrary error. A full ANOVA was 
conducted and shown in Table 6.6.  
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Table 6.6: ANOVA analysis for the measured responses. 
Response Variables p-values 
Young's Modulus                   Mucoadhesion (%) 
[CHT] 0.202 0.476 
[HPM] 0.110 0.205 
[CA] 0.819 0.420 
 
The complete regression equations generated for Young’s Modulus and % mucoadhesion are 
indicated below;  
𝑌𝑜𝑢𝑛𝑔′𝑠 𝑀𝑜𝑑𝑢𝑙𝑢𝑠 =  −0.3279 + 1.8093[𝐶𝐻𝑇] + 5.6234[𝐻𝑃𝑀] + 0.6961[𝐶𝐴] 
Equation 6.4 
% 𝑀𝑢𝑐𝑜𝑎𝑑ℎ𝑒𝑠𝑖𝑜𝑛 = 43.40 − 177.50[𝐶𝐻𝑇] + 787.10[𝐻𝑃𝑀] − 450.22[𝐶𝐴] 
Equation 6.5 
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Figure 6.7: Residual plots for the responses a) Young’s Modulus b) % Mucoadhesion  
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Young’s Modulus and mucoadhesion of the mucoadhesive layer are important factors influencing 
the degree of gastric retention and capability of the system to endure gastric transit post oral 
dosing. Data plots depicted in Figure 6.8 were utilized to illustrate the purposeful relationship 
between the experimental variables and achieved responses. The effects of CHT, CA and HPM 
on the tensile strength via Young's Modulus and % mucoadhesion; the desired Young's Modulus 
was within the range of 0.1-0.3, formulations having chitosan: hypromellose: citric acid ratios of 
approximately 0.25: 0.15: 0.3 were found to display the anticipated Young's Modulus.  It was 
observed that an increase in polymer and crosslinker concentrations lead to a lower Young's 
Modulus and thereby better polymeric film flexibility. It was noted that none of the factors were 
significant.  
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Figure 6.8: 
Response surface 
and contour plots depicting the effects of citric acid (CA), chitosan (CHT) and hypromellose (HPM) 
on Young’s Modulus.  
 
From the obtained surface plots for the % mucoadhesion shown in Figure 6.9 it was observed that 
mucoadhesion was shown to increase with a corresponding increase in the respective formulation 
constituents. This can be attributed to the additive mucoadhesive properties of the respective 
polymers. The highest % mucoadhesion ranged from 60-65% and showed the most desirable 
mucoadhesive capabilities, formulations having chitosan: hypromellose: citric acid ratios of 
approximately 0.20:0.10:0.26 were found to exhibit the predicted mucoadhesion.  
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Figure 6.9: Response surface and contour plots depicting the effects of citric acid (CA), chitosan 
(CHT) and hypromellose (HPM) on % mucoadhesion.  
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PART II:  Preliminary Drug Loaded Layer Characterization 
6.5. Physiomechanical and Physiochemical Characterization of the Drug Loaded Layer 
6.5.1. Determination of the chemical vibrational transition of the crosslinked drug loaded 
layer of the bioadhesive multilayered intestinal patch 
Fourier Transform Infrared Spectroscopy (FTIR) was utilized to determine the chemical structural 
composition of the design formulations as well as native polymers incorporated in the drug loaded 
layer. FTIR analysis was conducted as outlined earlier in Chapter 6, Section 6.3.1.  
6.5.2. Thermal event analysis of the drug loaded layer of the bioadhesive multilayered 
intestinal patch 
Differential Scanning Calorimetry (DSC) was conducted on the drug loaded layer design 
formulations. DSC studies provided information regarding the thermal stability of the formulations. 
DSC analysis was performed as detailed in Chapter 6, Section 6.3.2 for the mucoadhesive layer.  
6.5.3. Textural analysis of the drug loaded layer  
The mechanical strength of the drug loaded layer of the intestinal patch system is vital as it is 
required to endure the peristaltic motion and remain attached to the intestinal wall for a prolonged 
period. Mechanical strength of the drug loaded layer was evaluated via textural and NanoTensile® 
analysis as described in Chapter 6, Section 6.3.5 for the mucoadhesive layer.  The Young's 
Modulus was calculated as per Equation 6.6.  
6.5.4. Appraisal of swelling behavior of the drug loaded layer 
The degree of swelling of the drug loaded layer was analyzed via gravimetric analysis; gravimetric 
analysis was carried out in accordance to the method and equation detailed in Chapter 6, Section 
6.3.4.  
6.5.5. Determination of the Rheological Properties 
Understanding of the rheological properties within a micro structured system is vital in relation to 
the rate and degree of drug release as well as the mechanical features of the system as a whole. 
Thus, viscosity analysis was performed for the drug loaded layer polymeric solution as detailed 
previously in Chapter 6, Section 6.3.6.  
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6.5.6. Construction of a calibration curve for the ultraviolet spectrophotometric 
determination of valproic acid  
Utilizing UV spectroscopy, it was established that valproic acid (sodium valproate) exhibits a 
maximum wavelength at λ215, consistent with published literature on the absorption peak of 
valproic acid being at 215nm (Thakkar et al., 2012). Using a series of known concentrations (0.2-
1mg/mL) of valproic acid in PBS, a calibration curve at λ215 was conducted (Figure 6.10). The 
linear curve was plotted with the observed absorbance of sodium valproate as the dependent 
variable and the concentration of sodium valproate as the independent variable (Figure 6.10). The 
obtained R2 value of the calibration curve was 0.99 (Figure 6.10), indicating a perfect correlation.  
 
 
 
 
 
 
 
 
 
Figure 6.10: Calibration curve of sodium valproate in PBS at λ215. 
6.5.7. In vitro drug release from the drug loaded layer of the bioadhesive multilayered 
intestinal patch 
Release kinetics was evaluated using the USP type II apparatus (Caleva, model 7ST) at 50rpm. 
Dissolution vessels were filled with 900mL dissolution medium and samples were placed within 
dissolution vessels employing mesh rings placed into the lower part of the standard dissolution 
vessel to allow for intestinal drug loaded layer film attachment. Dissolution medium aliquots of 
5mL were withdrawn manually at predetermined time intervals during the 12 hour study and 
replaced with an equal volume of fresh dissolution medium to ensure sink conditions were 
maintained. The samples were then filtered and analyzed for drug release via Ultraviolet 
spectrometry (WinAspect Spectro-analytical software, Analytik Jena AG), at a wavelength of 215 
 
 
y= 1.017x + 0.00762 
R2= 0.99 
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nm employing a calibration curve obtained for the drug as detailed in Chapter 6, Section 6.5.6. 
(Thakkar et al., 2012).  
6.5.8. Response surface analysis of the employed responses 
Minitab® statistical software (V15, Minitab Inc., PA, USA) was utilized to perform the response 
surface analysis of the various response variables for the drug loaded layer. Results were 
established employing response surface and contour plots which were derived for the measured 
response (drug release) based on the experimental model.  
6.6. Results and Discussion  
6.6.1. Elucidation of chemical vibrational transitions of the drug loaded layer  
Crosslinking of sodium alginate with the use of calcium chloride in the direct presence of Eudragit® 
RS100 results in the formation of a polymer complex capable of controlling drug release. An 
increase in calcium chloride concentration results in a decrease in drug release rate. Calcium 
chloride at low concentrations reduces the tortuosity of the diffusion path thereby increasing drug 
release rates. At higher concentrations there is a greater quantity of calcium ions available to bind, 
thus forming an efficiently crosslinked strong gel that prevents excessive dissolution medium 
penetration leading to a reduction in release rates (Nokhodchi and Tailor, 2004).  
Analysis of crosslinking efficiency therefore becomes apparent, all design formulations (Figure 
6.11) displayed that distinguishing peaks existent within the FTIR spectra of the natural polymers 
were altered verifying that covalent interfaces between polymers ensued, thereby subsequent 
enhancement of drug release properties. FTIR investigation of the crude polymers employed in 
the formulation of drug loaded layers displayed the following characteristic peaks: all crude 
polymers displayed an O-H stretch related to normal polymeric stretching ranging between 
2349.84cm-1-3212.92cm-1. Alginate displayed additional peaks at 1404.87cm-1 descriptive of 
carbonyl ions, and a peak at 878.18cm-1 C-H aromatic ring (Figure 6.11a). Eudragit RS100 
exhibited peaks at 1722.54cm-1 representative of aldehydes, 1383.28cm-1 C-H alkanes, 
1142.86cm-1 C-O phenols and a peak at 847.95cm-1 C-H aromatic ring (Figure 6.11b). Spectra of 
calcium chloride dihydrate presented with peaks at 3362.84cm-1 illustrative of N-H amines, 
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1742.62cm-1 representative of an alkyl carbonate, 1139.67cm-1 expressive of C-O phenols, and a 
peak at 763.71cm-1 C-H alkene functional group (Figure 6.11d) (Krishnaraj et al., 2012).  
Figure 6.11: FTIR spectra of native polymers a) alginate, b) Eudragit RS 100 and d) calcium 
chloride employed in fabrication of drug loaded layer and c) a representative design formulation. 
 
FTIR spectra of drug loaded design formulations displayed characteristic peaks at a range of 
3320-3310cm-1 which is representative of alkyne related C-H stretching, a peak in the region of 
3200-2700cm-1 related to tetrahedral carbon hybridization as well aliphatic C-H stretching, 
followed by a peak within the range of 1675-1725cm-1 associated with C꞊O conjugated carboxylic 
acid stretch characteristic of native polymers, a peak between the range of 1640-1680cm-1 is 
representative of C=C alkene stretch, an additional peak at 1470-1430cm-1 illustrative of C-H 
methyl stretching, a modified peak at 1370cm-1 displaying strong tert-butyl unsymmetrical doublet, 
1270-1230cm-1 O-H aromatic ether, 1130-1190 C-N secondary amine (Durig and Fassihi, 2002) 
and a peak in the region of 800-1000cm-1 alkene out of plane C-H bending (Figure 6.11c). It was 
noted that an increase in polymer and crosslinker concentration led to a proportional higher shift 
of FTIR spectra wavelength. The additional and modified peaks verify the crosslinking of sodium 
alginate and Eudragit RS100 via calcium chloride.  
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6.6.2. Thermal characteristics of the drug loaded layer 
Crude polymers employed in the formulation of the drug loaded layer displayed DSC thermograms 
as follows: alginate displayed a Tg of 26.34˚C, an endothermic peak at 124.52˚ relating to solid-
solid transitions, an exothermic peak at 240.76˚C representative of crystallinity, endothermic peak 
at 260.58˚C relating to solid-solid transitions, and a peak at 281.16˚C showing melting with stable 
modification (Figure 6.12a) (Mettler Toledo, 2001). Calcium chloride dihydrate with a Tg of 27.41˚C 
presented with two distinct peaks, an exothermic peak at 146.28˚C descriptive of sample 
crystallinity, and an endothermic peak at 124.37˚C descriptive of melting with stable modification 
(Figure 6.12b) (Mettler Toledo, 2001). Eudragit RS100 displayed thermal events at 28.61˚C 
relating to its Tg, 200.48˚C relating to sample crystallinity and an exothermic peak at 231.65˚C 
demonstrative of melting with decomposition (6.12c) (Mettler Toledo, 2001).  
 
 
Figure 6.12: DSC thermograms of the native polymers a) alginate, b) calcium chloride and c) 
Eudragit RS100 employed in the fabrication of drug loaded layers and d) a representative design 
formulations.  
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Design formulations of the drug loaded layer displayed two distinct thermal events. The first being 
the glass transition (Tg) temperature which ranged between 25.67˚C -37.41˚C with a 
corresponding increase in Tg as the degree of crosslinking increased (Mettler Toledo, 2001). The 
second thermal observed was that of melting of stable modification which occurred at 245.61˚C- 
284.15˚C (Figure 6.12d). However, formulations 4 and 6 showed an additional melting peak at 
239.68˚C- 261.55˚C respectively, attributable to an increase in polymer concentration thus leading 
to a prolonged stable modification melting.  
6.6.3. Tensile assessment of the drug loaded layer  
In fabricating polymeric films that are intended as a dosage form for oral drug delivery, films should 
have adequate strength and flexibility to endure mechanical manipulation during production and 
administration. Young’s Modulus of the design drug loaded layers were determined utilizing the 
NanoTensile® 5000 and Texture Analyzer as described in Chapter 6, Sections 6.3.5 and 6.3.5.1. 
Young’s Modulus, which is the slope of the linear portion of the stress-strain curve, will be 
comparatively small for flexible materials (Leung and Ko, 2011).  
The average experimental values of Young’s Modulus (E), yield stress (QY) (extent of stress on 
the stress-strain curve at which considerable deformation occurs without any considerable 
increase in stress), ultimate strength (QU) (the maximum stress a material can withstand), ultimate 
strain (ɛu) and toughness (Uf) are outlined in Table 6.7. 
Table 6.7: Experimental average values obtained from NanoTensile (NT) and Textural analysis 
(TA) for the drug loaded design formulations. 
Formulation E(MPa) 
NT 
E(MPa) 
TA 
QY (MPa) QU(MPa) ɛu Uf(J/cm-3) 
Drug Loaded 
Layer 
11 0.09 0.24 0.4 0.11 0.03 
 
The average Young’s Modulus for design formulations was relatively low indicating that the films 
demonstrated satisfactory elasticity and flexibility. It was noted that tensile strength decreased 
with greater concentration ratios of the employed polymers and crosslinker. As the concentration 
of Eudragit® RS100 increased the measured tensile strength decreased, this may be attributed to 
the formation of brittle films as there is not sufficient polymer entanglement upon solvent 
evaporation.  
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6.6.4. Appraisal of swelling behavior of the drug loaded layer  
Swelling characteristics of a film influences its bioadhesive properties and drug release pattern; it 
also assists in ascertaining whether the formulation is able to maintain its integrity after moisture 
absorption (Kaur et al., 2014). Swelling is defined as a process of dissolution of a polymer in a 
specified solvent. Initially, solvent molecules slowly diffuse into the polymeric system to yield a 
swollen gel; this process holds true for polymer-polymer intermolecular forces that are strong due 
to crosslinking or strong hydrogen bonding. However, if these intermolecular forces are overcome 
by polymer-solvent interactions dissolution of the polymeric system may occur (Izák et al., 2007).  
Polymeric film swelling has been defined by two standpoints namely; ‘macroscopic swelling’ which 
is a bulk growth of polymer membranes; in the region of at least 1mm2 and ‘microscopic swelling’ 
where the alterations in film dimensions are measured from small-angle X-ray scattering. 
Macroscopic swelling is most commonly measured gravimetrically (Izák et al., 2007). Via 
gravimetrical swelling analysis it was revealed that drug loaded film layers gained in weight on 
exposure to intestinal simulated dissolution medium. This phenomenon allows for interpenetration 
of polymer chains thereby stabilizing interactions of the multiple layers as mentioned in Chapter 
6, Section 6.4.4 (Salamat-Miller et al., 2005; Roy et al., 2009). 
 
Figure 6.13: Percentage swelling of the drug loaded design formulations over 24 hours.  
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On exposure of the drug loaded layer to dissolution medium, polymer chains underwent swelling 
which is illustrated as percentage swelling over 24 hours in Figure 6.13. Films maintained their 
shape and macrostructure indicating that the cohesiveness of the polymers is proficient in 
affording the system stability to sustain pulsatile release. There was an observed rise in degree of 
swelling with a consistent increase in calcium chloride concentration. Calcium chloride in the 
current context is employed as a crosslinking agent; it is thus expected to retain water and thereby 
enhances the water uptake capability of the system as a whole.  
Once the system is exposed to dissolution medium, surface polymer chains absorb the 
surrounding medium and undergo swelling, with constant exposure to dissolution medium the 
surface layers eventually undergo dissolution and erosion, with underlying polymer chains 
subsequently being exposed to the same process. This results in the observed variations and 
fluctuations in degree of swelling over the experimental period.  
6.6.5 Assessment of rheological characteristics 
Viscosity analysis is a quick and simple method to evaluate the effectiveness of the homogeneity 
process. It characterizes the degree of solids and level of hydrolysis of solutions and its respective 
ability to form polymeric films. The degree of viscosity is a vital parameter that influences the 
fabrication and manufacturing process of polymeric films. Higher viscosities maintain stability of a 
solution by preserving homogeneity. However, viscosity that is too high will adversely affects the 
mixing, spreading and transferring process of the solution to the film casting surface (Lin and 
Pascall, 2014). The respective viscosities, determined through rheological analysis of the drug 
loaded layer polymeric solutions, are listed in Table 6.8. As illustrated in the table, an increase in 
% concentration of polymeric material increases the viscosity of the solutions. 
Table 6.8: Effect of polymer concentration on viscosity. 
Intestinal Patch Layer Solution Parameters Viscosity at shear rate of 
100 m/s (mPas) 
 
 
Drug Loaded Layer 
2% EUD+0.055% CaCl2 261.9 
2% EUD+0.01% CaCl2 488.8 
1.1% EUD+0.055 CaCl2 1066.9 
 
As shown in the table 6.8 the drug loaded layer displays an increase in solution viscosity when 
there is a related reduction in Eudragit: CaCl2 ratio. However, as the concentration of polymers 
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increased so did the viscosity which resulted in the formation of polymeric films with a greater film 
thickness and brittleness with a related reduction in tensile strength. Drug loaded layer films 
displayed a relatively constant surface morphology and tensile properties, with little variations 
among design formulations. The thickening capacity of some formulations is greater than others, 
which may be attributed to the significant differences in their polymer chain arrangement (Xuaet 
al., 2015). . 
6.6.6. In vitro drug release from the drug loaded layer  
In general, pulsatile release is termed as the timed release of drugs subsequent to programmable 
lag phases. Within the context of time-based pulsatile drug delivery systems inner mechanisms 
are responsible for the desired release which are expected to be independent of physiological and 
environmental markers (pH, enzymatic activity, intestinal motility and/or stimuli) (Gazzaniga et al., 
2008). In order to accomplish drug release that is independent of the environment, the lag phase 
prior to drug liberation has to be controlled principally by the delivery system (Anal, 2007).  
The clinical efficiency and tolerability of drug therapy may possibly be markedly improved by 
delivery systems projected to timely release drug after administration; thereby providing 
pharmacological protection without an unnecessary extended period of patient exposure to the 
active drug molecules and thus not influencing patient compliance to treatment (Gazzaniga et al., 
2008). Drug is released from the intestinal patch at two hours as the first pulsed release occurs. 
The remaining two drug loaded layers, control the rate of drug release via the concentration of 
polymer and the degree of crosslinking. Ideally, drug release should occur in three pulses over a 
24 hour period. 
All release profiles as displayed in Figure 6.14 display triphasic release; with an initial lag-phase 
observed in some formulations. The first pulse provides rapid drug release while the second and 
third pulses display controlled release. The rate at which drug is released during the second and 
third pulses are governed by the concentration of polymer and the corresponding degree of 
crosslinking as well as the interpenetrating mucoadhesive polymers. It was shown that an increase 
in calcium chloride concentration within the design formulation patches resulted in a corresponding 
reduction in drug release rate; this phenomenon allowed for the desired pulsatile release kinetics 
with drug being release at 6 hour intervals. 
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Figure 6.14: In vitro fractional drug release profiles for all design formulations.
A 
(a) 
(b) 
(c) 
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Formulation 1 displayed an initial lag phase followed by the first pulsed drug release at 2 hours, 
thereafter showing controlled release until approximately 10 hours when the second pulse release 
occurred. Drug release plateaued before the third pulse release occurred at approximately 18 
hours. Formulation 3 displayed a reduction in lag phase, with drug being released from the first 
hour; there was also an erratic and undesired drug release pattern over the 24 hour period this 
could be attributed to the low polymer and crosslinker concentration. Formulations 10 to 15 show 
the most efficient drug release profiles with distinct triphasic pulsatile release of drug as seen in 
Figure 6.14c. 
6.6.7. Response surface analysis of the Central Composite design 
With the purpose of determining the relationship between the response variables and predictor 
variables, a complete ANOVA analysis was performed of the measured formulation responses 
(Figure 6.15, Table 6.9), drug release (MDT). The aptness of the multiple regression models are 
assessed via residual analysis. Residual plot for MDT is depicted in Figure 6.15. Resilient linear 
relationships were observed for the response variable as indicated by the restrained grouping of 
the partial residuals. The scatter plot of the residual, in which the residuals were plotted against 
the model predictions, is empirically uniform and radiate around zero.  
Asymmetrical scatter was observed thus indicating that the fundamental hypothesis of multiple 
regression analysis was breached; some deviations and widely spread points were shown, 
revealing a degree of non-constant variance (du Toit et al., 2013). The normal probability plot of 
the residuals fell on a straight line indicating the data to be normally distributed with no affirmation 
of unknown variables. Distinctive patterning was not observed in any of the variable plots, showing 
non-contravention of the assumptions of zero means and constant variance of the regression 
model apart from the occurrence of a few outlying points in these plots. Deviations could have 
resulted from experimental error. The histogram for MDT was mostly symmetrical thus supporting 
the probability plots of constant and uniform distribution. The scatter plot, which is the residual vs. 
observation order, depicts the performance of the model. Scatter plots stayed within constant 
scale indicating non-arbitrary error. A full ANOVA was conducted and shown in Table 6.9.  
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Table 6.9: ANOVA analysis for the measured responses. 
 
Response Variables p-values 
MDT 
[Eudragit® RS100] 0.281 
[Calcium Chloride] 0.152 
 
The complete regression equation generated for MDT is indicated below;  
 
𝑀𝐷𝑇 = 3.719 + 2.790 [𝐸𝑢𝑑𝑟𝑎𝑔𝑖𝑡®] − 38.315 [𝐶𝑎𝑙𝑐𝑖𝑢𝑚 𝐶ℎ𝑙𝑜𝑟𝑖𝑑𝑒] 
Equation 6.6 
 
 
 
Figure 6.15: Residual plot for the response MDT.  
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MDT of the drug loaded layer is a vital factor affecting the drug release kinetics of the bioadhesive 
multilayered intestinal patch. A data plot as shown in Figure 6.16 was employed to depict the 
decisive relationship between the experimental variables and the achieved response. The effects 
of Eudragit® RS100 and CaCl2 on the MDT were illustrated with the help of surface and contour 
plots. From the results it was shown that with an increase in concentration of the respective 
variables there was a corresponding increase in MDT. It was found that formulations with a ratio 
of Eudragit® RS100: calcium chloride of (0.5-1) :( 0.05-0.1) resulted in the desired MDT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.16: Response surface and contour plots depicting the effects of Eudragit® RS100 and 
CaCl2 on the MDT.  
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6.6.8. Response optimization of the mucoadhesive and drug loaded layer of the 
bioadhesive multilayered intestinal patch  
Response optimization procedure (MINITAB®, V15, Minitab, USA) was employed to attain the 
desired levels of the chosen formulation components. An optimal formulation was fabricated 
subsequent to concurrent constrained optimization of mucoadhesion, Young's Modulus 
(mucoadhesive layer) and MDT (drug loaded layer) characteristics. Maximization of 
mucoadhesion, minimization of Young's Modulus (mucoadhesive layer) and maximization of MDT 
(drug loaded layer) to the appropriate levels for each patch so as to achieve pulsatile release were 
employed for response optimization. The optimized levels of the independent variables and their 
respective predicted responses were determined. The optimal levels of the independent variables 
as well as the constraint setting used which would accomplish the preferred mucoadhesion, 
Young's Modulus and MDT characteristics are listed in Table 6.10. The optimized levels of the 
independent variables, the aim for the responses, the predicted responses (y), at the present 
factor settings, and the individual and composite desirability scores are shown in Figure 6.17 
Table 6.10: Formulation constraints employed for response optimization. 
                       Responses                                                              Parameters 
% Mucoadhesion                                                                                Maximize 
Young's Modulus                                                                                 Minimize 
Drug Release (Total MDT)                                                            Maximize (according to pulses required)  
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Figure 6.17: Desirability plots representing the levels of chitosan, hypromellose, citric acid, Eudragit® RS100 and calcium chloride required 
to synthesize the respective optimized bioadhesive multilayered patch layers, a) bioadhesive layer and drug loaded layers b) 2h, c) 10h and 
d) 18h.
(a) (b) 
(c) (d) 
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6.7. Concluding Remarks  
The mucoadhesive and drug loaded layers of the bioadhesive multilayered intestinal patch 
component of the ODLS were successfully developed via statistical analysis and characterized. 
The Face- centered Central Composite Experimental Design generated 20 and 13 formulations 
for the mucoadhesive and drug loaded layer, respectively; of which the effects of independent 
variables on the dependent response variables was analyzed. The experimental and fitted values 
achieved good correlation, demonstrating a good fit of the design model. Analysis of Variance 
(ANOVA), correlation analysis and regression analysis was used to analyze the dataset, proving 
the statistical acceptability of the models proposed. Both mucoadhesive and drug loaded layer 
design formulations provided necessary mucoadhesive and drug release characteristics. 
Furthermore, this chapter demonstrated the manner in which the mucoadhesive and drug loaded 
layer formulations would behave on exposure to simulated intestinal conditions, providing vital 
information requisite to predict the formulation’s in vivo performance. Tensile analysis showed that 
design formulations of both layers possess satisfactory elasticity and flexibility required for oral 
administration targeted to the intestine for pulsatile release which in turn required prolonged 
residence time. The variations observed from gravimetric swelling studies are related to the 
physical alterations i.e. swelling and erosion of the system occurring upon exposure to simulated 
intestinal conditions.  
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CHAPTER 7 
FABRICATION AND CHARACTERIZATION OF THE STATISTICALLY OPTIMIZED 
MULTI-LAYERED BIOADHESIVE INTESTINAL PATCH FOR PULSATILE BIOACTIVE 
RELEASE 
 
7.1. Introduction  
The importance of developing controlled-release drug delivery systems has been outlined 
previously, this allows for the maintenance of desired blood plasma levels of the selected drug for 
prolonged time periods without reaching toxic levels or falling below the minimum effective 
concentration (Gavrovic-Jankulovic and Prodanovic, 2011). Mucoadhesive drug delivery systems 
are drug carriers that employ bioadhesive properties of particular polymers that become adhesive 
upon hydration and may thus be utilized for targeted drug delivery to a specific region of the body 
for prolonged periods of time, as is the case in sustained and pulsatile drug release, mucoadhesive 
patches and microparticles have been commonly used for this purpose (Gavrovic-Jankulovic and 
Prodanovic, 2011). The use of mucoadhesive polymers within pharmaceutical formulations may 
alter the permeability of mucosal tissue and thus aid the adsorption of drug molecules. In addition 
the interaction between mucoadhesive systems and mucosal surfaces allows for prolonged 
residence time of the dosage forms at the target site, thereby decreasing the dosing frequency 
and improving patient compliance (Yu, et al., 2014), which is a great concern among the 
schizophrenic community as the reduction in normal functioning reduces the ability of 
schizophrenic patients to adhere to therapeutic regimens.  
Mucoadhesion is defined as two materials, with at least one being of biological origin, held together 
for a prolonged period of time via interfacial forces (Yadav, et al., 2010). Polymeric properties 
required for mucoadhesive interactions at specific sites include hydrophobicity, negative charge 
and the presence of hydrogen bonding groups. Furthermore, polymers should possess adequate 
flexibility to penetrate mucus networks and be biocompatible, non-toxic and affordable. 
Mucoadhesive polymers are categorized as; polymers that are bioadhesive due to their stickiness 
upon hydration; polymers that adhere via non-specific, non-covalent, primary electrostatic 
interactions and polymers that bind to specific receptors on the cell surface. To improve 
bioadhesive characteristics of drug delivery systems it is requisite to divulge structural features of 
epithelial surfaces for which the delivery system is targeted. Mucus is a composite viscous 
secretion synthesized by specialized goblet cells in columnar epithelium that lines organs such as  
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the GIT. The mucus blanket lining these organs are highly hydrated (95% water content), with the 
principle component; glycoprotein mucin being responsible for it viscosity (Gavrovic-Jankulovic 
and Prodanovic, 2011). Mucins are large (0.5-20 MDa) membrane bound, extracellular 
glycoproteins. They are glycosylated and compose of 80% carbohydrates, primary N-acetyl-D-
galactosamine, N-acetyl-D-glucosamine, fructose, galactose and sialic acid. The oligosaccharide 
chains, comprising of 5-15 monomers, display moderate branching and are attached to the protein 
core by O-glycoside bonds via hydroxyl side chains of serine and threonine (Perez-Vilar and Hill, 
1999; Gavrovic-Jankulovic and Prodanovic, 2011). Bioadhesion is also known to improve 
bioavailability of drugs via various functions such as i) higher bioactive concentration at the site of 
adhesion and absorption, ii) a decrease in the diffusion path from the drug delivery system to 
absorbing biological membrane, iii) prolonged GIT residence time, thus enhancing absorption and 
iv) absorption from the drug delivery system without preceding degradation or dilution of drug in 
luminal fluids.  
The phenomena of bioadhesion occur via a multifaceted mechanism. Six mucoadhesion theories 
have been proposed which can detail the mechanism of bioadhesion. Theories include: i) the 
wetting theory which describes bonding between the formulation and the mucosal surface tissue 
as intermolecular interaction and interfacial tension (Figure 7.1). This theory applies to liquid or 
low viscosity mucoadhesive systems and is primarily a measure if ‘spreadability’ of the system 
across the biological substrate tissue. Adhesive forces between a liquid and solid allow a liquid 
droplet to spread across the surface, while cohesive forces within the liquid lead to the droplet to 
ball up and avoid contact the surface. Contact angles less than 90˚ show that the wetting of the 
surface is favorable and the liquid can spread across a large surface area. Contact angles greater 
than 90˚ indicates the wetting of the surface is unfavorable; interactions between liquid molecules 
preserves the droplet shape and thereby minimizes contact with the substrate surface. (Dodou, et 
al., 2005; Khutoryanskiy, 2011; Mythri, et al., 2011; Yu, et al., 2014). Contact angles may be 
experimentally calculated.  
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Figure 7.1: Illustration of a) the wetting theory and b) the diffusion theory of mucoadhesion.  
 
Where ᵞSG is the interfacial tension between solid and gas; ᵞSL is interfacial tension between solid 
and liquid; ᵞLG is the interfacial tension; and θ is the contact angle between solid and liquid 
interface; (Yu, et al., 2014); ii) Electronic theory where mucoadhesion occurs due to transfer of 
electrons between mucus and the mucoadhesive system,  leading to the formation of double-
layered electronic charge at the interface (Khutoryanskiy,  2011; Mythri, et al.,  2011; Yu, et al., 
2014); iii) the adsorption theory offers that intermolecular forces such as hydrogen bonding, Van 
der Waals forces and covalent bonds, provide the adhesive attraction between mucus and 
mucoadhesive polymers (Khutoryanskiy, 2011; Yu, et al., T., 2014); iv) the diffusion theory is the 
most commonly used to describe mucoadhesion and describes the interpenetrative entanglement 
between polymer and mucus chains (Figure 7.1b). The initial step involves the contact between 
bioadhesive polymer chains and mucus chains. In this initial step, weak physical forces (attractive 
and electronic forces) control the mobility of polymer chains. The subsequent step involves the 
interpenetration of polymer chains from the delivery system into the mucus lining to allow for 
a) 
 
 
 
 
 
 
b) 
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mucoadhesion via extensive bond formation (Khutoryanskiy, 2011; Mythri, et al., 2011; Yu, et al., 
2014). The process of the diffusion theory is shown in Figure 7.2b; v) the mechanical theory 
considers only the adhesion between liquid and a rough or porous surface.  
The theory proposes that adhesion between the substrates is due to mechanical meshing/ 
interlocking of the adhesive into irregularities on the substrate surface (Dodou, et al., 2005; 
Khutoryanskiy, 2011; Mythri, et al., 2011; Yu, et al. 2014); and the fracture theory in which 
adhesive strength (fracture strength) is interrelated to the force necessary to separate the platform 
and mucosal surface. Fracture theory is considered the most widely accepted theory of 
mucoadhesion. The equation of Young's modulus of elasticity is used to determine the fracture 
strength (Dodou, et al., 2005; Khutoryanskiy, 2011; Mythri, et al., 2011; Yu, et al., 2014). The 
mucoadhesive ability and adhesive strength can be influenced by the polar functional groups. The 
most commonly employed polymers are composed of polar functional groups such as hydroxyl (-
OH), amide (-NH2), and carboxyl (-COOH) that are capable of interaction with mucin 
glycoprotein's. Interactions of polymers with mucin involve physical entanglement and secondary 
interactions such as hydrogen bonds, these aids in the formation of strong crosslinked networks 
and thus mucoadhesion. 
Lectins are a highly heterogeneous group of proteins and glycoprotein's of non-immune origin that 
bind to carbohydrates specifically and non-covalently. Lectins are involved in cell to cell 
recognition and communication, adhesion and attack of infectious agents and clearance of 
glycoproteins from general circulation. The use of lectin facilitated drug delivery system targeting 
is based on the knowledge that cell surface proteins and lipids within the plasma membrane are 
glycosylated and these glycans act as ligands for lectins. Plant derived lectins are key candidates 
in targeting drug to the GIT epithelium due to their capability to bind with specificity to epithelial 
cells (Gabor, et al., 2004). In addition, the viscous mucosal lining of the epithelium may prevent 
absorption. Hence the need for bioadhesive delivery systems becomes apparent.  
7.2. Materials and Methods  
7.2.1. Materials  
The materials employed were as described in Chapter 6, Section 6.2.1 for the optimized 
mucoadhesive and drug loaded layers. For preparation of the mucus cleaving layer; Gellan Gum 
(GelzanTM CM), N-acetylcysteine (≥99%) and chitosan (deacylated chitin) medium molecular 
weight were procured from Sigma-Aldrich® (St. Louis, USA). Ethylcellulose (EC, 10 cP) was used 
to prepare the backing layer; procured from Sigma-Aldrich® (St. Louis, USA). All other reagents 
were of analytical grade and are used as received.  
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Ethical Clearance  
This study had received the approval of the Animal Ethics Screening Committee of the University 
of the Witwatersrand with ethics clearance number 2013/23/04 (Appendix 11.3). The ethics 
clearance was granted for both the ex vivo and in vivo studies.  
7.2.2. Preparation of the respective layers of the optimized bioadhesive intestinal patches 
The preparation methods utilized were as described in Chapter 6, Section 6.2.3 for the optimized 
mucoadhesive and drug loaded layers. The drug loaded layer for the three patches were optimized 
in accordance with timed release, hence the optimized formulation compositions varied between 
the 2, 10 and 18 hour patches; optimized mucoadhesive and drug loaded layers compositions are 
outlined in Table 7.1. The backing layer was prepared by the solvent casting technique from a 
plasticizer-containing ethylcellulose solution. Elasticized polymer solution (11%w/v) was prepared 
by dissolving the required amount of ethylcellulose in a 5mL mixture of methylene chloride and 
methanol (4:1) and subsequently adding glycerin as a plasticizer. The mucus cleaving layer was 
prepared from a polymer blend of gellan gum: chitosan incorporated with N-acetyl-cysteine. A 
1%w/v gellan gum solution was prepared to which an equal concentration of chitosan was added, 
the polymer blend was allowed to homogenize after which N-acetyl-cysteine was incorporated 
(200mg).  
 
 
 
 
 
 
 
 
 
 
 
186 
 
 
 
 
Table 7.1: Outline of optimized patch layer compositions.  
Multilayered Intestinal Patch 
Layer 
Polymeric Composition 
Mucus Cleaving Layer - Gellan Gum 1% w/v 
- Chitosan 1% w/v 
-  N-acetyl-cysteine 
Mucoadhesive Layer - Chitosan 0.25 
- Hypromellose 0.15 
- Citric Acid 0.30 
Time controlled Drug Loaded 
Layers 
2 hour 
- Eudragit® RS100 0.10 
- Calcium Chloride 0.0301 
- Alginate 1% w/v 
10 hour 
- Eudragit® RS100 0.5510 
- Calcium Chloride 0.0711 
- Alginate 1% w/v 
18 hour 
- Eudragit® RS100 0.6299 
- Calcium Chloride 0.10 
- Alginate 1% w/v 
Backing Layer - Ethylcellulose 11% w/v 
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7.2.3. Physiomechanical and Physiochemical Characterization of the layers of the 
Optimized Multilayered Bioadhesive Intestinal Patches 
7.2.3.1. Evaluation of membrane uniformity 
The uniformity of the respective patch layers was determined by accurately weighing a number of 
samples (n=10) on a calibrated Mettler Toledo Balance (Model AB104-S, Mettler Toledo, 
Switzerland). The average weight was calculated followed by determination of the standard 
deviation. In addition, the thickness of the polymeric films was determined utilizing an Electronic 
Vernier Digital Fractional 150mm caliper (n=10). Various regions within a single film were also 
measured for thickness so as to determine the consistency of individual films; the average 
thickness was determined and the standard deviation calculated. All samples were for this purpose 
cut into 10x20mm dimensions. The polymeric films were visually evaluated for color, presence of 
air bubbles and transparency.  
7.2.3.2. Determination of the tensile properties and Young's Modulus of the respective 
layers of the optimized bioadhesive multilayered intestinal patch  
Young's Modulus and other tensile properties of the layer of the optimized intestinal patch layers 
(n=3) were determined using the NanoTensile® 5000 (Hysitron Inc. Nanomechanical Test 
Instrument, Minneapolis, MN, USA). The NanoTensile® (NT) apparatus was calibrated prior to 
testing to ensure accuracy. Samples were cut into 2x15mm strips and then mounted onto NT 
mounting brackets, as demonstrated in Figure 7.2. The mounting brackets were held together with 
a cardboard frame to allow for sample placement, samples were attached to the brackets using 
cyanoacrylate based adhesive, thereby holding the samples in place during the experiment. 
Samples were allowed to cure; subsequently they were accurately measured for their width, 
thickness and length utilizing a digital caliper. The upper sample bracket was attached to the upper 
sample holder of the NT head, the cardboard frame was cut at the yellow points illustrated in 
Figure 7.2 to prevent interference during testing, and thereafter the mass was measured. The NT 
head was then lowered and the lower sample bracket attached to the lower sample holder on the 
NT platform. The mounting brackets were pulled apart at a constant rate of displacement of 
100µm/sec and the tensile properties of the sample were measured. 
188 
 
Figure 7.2: Illustration of NanoTensile® sample preparation and set-up.  
For comparative analysis the Young's Modulus of the optimized intestinal patch layers were 
determined using the Texture Analyser TA.XTplus (Stable Microsystems, England). Samples were 
cut into strips of approximately 12x5mm and were then mounted onto the tensile apparatus of the 
texture analyzer. The upper and lower ends of the polymeric film strip were secured into the upper 
and lower sample grips respectively. Samples were accurately measured in respect to their width, 
thickness and length using a digital caliper. Sample grips were moved apart at a constant speed 
and distance according to the test parameters. Test parameters were as follows: pre-test speed 
0.5mm/sec, test speed 0.5mm/sec, post-test speed 5mm/sec, trigger force 0.05N and distance 
20mm.  
7.2.3.3. Analysis of surface morphology of the optimized mucoadhesive and drug loaded 
layers  
Surface morphology of the optimized mucoadhesive and drug loaded layers were analyzed on a 
PhenomTM Scanning Electron Microscope (SEM) (FEI Company, Hillsboro, Oregon, USA). To 
qualitatively interpret the surface morphology of the respective layers in relation to surface area. 
Samples were firmly mounted onto aluminum stubs with carbon tape. They were then subjected 
to gold sputter coating under the influence of a vacuum of 0.1Torr with argon gas in a SPI-
ModuleTM Sputter Coater and SPI-ModuleTM Control (SPI Supplies, Division of Structure Probe 
Inc., West Chester, PA, USA). Individual samples underwent 90 seconds of coating to allow for 
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sufficient coverage of the sample. Microscopic imaging was then conducted on the PhenomTM 
SEM. 
7.2.3.4. Evaluation of the polymeric structural and vibrational frequency vibrations of the 
optimized mucoadhesive and drug loaded layers 
The vibrational molecular transitions of the optimized mucoadhesive and drug loaded layers upon 
conjugation and crosslinking reactions was characterized to attain vital micro-structural 
information via the use of an Attenuated Total Reflectance Fourier-Transform Infrared (ATR-FTIR) 
spectroscopy, recorded on a PerkinElmer® Spectrum 100 series fitted with a universal ATR 
polarization accessory (PerkinElmer® Ltd., Beaconsfield,UK). Samples were placed directly on the 
ATR crystal and FTIR spectra were recorded in the range of 4000-650cm-1.  
7.2.3.5. Evaluation of the degree of swelling and its effect on mucoadhesive characteristics 
of the optimized patch layers upon intestinal environment exposure  
The differences in the swelling of the optimized formulation layers with the exception of the backing 
layer (due to minimal swelling of the impermeable layer) were evaluated by exposing the 
respective layers to simulated intestinal conditions as described in Chapter 6, Section 6.3.4 (n=3). 
The degree of swelling and its effect on mucoadhesive characteristics were determined at 0, 2, 4, 
6, 8, 10, and 12 hours; fresh samples were assessed at each time point. The degree of swelling 
promotes polymer chain entanglement with the mucin on the intestinal epithelium, thus swelling 
affects the mucoadhesive characteristics of a drug delivery system; as a system undergoes 
erosion preceding swelling additional surface area is exposed for mucoadhesion to occur. Hence, 
gravimetric swelling analysis was conducted, where the respective optimized patch layers were 
subjected to the exact experimental conditions outlined in Chapter 6, Section 6.3.4. Each patch 
layer was removed from the dissolution apparatus at predetermined time points (0, 2, 4, 6, 8, 10 
and 12 hours). Excess dissolution medium (phosphate buffered saline (PBS) pH 6.8) was removed 
by placing the polymeric films on laboratory blotting paper for 1 minute prior to gravimetric 
analysis. The degree of swelling at each time point, stated as a percentage of PBS uptake was 
calculated based on the increase or decrease in weight of the formulation, Equation 7.1 was 
employed for this purpose;  
 
𝑆𝑤𝑒𝑙𝑙𝑖𝑛𝑔 %
(𝑃𝐵𝑆𝑢𝑝𝑡𝑎𝑘𝑒)=(
𝑊𝑡−𝑊0
𝑊0 )×100
 
Equation 7.1 
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Where swelling % is the percentage of PBS uptake by the respective polymeric patch layer at the 
specified time point, Wt. is the weight of the layer at the specified time point, and W0 is the initial 
weight prior to gravimetric analysis.  
7.2.3.6. Characterization of thermal transitions employing Differential Scanning 
Calorimetry 
With the intention of ascertaining chemical reaction and phase temperatures, as well as melting 
points (Tm) and glass transitions (Tg) of the optimized intestinal patch layers, the optimized 
mucoadhesive and drug loaded layers underwent thermal analysis employing a Temperature 
Modulated or Advanced DSC (TMDSC/ADSC) (Mettler Toledo DSC-1 STARe System, 
Schwerzenback, ZH, Switzerland) to assess the thermal characteristics of the statistically 
optimized system layers.  
Thermal transitions were analyzed in accordance with the measured Tg temperature in reaction to 
differences in crystallization (Tc) and melting temperatures (Tm). The instrument was calibrated in 
terms of temperature and enthalpy using indium. Thermal transitions of native polymers employed 
in the formulation of the respective optimized layers; namely hypromellose, chitosan, citric acid, 
Eudragit® RS100, calcium chloride and sodium alginate were compared to their related optimized 
formulation layers. Samples (±10mg) were accurately weighed into standardized 40µL aluminum 
sample pans which were then perforated and hermetically sealed. Samples were then heated from 
25-100˚C and held at 100˚C for 2 minutes so as to evaporate excess moisture present in the 
sample. The sample pans were then heated at 10˚C/minute between a temperature range of 25-
300˚C under constant purge of an inert nitrogen (N2) atmosphere (100mL/minute) do minimize 
oxidation.  
7.2.3.7. Ex vivo determination of mucoadhesive properties via textural analysis  
So as to evaluate the mucoadhesive properties of the optimized intestinal patch layers, the Work 
of Adhesion (WA) and the Maximum Detachment Force (MDF) needed to detach a hydrated 
polymeric film layer from an appropriately sized fragment of pig intestinal epithelial tissue was 
determined, employing a Texture Analyzer TA.XTplus (Stable Microsystems, England), utilizing 
the parameters as follows: pre-test speed of 0.5mm/sec, test speed of 0.5mm/sec, post-test speed 
of 10mm/sec, applied force of 5N, contact time of 10 seconds and trigger force of 0.05N (n=3). A 
portion of the pig intestinal epithelial was secured to a cylindrical flat tip TA probe, while a hydrated 
piece of the respective optimized polymeric layer was secured to the TA sample platform. 
Polymeric film layers were pre-impregnated with PBS; pH 6.8 prior to mucoadhesive testing for 
simulation of intestinal conditions. The probe was lowered to make contact with the mounted 
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polymeric patch layer inducing a test force, and consequently raised, while simultaneously 
measuring the MDF. Required data was captured textural profiles of Force: Distance curves.  
The WA (mJ) was derived from the Area Under the Curve of the force: distance curve (AUCFD) 
and the MDF (N) needed to detach the intestinal tissue from the polymeric patch layer was 
determined by measuring the maximum peak force from the force: distance curve. The Work of 
Adhesion per unit area (WA αβδ), was described by the work used on the matrices when the two 
contact phases i.e. the tissue (α) and the polymeric layer (β), formed an interface of unit area were 
then separated to form unit areas of each of the αδ and βδ interfaces. This is mathematically 
characterized by Equation 7.2.  
 
𝑊𝐴𝛼𝛽𝛿 = 𝛾𝛼𝛿 + 𝛾𝛽𝛿 − 𝛾𝛼𝛽 
Equation 7.2 
Where, γαβ, γαδ and γβδ are surface tensions between the phases comprising the intestinal tissue 
and polymeric film layers, α, β; α, δ and β, δ respectively. 
The ex vivo tensile mucoadhesive test outlined is adept to emulate in vivo processes to a certain 
degree. This method of testing provides information on the mucoadhesiveness of a delivery 
system and allows for characterization of mucoadhesive properties based on their respective 
performance. It is indicated that detachment of the dosage form from the biological tissue or 
substrate is a complex physical process, dependent on deformation and mechanical 
characteristics of the individual phases (Khutoryanskiy, 2011).  
7.2.3.8. In vitro perfusion studies  
In vitro perfusion tests were conducted to discern the dissolution process of the tablet encased 
mini gastrointestinal films as well adhesion of the films after dissolution of the encasing tablet 
(n=3).  During the experiment, an excised portion of the porcine intestine was placed horizontally 
in a Franz Diffusion Cell and the lumen was connected to tubing so that it could be perfused with 
phosphate buffered saline (pH 6.8). A longitudinal incision was made along the intestinal surface 
for observation. A tablet encapsulating 3 mini intestinal films was placed in the intestine and 
periodically observed so as to note the release, attachment and residence time of the optimized 
intestinal patches (Whitehead, et al., 2004). 
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7.2.3.9. Ex vivo drug permeation studies  
Ex vivo permeation studies were conducted to ascertain the effectiveness of the optimized 
intestinal patch as well as permeability of porcine intestinal mucosal tissue to sodium valproate. 
Studies were performed utilizing a Franz Diffusion Cell apparatus (PermeGear Inc., Bethlehem, 
PA, USA) equipped with a 12mL receptor compartment, clamp, stirrer bar and thermostat 
maintained water jacket (Figure 7.3). Porcine intestinal tissue which was excised following 
euthanasia of the animal subsequent to ethics approval was employed; the adhering fat and 
visceral debris was removed and the excised intestinal tissue washed with saline.  
Figure 7.3: Pictorial illustration of the Franz diffusion cell set up.   
 
Excised porcine samples with a thickness of 1mm were  clamped to the membrane platform of the 
Franz diffusion cell with the outside wall of the tissue facing the donor chamber, the receptor 
chamber equipped with a magnetic stirrer and sampling port was filled with simulated plasma 
(PBS; 12mL; pH 7.4; 37C). A known concentration of sodium valproate (2.5mg/mL) was placed 
in the donor compartment and permeation was determined via analysis of sodium valproate 
concentration in the receptor compartment by withdrawal of samples (100L) over a period of 8 
hours (Dureja, et al., 2001; Patel, et al., 2010). All samples were analyzed using UV Spectroscopy 
(IMPLEN Nanophotometric™ Implen GmbH, München Germany) and the concentration of sodium 
valproate determined via utilizing the calibration curve constructed in Chapter 6, Section 6.5.6 
(n=3). The flux (mg.cm-2.hr-1) of sodium valproate across the intestinal mucosa was calculated per 
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unit area at steady state concentration by linear regression analysis of permeation data employing 
Equation 7.3:  
𝐽
𝑑= 
𝐶𝑟
𝐴 ×𝑡
 
 Equation 7.3 
Where, Jd is the flux; Cr is the quantity of sodium valproate that diffused through the intestinal 
mucosa into the receptor compartment (mg); A is the cross-sectional area accessible for drug 
permeation (1.466 cm2) and t is the time of drug contact with the intestinal mucosa (hours).   
The permeability coefficient (P), subsequent to use of Fick's law, can be calculated with the use 
of Equation 7.4:  
𝑃 =
𝐽𝑑
𝐶𝑑𝑜𝑛𝑜𝑟
 
Equation 7.4 
Where P is the permeability coefficient; Jd is the flux and Cdonor is the drug concentration in the 
donor compartment.  
7.2.3.9.1. Integrity evaluation of the intestinal mucosal tissue 
Substantiation of tissue integrity is a crucial element for ex vivo analysis, as compromised tissue 
integrity for the duration of any preliminary tissue handling may misrepresent permeation results 
(Roberts, 1991). Tissue integrity was evaluated via ionic conductivity using a SevenMulti S40 
pH/electrical conductivity meter (Mettler-Toledo, Zurich, Switzerland) prior to and subsequent to 
experimental procedures.  The resistance Reduction Factor (RF) was calculated. RF is defined as 
the ratio of the initial resistance value at time 0 to the resistance value of the sample obtained at 
time t (Lavon, et al., 2005). The; as depicted by Equation 7.5:  
𝑅𝐹 =
𝑅0
𝑅𝑡
 
Equation 7.5 
Where R0/Rt is the ratio of the initial mucosal resistance to the mucosal resistance at time t.   
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7.2.3.10. In vitro drug release analysis  
The in vitro drug release studies on the optimized bioadhesive intestinal patches were carried out 
in a USP type II apparatus (Caleva, model 7ST) at 50rpm as described in Chapter 6, Section 6.5.7 
(n=3). Drug release samples were removed at predetermined time intervals over 24 hours with 
sink conditions being maintained with replacement of fresh dissolution medium. Samples were 
analyzed via UV spectroscopy as detailed in Chapter 6, Sections 6.2.7. 
7.3. Results and Discussion  
7.3.1. Physical characterization of optimized patch layers: Analysis of membrane 
uniformity 
Membrane uniformity evaluation of the optimized patch layers provided insight into the inter and 
intra formulation variability. Uniformity and constancy of the respective intestinal patch layers were 
important features to assess, as these parameters influence the mucoadhesive properties. The 
mean weight and thickness as well as the corresponding standard deviations of the respective 
intestinal patch layers are provided in Table 7.2. The standard deviations for tested parameters 
were<10% for all intestinal patch layers, thus indicating that all patch layers were consistent and 
uniform with a limited variability index. Upon visual examination the mucoadhesive and mucus 
cleaving layers displayed a yellow tint, with the mucus cleaving layer presenting a darker yellow. 
The drug loaded and backing layers were clear and translucent; all patch layers showed minimal 
bubble formation.  
Table 7.2: Optimized patch layers and their respective average weight and thickness.  
Optimized  Multilayered                                        
Intestinal Patch Layer 
Physical Parameters 
(Mean ± s.d, n=3) 
Mucus Cleaving Layer  Average weight: 10.19±0.6 
 Average thickness: 0.14±0.03 
Mucoadhesive layer  Average weight: 20.8±2.5 
 Average thickness: 0.18±0.04 
Drug Loaded Layer  Average weight: 16.53±5.5 
 Average thickness: 0.14±0.05 
Backing Layer  Average weight: 10.3±0.52 
 Average thickness: 0.15±0.02 
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7.3.2. Assessment of the tensile properties and Young’s Modulus of the optimized intestinal 
patch layers  
The stress-strain correlation of a particular material is greatly reliant on the flexibility of the 
respective compositional polymer chains and corresponding strength of the material as a whole. 
When a minor extent of stress is necessary to create a great amount of strain, the material is 
understood to be flexible and the analogous Young’s Modulus, highlighted in Figure 7.4a-d (which 
is the linear segment of the stress-strain curve) will be comparatively small (Leung and Ko, 
2011).Tensile characterization was performed as the bioadhesive intestinal patches are to be 
placed within an oral dosage form, which requires good tensile properties so as to withstand oral 
delivery. The average experimental values of Young’s Modulus (E), yield stress (σy) (magnitude 
of stress on stress-strain curve at which deformation occurs without significant increase in stress), 
ultimate strength (σu) (maximum stress endurable), ultimate strain (Ɛu) and toughness (uf) are 
outlined in Table 7.3. 
Table 7.3: Experimental values obtained from NanoTensile® and Textural Analysis of optimized 
patch layers (Mean ± s.d, n=3).  
Formulation E(MPa) E(MPa) NT σy (MPa) σu (MPa) Ɛu Uf (J/cm-3) 
Mucus Cleaving 
Layer 
0.27±0.249412 0.17±0.06321 0.01±0.05694 0.10±0.1251 0.629±0.2132 0.02±1.2460 
Optimized 
Mucoadhesive 
Layer 
0.05±1.512697 0.11±0.02346 0.01±0.06141 0.02±0.1121 0.391±0.1371 0 
Optimized Drug 
Loaded Layer 
13.09±0.42113 0.07±0.162133 0.31±0.15128 0.50±0.0043 0.100±0.1154 0.04±1.1170 
Backing Layer 0.26±0.349033 0.15±0.04211 0.07±0.04549 0.07±0.1261 0.350±0.1224 0.01±0.11 
  
The Young’s Modulus values were low indicating that the optimized patch layers demonstrated 
excellent elasticity and flexibility. The optimized Mucoadhesive layer containing CHT and HPM 
displayed higher elasticity (lower Young’s Modulus values), as compared to the drug loaded layer 
containing Eudragit®RS 100 and alginate. Both the mucus cleaving and backing layers revealed 
good elasticity indicated by low Young’s Modulus values. All polymeric film layers exhibited 
satisfactory degrees of strength and toughness to be able to endure/withstand placement within a 
tablet core and the process of oral drug delivery. 
 
196 
 
 
Figure 7.4: Typical stress-strain NanoTensile® profile of a) mucus cleaving layer b) optimized 
mucoadhesive layer c) optimized drug loaded layer and d) backing layer.  
 
7.3.3. Evaluation of surface morphology of the optimized mucoadhesive and drug loaded 
layers 
Scanning electron microscopy (SEM) studies were conducted to appraise the surface structural 
characteristics of the optimized patch layers (mucoadhesive and drug loaded layers). As 
previously discussed, micro-cracks and pores within a system promote mucoadhesion via the 
formation of an interlocking network thereby enhancing adhesion (Dodou, et al., 2005; Harsulkar, 
et al., 2011; Tangri and Madav, 2011).  
The mechanical premise of mucoadhesion as outlined in Chapter 7, Section 7.1 theorizes that 
surface irregularities and asymmetry promotes mucoadhesion via an increase in contact area. As 
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illustrated by the SEM images at a magnification of x4000 (Figure 7.5), both the mucoadhesive 
and drug loaded optimized formulations possess surface morphology idyllic for promotion of 
mucoadhesion. The optimized drug loaded layers (2,10 and 18 hours) formulations showed similar 
surface structures, the surface structure was noted to be smooth prior to exposure to simulated 
intestinal conditions (Figure 7.5a); however once exposed to intestinal conditions majority of the 
surface morphology remained smooth with the occurrence of small pores as illustrated with red 
circles in Figure 7.5c. The observed pores can be attributed to polymer erosion out of the film, 
with concurrent drug release. Conversely, the optimized mucoadhesive layer displayed micro-
cracks or fissure-like surface structure as shown by yellow arrows in Figure 7.5d. Due to these 
fissures not being present prior to swelling studies and taking into consideration that it is the focal 
physical variation upon exposure to simulated intestinal conditions, it may concluded that the 
observed fissuring is as a result of slower swelling areas forming the ridges illustrated by the yellow 
arrows in Figure 7.5d as compared to the smooth surface morphology of the optimized 
mucoadhesive film before swelling in Figure 7.5b. In addition, it was observed that there were no 
significant deviations in surface structure or morphology that would result in exorbitant differences 
in the comprehensive polymeric film performance, both within an individual film layer or between 
differing films.  
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Figure 7.5: Scanning electron micrographs depicting the surface morphology of a) optimized drug 
loaded layer and b) the optimized mucoadhesive layer c) optimized drug loaded layer after 
swelling and d) optimized mucoadhesive layer after swelling. 
 
7.3.4. Appraisal of the polymeric structural and vibrational frequency variations of the 
optimized mucoadhesive and drug loaded layers 
Fourier Infrared Spectroscopy (FT-IR) studies were performed for the optimized mucoadhesive 
and drug loaded layers due to the crosslinking and amalgamation reactions involved in their 
formulation processes. FT-IR spectra of the native polymers employed in the respective polymeric 
film layers were analysed in relation to the spectrum of the optimized formulations; to determine 
whether any constituents within the formulation interacted as a result of the polymer blending, 
crosslinking and film-casting procedures.  
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CHT (Figure 7.6a) demonstrates a characteristic peak at 1697.08cm-1 corresponding to the amide 
group; the hydroxyl group at 3443.28cm-1 and the C-O stretching at 1053.30cm-1. The FT-IR 
spectra of hypromellose (Figure 7.6b) depicts characteristic C=O aldehyde band at 1670cm-1 
(1690-1760cm-1), a strong transmittance band at 3497cm-1 relating to a normal O-H polymeric 
stretch; the transmittance band at 1138cm-1 is related to C-O phenol functional groups; N-H amine 
groups at 3354cm-1. In the FT-IR spectra  of citric acid (Figure 7.6c) carboxylic acid functional 
group at 2635.93cm-1 and C-H alkene functional group at 766.94cm-1. The spectra of lectin (Figure 
7.6d) displayed characteristic bands at 3253.65cm-1 descriptive of hydrogen bonded alcohols O-
H, 1639.46cm-1 representative of C=C alkyl stretch, an absorption band at 1518.09cm-1 related to 
NO2 nitro functional groups, and aryl/vinyl ethers at 1237.22cm-1. Analysis of the optimized 
mucoadhesive formulation (Figure 7.6e) revealed that all characteristic peaks present in the 
spectra of the native polymers were unaltered thus providing evidence that no covalent 
interactions between the polymers occurred; eliminating any detrimental effects on the 
mucoadhesive properties of the system. However, additional peaks in the region of 2100-2260cm-
1 was observed which represents C≡C terminal alkyne and 1590-1650cm-1corresponding to C=C 
aromatic double bond was noted. The appearance of two additional peaks demonstrates the 
successful lectin amalgamation to the chitosan: hypromellose blend. 
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Figure 7.6: FT-IR spectra of native polymers a) chitosan; b) hypromellose; c) citric acid; and d) 
lectin employed in fabrication of e) the optimized mucoadhesive layer.  
 
Figure 7.7a illustrated the FT-IR spectra of Eudragit® RS100, the characteristic peaks associated 
with Eudragit® RS100 includes an aldehyde functional group at 1722.54cm-1; 1383.28cm-1 C-H 
alkanes, and a peak at 1142.86cm-1 representative of C-O phenols. Alginate (Figure 7.7b) 
displayed characteristic absorption bands at 1404.87cm-1 descriptive of carbonyl ions, and a peak 
at 878.18cm-1 C-H stretch. N-H amine at a transmittance band of 3362.84cm-1 is characteristic of 
calcium chloride (Figure 7.7c); a peak at 1742.62cm-1 is representative of an alkyl carbonate; 
1139.67cm-1 expressive of C-O phenols, and a peak at 763.71cm-1 is descriptive of C-H an alkene 
functional group. Similarly, analysis of the native polymer spectra (Figure 7.7a-c) along with the 
optimized drug loaded layers (2, 10 and 18 hour) formulations (Figure 7.7d-f) revealed there were 
additional modified absorption bands that were indicative of the successful crosslinking reaction. 
Additional peaks at 1470-1430cm-1 illustrative of C-H methyl stretching, O-H aromatic ether at 
1270-1230cm-1; a transmittance absorption band at 1130-1190 representing C-N secondary 
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amine; a modified peak at 1370cm-1 displaying strong tert-butyl unsymmetrical doublet and a peak 
in the region of 800-1000cm-1 alkene out of plane C-H bending (Durig and Fassihi, 2002). The 
three optimized drug loaded formulations did not show any significant variations in spectra aside 
from the slight shift to higher frequencies as the crosslinking density increased. 
 
Figure 7.7: FT-IR spectra of native polymers a) Eudragit®RS100; b) alginate and c) calcium 
chloride employed in the fabrication of d) optimized 2hour; e) optimized 10hour and f) optimized 
18hour drug loaded layer formulations.  
 
 
 
 
202 
 
7.3.5. Elucidation of the degree of swelling and its effect on mucoadhesive characteristics 
of the optimized patch layers upon intestinal environment exposure  
The average degree of swelling and erosion of the drug loaded layers (2, 10 and 18 hour) was 
employed. Through gravimetrical analysis it was illustrated that with an increased exposure to 
simulated intestinal fluids, the optimized formulations swelled, resulting in a corresponding 
increase in weight of the polymeric films (Figure 7.9). The hydration of the polymeric chains allows 
reciprocal interpenetration between the polymeric film and mucin molecules, consequently 
creating stabilized interactions and thus strengthening the mucoadhesive characteristics of the 
optimized formulations (Salamat-Miller, et al., 2005; Roy, et al., 2009). Upon contact of the surface 
layer of the polymeric films to simulated intestinal conditions, surface occurring polymeric chains 
swelled permitting both mucoadhesion and weight gain (swelling) (Figure 7.8a). With constant 
exposure, the surface layer disintegrates and undergoes erosion out of the film, resulting in a 
decrease in weight (erosion) (Figure 7.8b).  The underlying polymeric chains subsequently 
become exposed to the surrounding dissolution medium and experience supplementary swelling, 
promoting mucoadhesion. Hence, fluctuating degrees of swelling was observed at various time 
points resulting in variations in percentage mucoadhesion over time.  
 
Figure 7.8: Schematic illustration of the proposed process resulting in the fluctuations observed 
in swelling and hence in mucoadhesion characteristics of the optimized formulations.  
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All system layers gravimetrically studied displayed relatively intermediate rates of erosion (Figure 
7.9). As a result, fluctuations in the degree of swelling as a function of time was observed. 
However, the reduction in percentage swelling did not significantly hinder the mucoadhesive 
characteristics of the formulations, as seen in mucoadhesion results in Chapter 7, Section 7.3.7. 
It may thus be deduced that the polymeric patch layers displayed satisfactory swelling properties 
over the specified test period and thus promoted and maintained adequate mucoadhesion over a 
prolonged period of time, allowing for a greater residence time necessary for pulsatile drug 
delivery.  
 
 
 
 
 
 
 
 
 
 
Figure 7.9: Graphical illustration of the variations in degree of swelling and erosion of a) optimized 
mucoadhesive layer b) optimized drug loaded layers and c) the mucus cleaving layer. 
 
7.3.6. Analysis of thermal transitions  
Thermal evaluation was conducted for the optimized mucoadhesive and drug loaded layers so as 
to ascertain the effect of crosslinking and amalgamation reactions on the thermal characteristics 
of the respective layers. DSC thermograms of native polymers used in the formulation process of 
the optimized mucoadhesive (Figure 7.10A; a-d) and drug loaded (Figure 7.10B; a-c) layers were 
evaluated in comparison to the thermogram of the optimized formulations.  
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Thermal analysis of the optimized mucoadhesive formulation displayed a single small Tg related 
to enthalpy relaxation at 25.07C; this indicates that the native polymer components employed 
have exceptional miscibility and there exists strong hydrogen bonding interactions between the 
respective polymer networks (Figure 7.10A; e). In the case of native polymer components being 
immiscible there would be two Tg peaks observed within the thermograms corresponding to the 
respective native polymers (Zhang et al., 2004; Yue et al., 2008). A crystallization peak is observed 
at 117.62C, this crystallization peak is reciprocated in the thermograms of CHT (Figure 7.10A; a) 
and lectin WGA (Figure 7.10A; d) at higher temperatures of 211.56 and 238.57C respectively, 
this represents shift of the polymers to a more ordered state. These thermal events are followed 
by sample melting at 192.02C which illustrates the return of the polymer system to a less ordered 
form, this is followed by decomposition of the sample at 242.82C. Solvent evaporation from the 
optimized formulation occurs at 261.05C thus resulting in complete dehydration of the system.   
DSC evaluation of the optimized drug loaded layers (2, 10 and 18 hour formulations) (Figure 
7.10B; d-f) all displayed Tg in the range of 86.36-101.15C; it was noted that as the degree of 
crosslinking was increased the Tg shifted to higher temperatures. The optimized drug loaded layer 
formulations (2, 10 and 18 hour) displayed crystallization peaks at 144.47C; 146.25C and 
143.82C respectively, which may be attributed to the crystallization of the system with the 
emergence of nuclei of calcium chloride. The optimized 18 hour drug loaded formulation illustrated 
a peak at 283.00C representative of partial oxidation of samples with residual oxygen within the 
hermetically sealed pan. All formulations then displayed melting peaks between a temperature 
ranges of 210.19-283.34, this indicates that they undergo a transition from an ordered to an 
amorphous state and approximately 200C.  
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Figure 7.10: DSC thermograms of A) the optimized mucoadhesive layer (e); and native polymers a) CHT; b) hypromellose; c)citric acid; d)  
lectin WGA and B) the optimized drug loaded layers 2,10 and 18 hours (d-f); and the native polymers a) Eudragit®RS100; b) alginate and c) 
calcium chloride.
A)                                                                                                         B) 
Tg 
Tg 
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7.3.7. Ex vivo determination of mucoadhesive properties via textural analysis and a 
comparative evaluation via ex vivo perfusion 
Film-casting formed polymeric films that were uniform, clear, and flexible all through its structure 
for the drug loaded and backing layers; whereas in addition to these properties the mucoadhesive 
and mucus cleaving layers displayed a yellow tint. Figure 7.11 illustrates a typical force: distance 
curve obtained via mucoadhesive textural analysis. The MDF (N) (highlighted with a blue arrow) 
and the WA (mJ) (area highlighted in pink) are related to mucoadhesive properties, where the 
higher the MDF and WA the stronger the mucoadhesive properties.  
 
 
Figure 7.11: Typical textural profile demonstrating the MDF (N) and WA (AUCFD) (mJ). 
Mucoadhesion was achieved from the mucoadhesive, drug loaded, mucus cleaving and backing 
layers respectively (Figure 7.12). All intestinal patches displayed satisfactory mucoadhesion in 
respect to their individual functionalities within the system.  
Mucoadhesive analysis revealed that the mucoadhesive and mucus cleaving layers displayed the 
highest levels of mucoadhesion (MDF=5.9±0.0015; AUCFD= 6.179±0.001mJ) and 
(MDF=4.5±0.004; AUCFD=4.779±0.002mJ) respectively (Figure 7.12). The greater degree of 
mucoadhesion observed may be attributed to the presence of CHT, hypromellose and lectin WGA 
N-acetyl-cysteine and all known for their mucoadhesive characteristics. However, the fact that 
Force (N)
Distance (mm)
12
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CHT and hypromellose are cationic and non-ionic polymers respectively it is most likely that the 
mucoadhesive characteristics observed are attributable to lectin WGA and N-acetyl-cysteine. The 
mucoadhesion observed by the presence of hypromellose is related to the diffusion theory; where 
polymeric chains interpenetrate with the mucin layer thus promoting mucoadhesion. The drug 
loaded and backing layers demonstrated intermediate mucoadhesion (MDF=3.5±0.002; 
AUCFD=3.761±0.001mJ) and (MDF=2.121±0.004; AUCFD=2.4±0.003mJ) this may be associated 
with the mucoadhesive characteristics of alginate and ethyl cellulose.  
  
Figure 7.12: A comparison of a) Maximum Displacement Force (MDF)(N) and b) Work of 
Adhesion (AUCFD) (mJ) of intestinal patch layers in phosphate buffered saline (pH 6.8) (n=3; SD 
˂ 0.025).  
 
As the proposed drug delivery system requires mucoadhesion to ensure site-specific prolonged 
drug delivery, it was thought necessary to study the release, adhesion and dissolution of the 
intestinal patches. The prolonged contact of patches with the mucosa was confirmed by ex vivo 
perfusion studies; the results were documented via images (for clear illustration of the 
observations they have been schematically presented). Perfusion studies demonstrated that the 
patches adhered to the luminal wall by the most mucoadhesive surface exposed i.e. mucus 
cleaving layer. There were no patches that adhered via their backing layer region. When delivered 
in a tablet, the patches exited the tablet upon dissolution and adhered to the mucosa within ± 10 
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minutes (Figure 7.13a and b); thereafter the patches remained attached to the intestinal mucosa 
for the residual duration of the study with slow dissolution (Figure 7.13c).  
 
 
Figure 7.13: Schematic illustration of perfusion study observations.  
 
7.3.8. Ex vivo drug permeation studies  
Permeability studies of sodium valproate demonstrated a constant increase in the rate of flux over 
a period of 3, 4 and 5 hours respectively for the optimized drug loaded formulations (2, 10 and 18 
hours) to steady state concentration (Figure 7.14). At this particular point a plateau was reached 
due to saturation of the intestinal mucosa, and thus no additional molecules entered the receptor 
compartment of the FDC apparatus. This assessment illustrates the high degree of   permeability 
of sodium valproate, which may be accredited to its solubility characteristics resulting in increased 
dissolution. There was an observed variation in diffusion amongst the optimized drug loaded 
layers this is attributed to the difference in composition; with an increase in polymer and 
 
a) 
b) 
c) 
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crosslinking concentration so as to prolong drug release respective to the times chosen. It was 
shown that the flux was minimally reduced as the polymer concentration and crosslinking density 
increased; while permeability was satisfactory among all optimized drug loaded layers despite the 
variations in their composition so as to enable time controlled drug release.  
The flux at the plateau was determined to be 0.6116 mg.cm-2.hr-1; 0.6122 mg.cm-2.hr-1 and 0.5593 
mg.cm-2.hr-1 respectively for the optimized drug loaded formulations (2, 10 and 18 hours) with the 
permeability coefficient determined to be 1.1366; 1.136 and 1.0831 respectively (Table 7.4). The 
data obtained determined that in the pig model, sodium valproate would undergo relatively quick 
absorption.  
 
Figure 7.14: Ex vivo permeation profile of sodium valproate across excised porcine intestinal 
mucosa (n=3; SD ≤0.02 in all cases).  
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Table 7.3: Sodium valproate flux and permeability coefficient as determined via ex vivo 
permeability analysis. 
Drug Loaded 
Layer 
Flux (Jd;mg.cm-2.hr-1) Permeability 
Coefficient  
DL 2hr 0.6116±0.004 1.1366±0.012 
DL 10hr  0.6122±0.002 1.136±0.011 
DL 18hr 0.5593±0.004 1.0831±0.011 
 
7.3.8.1. Porcine intestinal mucosa integrity evaluation  
Evaluation of the porcine intestinal mucosa displayed a RF of 1±0.03. This analysis thereby 
elucidated that the intestinal mucosa had maintained its integrity with negligible variation in 
resistance factor notwithstanding its delicate structure. The RF calculated validates the sodium 
valproate permeation results.  
7.3.9. In vitro drug release analysis  
Drug release occurs after a short lag-phase (due to the dissolution of enteric coating and tableting 
excipients) from patch 1 (DL 2hr) corresponding to the first pulse release. The concentration of 
polymer and degree of crosslinking within the patch 2 (DL 10hr) and patch 3 (DL 18hr) govern and 
control the rate of release from these respective layers. The optimized patches protect drug from 
release for approximately 6 hours respectively to allow for the ''switch-off'' phase. Theoretically 
release should not occur from any two patches at the same time. A schematic of this process is 
outlined in Figure 7.15.  
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Figure 7.15: Schematic illustrating ideal drug release profile requisite for the bioadhesive 
multilayered intestinal patch system.  
 
In vitro performance studies demonstrated that bioactive release from the optimized device is a 
complex interplay of system structure and composition of excipients employed in the formulation 
process.  Figure 7.16 depicts the drug release profile of the optimized bioadhesive multilayered 
intestinal patch formulation. The observed release profile mirrors triphasic release with an initial 
lag-phase attributed to the tablet dissolution process and attachment of the patch to the intestinal 
wall via the mucus cleaving and mucoadhesive layers as well as swelling of these respective 
layers. The initial pulse provides rapid drug release with 40% of loaded drug (DL 2hr) being 
released within approximately 3 hours; while the second and third patches allow for controlled 
drug release. The rate of drug release during the second and third pulses are governed by the 
concentration of polymer, degree of crosslinking, and interpenetrating polymer networks present 
between patches and patch layers. The system displayed ˃70% bioactive release over 24 hours.  
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Figure 7.16: Drug release profile of the optimized bioadhesive multilayered intestinal patch 
device. 
 
For analytical conclusion of drug release, in vitro release data obtained via dissolution studies 
were plotted as a function of fractional release vs. time (Figure 7.16). Linear regression analysis 
of the data provides an R2= 0.9568 (t0-24). Hence, the optimized formulation does not follow zero-
order kinetics as predicted. When drug release data was plotted employing the Higuchi model, the 
resulting plot demonstrated release of bioactive from the optimized system as a square root of 
time.   
7.4. Concluding Remarks  
Both optimized layers (mucoadhesive and drug loaded) formulations achieved a high desirability 
with optimization. This chapter demonstrated the manner in which the optimized formulation layers 
would react upon exposure to simulated intestinal conditions, providing constructive information 
required to predict the formulation's in vivo performance. Tensile analysis revealed that the 
optimized formulation layers possesses suitable elasticity and flexibility, necessary for embedding 
within a tablet and for oral drug delivery. SEM displayed that physical structure of the polymeric 
film layers were satisfactory and in line with interactions upon swelling. Variations observed in the 
mucoadhesive characteristics were related to the physical alterations (concurrent swelling and 
erosion) of the optimized system upon exposure to simulated intestinal conditions. Drug release 
studies displayed ideal triphasic release over 24 hours.  
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CHAPTER 8 
IN VIVO ANALYSIS OF THE DUAL LAYERED ORAL DRUG DELIVERY SYSTEM 
COMPONENTS IN RELATION TO MARKETED GOLD STANDARD 
FORUMULATIONS 
 
This study had received the approval of the Animal Ethics Screening Committee of the 
University of the Witwatersrand with ethics clearance number 2013/23/04 (Appendix 11.3). 
Ethics clearance was granted for the ex vivo and in vivo studies.  
8.1. Introduction  
A fundamental step in the design and fabrication of a new drug delivery system is performing in 
vivo animal studies. Information generated can be used to assess the safety and efficacy of a 
dosage form and mostly to predict the pharmacokinetics and pharmacodynamics of the system in 
humans (Dali et al., 2006). Selection of an applicable/appropriate animal model depends greatly 
on the specified dosage form and frequency of dosing (Hildebrand, 1991).  
The Large White Pig model is assuredly expedient over other animal models such as rabbits and 
dogs for more accurate validation and correlation of data with human doses. As the use of rabbits 
and rodents are excluded due to the size of oral dosage forms and the multiple samples required; 
the use of dogs is limited due to their restricted availability and high costs (Kostewicz et al., 1996). 
The pig (Sus scrofa domestics) has attained acclaim as an animal model in biomedical research 
fields mostly due to the anatomical similarities it shares with humans. In addition, they are large 
animals thereby allowing for multiple blood sampling and have similarities to humans in terms of 
metabolism, biotransformation (CYP450) and dietary habits amongst others (Brunet et al., 2006).  
With frequent blood sampling the comprehensive identification and quantification of drug release 
is achievable. The explicit prevalent utilization of the pig model for in vivo drug delivery studies on 
an ethical level adds supplementary validity to the use of the Large White Pig model for 
assessment of the optimized dual-layered xerogel-bioadhesive intestinal patch tablet components. 
Thus this Chapter involves the in vivo administration of the conventional drug products and the 
optimized dual- layered xerogel-bioadhesive intestinal patch tablet components containing 
sulpiride (xerogel component) and sodium valproate (bioadhesive intestinal patches component), 
for assessment of the performance, safety and tolerability of the optimized formulations in the 
Large White Pig model.  
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The purpose of this study was the development of an innovative 'smart' dual-layered oral delivery 
system intended to deliver multiple drugs individualistically within the intestine. The preceding 
Chapters of the current thesis identified and detailed the various formulation variables employed 
in fabrication of the drug delivery system and are further summarized in Figure 8.1. The system is 
composed of two components, intended for delivery of sulpiride and sodium valproate 
respectively. Layer one of the dual-layered tablet comprises an s-IPN xerogel for sustained 
release of sulpiride; whereas Layer two comprises bioadhesive multilayered intestinal patches 
(n=3) for the pulsatile delivery of sodium valproate, each  patch includes; a mucus cleaving layer, 
a mucoadhesive layer, a drug loaded layer and a backing layer.  
 
Figure 8.1: Summary of system assembly. 
8.2. Materials and Methods  
8.2.1. Materials 
The materials described in Chapter 5, Section 5.2.1 were employed in the fabrication of the s-IPN 
xerogel component (Layer 1 of the dual-layered system), while the bioadhesive multilayered 
intestinal patches (Layer 2 of the dual-layered system) were fabricated employing the materials 
described in Chapter 7, Section 7.2.1. Carboxymethylcellulose sodium (CMC) and magnesium 
stearate purchased from Sigma Aldrich (Sigma Aldrich (Pty) Ltd., St. Louis, MO, USA) were 
System Assemblage: The system was assembled 
with the use of the solvent casting method. Each 
polymeric layer was casted onto the previous 
solvent casted dried layer as a solution and placed 
under the fumehood until all layers were 
successfully adhered to one another. The patches 
were then embedded within a polymeric tablet 
which was in turn attached to the s-IPN xerogel 
layer via the application of a compression force 
employing the manual carver press.  
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utilized to assemble the dual-layered tablet. Solvents employed for UPLC-MS/MS measurements 
were of UPLC grade and all other reagents were of analytical grade. Double deionized water was 
obtained from a Mili-Q water purification system (Mili-Q, Millipore, Bedford, MF, USA).   
For UPLC analysis of sulpiride: UPLC grade solvents employed for UPLC measurements included 
Acetonitrile (ACN) 200 (ROMIL- SpS™ Super Purity Solvent (CH3CN), Assay ˃99.9%), Acetone 
purchased from Merck (Darmstadt, Germany), Dichloromethane, Triethylamine and 
Metocloperamide, utilized as an internal standard were all purchased from Sigma Aldrich (Sigma 
Aldrich (Pty) Ltd., St. Louis, MO, USA), all of which were of analytical grade and employed without 
any further purification. A marketed gold standard formulation was obtained from Sanofi-Aventis 
(Sanofi-Aventis (Pty) Ltd., Paris, France).  
UPLC analysis of sodium valproate: UPLC grade solvents employed for UPLC measurements 
included Acetonitrile (ACN) 200 (ROMIL- SpS™ Super Purity Solvent (CH3CN), Assay ˃99.9%), 
Methanol purchased from Merck (Darmstadt, Germany), Orthophosphoric acid, Ammonium 
acetate, and hydrochlorothiazide (internal standard) all of analytical grade were purchased and 
from Sigma Aldrich (Sigma Aldrich (Pty) Ltd., St. Louis, MO, USA). A marketed gold standard 
formulation was obtained from Sanofi-Aventis (Sanofi-Aventis (Pty) Ltd., Paris, France). A total of 
10 female Large White Pigs were employed in the study, each healthy and of an average weight 
of 35kg. Fresh blank (control) plasma was routinely withdrawn via catheterized pigs. The acquity 
UPLC® BEH Shield C18 RP 1.7m column (2.1x100mm) was utilized to separate analytes. The 
sample vials used were 2mL ANSl48 vials which were LCMC certified and clear, pre-slit silicone 
screw-top vial.  
8.2.2. Preparation of system components  
The ODLS components (s-IPN xerogel and bioadhesive intestinal patches) were prepared in 
accordance with the methodologies detailed in Chapters 5 and 7, Sections 5.2.2 and 7.2.2 
respectively. 
8.2.3. Habituation of pigs prior to drug study commencement  
Pigs were housed in a farm unit maintained under a 12 hour light and dark cycle and fed a 
commercial diet. Figure 8.2 is a digital photograph showing the farm unit and housing of the pigs 
and the daily habituation process. Habituation was necessary prior to dosage form administration 
so as to reduce the challenges associated with handling the animals for administration of 
formulations and blood sampling. The habituation involved visiting the animals twice daily and 
during these visits feeding them ''treats' such as raisins as well as patting and brushing them.  
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Figure 8.2: Farm unit, housing, daily habituation (feeding and behavioral learning) of the Large 
White Pig. 
8.4.4 Surgical implantation of a chronic catheter into the left jugular vein 
It was decided that the most efficient way to sample blood from the pig was via insertion of a 
jugular catheter due to it resulting in the least distress to the animal as compared to the drawing 
of blood via a marginal ear vein. The surgical procedure was performed by the chief veterinarian 
and supporting staff of the Central Animal Services (CAS) at the University of the Witwatersrand.  
Prior to catheterization the pigs were anaesthetized (using Ketamine (11mg/kg I.M; Midazolam 
(0.3mg/kg I.M)) and then transported to the operating room for preparation for surgery. The 
preparation prior to surgery included the administration of antibiotics and analgesics 
(Buprenorphine 0.05mg/kg I.M; Carpofen 4mg/kg I.M).  
The surgical area (left neck and shoulder) of the pigs were prepared by shaving and sterilization 
of the area. Once intubated, anesthesia was maintained with 2% isoflurane in 100% oxygen as 
shown in Figure 8.3.    
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Figure 8.3: Digital images demonstrating a) oxygen supply to animal after anesthesia; b) 
administration of injections and c) shaving of the surgical area (indicated by red circle).  
Figure 8.4 a-d are digital images demonstrating the preparation for surgery. Within an aseptic 
environment, the left jugular vein was exposed by an incision made dorsal to the jugular groove 
on the left lateral aspect of the neck. To prevent jugular vein collapse during surgery the catheter 
(a 7 French gauge double lumen 35cm catheter (CS-28702) obtained from Arrow Deutschland 
GmdH, Erding, Germany) was first tunneled subcutaneously to the exit point located on the cranial 
aspect of the scapular. The external ports of the catheter were sutured to the skin of the pig to 
limit displacement and bending. Subsequently, the catheter was surgically inserted approximately 
10cm into the left jugular vein as shown in Figure 8.4. The lumen of the catheter was fastened to 
the wall of the vein employing a purse suture. To evaluate the functionality of the catheter, blood 
was withdrawn from the catheter after which the catheter was flushed with heparinized saline 
(1000i.u of heparin in 1L of 0.9% saline). Throughout the period of surgery, the pigs' vital signs 
(i.e. heart rate, blood pressure, respiratory rate, body temperature) were constantly monitored. 
Following surgery, the pigs underwent a 10 day recovery period. For the duration of this time the  
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habituation process facilitated blood sampling and flushing of the catheters three times daily with 
heparinized saline. In addition, the surgical entry and exit points were continuously observed for 
any sign of infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.4: Digital images of surgical implantation of the jugular catheter.  
8.4.5 Administration of the marketed gold standards and the optimized system 
formulations to the Large White Pig model  
The dosing procedure was performed in conjunction with the animal technicians at the CAS. To 
assist dosage administration, pigs were sedated to allow for insertion of an intra-gastric tube. A 
Intubation 
Vital Signs 
Monitoring 
Surgical 
incision 
Exposure 
of jugular 
vein 
 
Catheter 
Insertion 
External 
Ports 
a) b) 
c) d) 
e) f) 
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total of 5 pigs (n=5) were orally dosed with either the optimized formulation components (as the 
dual-layered system as whole would not be able to be administered to the pig due to size 
restrictions; in addition, the system components act independently of each other and separate 
upon exposure to intestinal conditions) or the respective marketed gold standard formulation via 
an intra-gastric tube as illustrated in Figure 8.5. This aided in averting physical alteration or 
damage to the system which may arise from mastication by the pigs. For anesthesia Dormicum® 
and Anaket® were administered directly into the jugular vein catheter. Sedation was maintained 
with 2% isoflurane and 100% oxygen with the pigs' vital signs being continuously monitored. 
Subsequently, the intra-gastric tube was inserted into the stomach of the pig while being held 
upright. To make certain that the drug delivery system was not lodged in the intra-gastric tube, 
50mL of water was poured down the tube before removal of the intra-gastric tube. Whilst still under 
sedation, all surgical sites were examined for infection or injury. Thereafter, the animal was 
returned to its housing unit for recovery under observation.  
 
 
Figure 8.5: Sequential digital images depicting the process of dosage administration.  
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8.2.6. Blood sampling protocol from the surgically implanted jugular vein catheter 
Administration of the respective dosage forms were performed with the use of 5 pigs at a time, 
which were dosed separately with a 3 day wash out period between each dosing in accordance 
with the half-life of the respective drugs. Dosage administration was divided into six groups (Figure 
8.6). Following administration of the respective dosage forms and the wearing off of anesthesia, 
blood sampling occurred at pre-determined time intervals over a 24 hour test period (0 ,2, 4, 6, 8, 
10, 12, 16, 20, and 24 hours). Animals were preoccupied with food which allowed for effortless 
blood sampling. The surgically implanted jugular catheter external ports were disinfected, flushed 
with heparinized saline to remove any blood cloths and then 10mL of blood was withdrawn and 
placed in a lithium heparin vacutainer®. Thereafter, the external jugular ports were again flushed 
to clear away any residual blood in the ports so as to prevent clotting and hence blockage of the 
catheter. Withdrawn blood samples were centrifuged at 5000rpm for 15 minutes to aid in the 
extrication of red blood cells, the plasma supernatant was removed and frozen at -70C until 
analysis.  
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Figure 8.6: Schematic illustrating the quantity of pigs required and the procedural steps involved 
during in vivo studies    
5 pigs in each group 
Anesthesia: Ketamine HCl 40mg/kg; 
Xylazine HCl (10mg/kg) and topical 
procaine HCl (0.5%). 
Blood sampling: 10mL blood samples 
withdrawn from catheterized jugular vein 
at 0, 2, 4, 6, 8, 10, 12, 16, 20 and 24 
hours. Samples were centrifuged and 
stored at -70C. 
UPLC analysis: 
plasma drug 
concentration 
analyzed employing 
Wash out period: Pigs were 
put back into stock and were 
then returned to the study 
after a wash out period of 3 
days before the next dosing.  
Total Study Group: 15 Pigs 
Drug Delivery Systems:  
 Group 1: Optimized s-IPN xerogel  
 Group 2: Conventional 50mg 
 Group 3: s-IPN xerogel loaded with sulpiride 
alone (control) 
 Group 4: Optimized bioadhesive intestinal 
patches. 
 Group 5: Conventional 200mg  
 Group 6: Placebo intestinal patch 
222 
 
8.3. Quantification of In Vivo Release of the Model Drugs Employed Utilizing Ultra-
Performance Liquid Chromatography Analysis 
The optimized dosage form encompassing both the s-IPN xerogel layer and the bioadhesive 
multilayered intestinal patch layer resulted in a dosage form that exceeded the size restrictions of 
the CAS's ethical protocol as dosage forms that are above the intra-gastric tube size restrictions 
specific to animal weight and size may result in esophageal hemorrhage and ultimately death of 
the animal (Tablet size specifications: Thickness= 0.7cm and width= 0.8cm). The animals 
employed in the study had an average weight of 45kg’s, for this reason a smaller intra-gastric tube 
is utilized. Therefore, due to the respective layers detaching from each other upon contact with 
dissolution medium and thus functioning independently of each other it was not deemed necessary 
to dose them together. For this reason the respective system layers were dosed separately and 
analysis was conducted independently.  
An Ultra-Performance Liquid Chromatography (UPLC) method was employed using a Waters® 
ACQUITYTM LC system (Waters®, Milford, MA, USA) coupled with a photodiode array detector 
(PDA), and Empower® Pro Software (Waters®, Milford, MA,USA). The UPLC apparatus was fitted 
with an Acquity UPLC® BEH Shield C18 RP column (2.1x100mm), with a particle size of 1.7m. 
For analysis of sulpiride from the s-IPN xerogel layer an isocratic method with a run time of 1 
minute was used employing triethylamine (0.5%): acetonitrile: methanol [10:5:85 v/v/v] (solvent A) 
and acetonitrile 100% (solvent B) as the mobile phase in a 50:50 ratio. The flow rate was 
0.3mL/minute with an injection volume of 10L. The PDA detector was set at 300nm. 
Metocloperamide was used as the internal standard (IS) (Giorgi, et al., 2015).  
For UPLC analysis of sodium valproate from the pulsatile release bioadhesive multilayered 
intestinal patches the mobile phase was ammonium acetate 10mM (solvent A) and acetonitrile 
100% (solvent B) at a run time if 3 minutes employing an isocratic method (50:50 ratio). The flow 
rate was set at 0.15mL/minute with an injection volume of 10L. The PDA detector was set at 
215nm; hydrochlorothiazide was utilized as the IS. The analysis was conducted at room 
temperature (21C) (Proença et al., 2011). Table 8.1 details the mobile phases/solvents used 
during UPLC analysis:  
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Table 8.1: Mobile phases and priming solvents used for determination of sulpiride and sodium 
valproate in plasma samples. 
 
Solvent/ Mobile phase  
 
Solvent Concentrations 
 
Sulpiride Sodium Valproate 
Strong wash Acetonitrile (ACN) (90%): 
Double de-ionized water 
(10%). 
Acetonitrile (ACN) (90%): 
Double de-ionized water 
(10%). 
Weak wash Acetonitrile (ACN) (10%): 
Double de-ionized water 
(90%). 
Acetonitrile (ACN) (10%): 
Double de-ionized water 
(90%). 
Solvent A line  Triethylamine (0.5%): ACN: 
Methanol [10:5:85] 
Ammonium acetate 10mM 
Solvent B1 line  Acetonitrile (ACN) (100%) Acetonitrile (ACN) (100%) 
Solvent B2 line  Methanol (100%) Methanol (100%) 
 
8.3.1. Preparation of calibration standards 
Standard stock solutions of sulpiride and sodium valproate, as well as their respective IS's 
metocloperamide and hydrochlorothiazide were prepared in ultra-pure double de-ionized water 
(Milli-Q, Millipore, Johannesburg). A working standard solution of sulpiride and sodium valproate 
(0.25mg/50mL) was used to prepare the calibration standards with concentrations ranging 
between 0.2-100g/mL via dilution of appropriate quantities of the stock solution with de-ionized 
water prior to injection into the UPLC.  
8.3.2. Calibration sample preparation of plasma employing liquid-liquid extraction 
In vivo frozen blank plasma samples were allowed to thaw at room temperature (±25C). Extraction 
of plasma containing sulpiride: aliquots of plasma (1000L) was transferred to polypropylene 
tubes. A 1000L aliquot of drug stock solution; 1N sodium hydroxide (1000L) and ethyacetate: 
methanol (5:1v/v) (6000L) was then added to the tube and vortexed for 2 minutes. Thereafter the 
mixture was centrifuged at 5000rpm for 10 minutes. The supernatant was collected and placed in 
a polytop bottle, to which 200L of mobile phase was added; subsequently the mixture was dried 
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under the influence of liquid nitrogen. To the dried residue 1000L of mobile phase was added for 
dilution of the drug residue. To a 500L aliquot of plasma, the IS standard solution (0.25mg/50mL, 
1000l) was added and vortexed for 1 minute prior to injection.  
For analysis of sodium valproate containing plasma: aliquots of frozen blank plasma samples 
(500L) were transferred to polypropylene tubes. The IS solution (0.25mg/50mL; 1000l); 10% 
ortho-phosphoric acid (v/v) (1000L) and 2000L of double de-ionized water was added to the 
tube. The mixture was vortexed for 2 minutes, followed by centrifugation at 5000rpm for 10 
minutes. The sodium valproate was then eluted with the addition of 2000L methanol, after which 
the mixture was dried with the use of liquid nitrogen. The dried extract was then reconstituted with 
2000L mobile phase. Solutions after completion of extraction were transferred to Waters® 
certified UPLC vials (ANSl48) for analysis. UPLC measurements were conducted in triplicate.  
8.3.3. Validation of liquid-liquid extraction methodologies 
The meticulousness and accuracy of the extraction procedures was determined via repetition of 
the extractions mentioned in Chapter 8, Section 8.5.2 on three consecutive days so as to establish 
the inter-day precision and accuracy, and intra-day variability which involved numerous UPLC 
analysis runs of samples within a 24 hour period. A measure of accuracy was achieved by 
employing the mean percentage error, which is centered on the variances between actual and 
predicted concentrations. The percentage yield of extraction was calculated by comparison of the 
peak areas when extracted from plasma (AUCplasma) and when extracted from standard solutions 
(AUCstandard solution) at an equal concentration using Equation 8.1:  
% 𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 𝑌𝑖𝑒𝑙𝑑 =  
𝐴𝑈𝐶𝑝𝑙𝑎𝑠𝑚𝑎
𝐴𝑈𝐶𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
× 100 
Equation 8.1 
8.3.4. Construction of calibration curves for the quantification of sulpiride and sodium 
valproate release from the dual-layered oral device  
Blank plasma samples were thawed at room temperature (±25C). Aliquots (100L) of blank 
plasma were transferred to polypropylene tubes and was then spiked with standard solutions of 
the model drugs (sulpiride/sodium valproate) and IS's (metocloperamide/ hydrochlorothiazide) at 
varying concentrations. The mixture was then vortexed for 2 minutes and the respective extraction 
procedure was performed described in Chapter 8, Section 8.5.2. The drug/IS peak area ratios 
were plotted against the corresponding drug concentration (ng/mL) and the statistical R2 value 
was derived for the obtained curve. 
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8.4. Pharmacokinetic Modeling Employing Non-compartmental and Compartmental 
Algorithms 
Based on the in vitro and in vivo release dynamics of sulpiride and sodium valproate from the 
respective components of the dual-layered oral device, compartmental analysis was performed 
utilizing pharmacokinetic data analysis and the use of PKSolver, a menu-driven add-in program 
for Microsoft Excel (Zhang et al., 2010). Polynomial regression analysis was employed for 
correlation of the observed and predicted values.  
Compartmental analysis was applied so as to quantitatively evaluate and predict in vivo outcome 
of sulpiride and sodium valproate from the dual-layered oral device via modeling of the 
concentration-time data by means of an appropriate pharmacokinetic compartmental model. The 
dual-layered oral device was considered a single extravascular dose with the bioadhesive 
multilayered intestinal patch component instituting an absorption lag. For this purpose four 
pharmacokinetic algorithms were employed as follows:  
 Non-compartmental 
 One compartmental 
 One compartmental with Tlag 
 Two compartmental with Tlag 
8.4.1. Pharmacokinetic analysis: in vitro-in vivo correlation establishment  
WinNonLin® software (V5.3 with IVIVC Toolkit Build 20091211139, Pharsight Software, Statistical 
Consultants Inc., Apex, NC, USA) was used for the development of a level A IVIVC; where the 
input data included in vitro sulpiride and sodium valproate release data and in vivo plasma drug 
release data. A requirement for the evaluation of IVIVC data is development and validation. Thus, 
the development of a level A IVIVC model follows a two-stage process:  
a) Deconvolution- where the observed fraction of drug absorbed is estimated based on the 
Wagner-Nelson method (Wang and Nedelam, 2002). After which the IVIVC model is developed 
utilizing the observed fraction of drug absorbed and the fraction of drug dissolved. Depending on 
the IVIVC model employed, the predicted fraction of drug absorbed is then calculated from the 
observed fraction of drug dissolved.  
b) Convolution- where the predicted fraction of drug absorbed is then convolved/intertwine with 
the predicted concentrations initiating the convolution method. The predictability of a level a 
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correlation's focal point is estimation of the percentage prediction error (%PE) between the 
observed and predicted concentration profiles.  
8.5. Results and Discussion  
8.5.1. Behavioral evaluation of pig’s post-surgical implantation of the jugular vein catheter 
and administration of the optimized formulations 
Post-surgical implantation of the jugular catheter (day 1), the pigs were slightly lethargic due to 
the effects of the anesthesia. Once the anesthesia wore off the animals displayed their usual levels 
of activity and appetite comparative to behavior monitoring prior to surgery. Blood sampling proved 
to be non-complex and time efficient thus demonstrating the feasibility of using jugular catheters 
for this purpose. Administration of both the components of the dual-layered oral device to the 
animals showed no adverse effects thus substantiating their biocompatibilities; in addition the 
dosing procedure employed i.e. dosing of the respective layers of the dual-layered oral device 
separately, and not as part of a single dosing proved to be advantageous as there was a 100% 
survival rate amongst both study groups therefore eliminating the likely harm to the animal upon 
intra-gastric dosing of large doses.  
8.5.2. Validation of the extraction procedure  
The mean variation of the intra-day and inter-day precision validation studies was determined to 
be 0.19% and 0.22% (sulpiride extraction) and 0.21% and 0.15% (sodium valproate extraction). 
Mean extraction yield of sulpiride and sodium valproate respectively from plasma was determined 
to be 93.5% and 91.3% (SD≤3.35 and 4.15 respectively). The liquid-liquid extraction procedures 
employed were thus verified as the optimum methodologies that provided a high degree of 
recovery of sulpiride and sodium valproate respectively.  
8.5.3. In vivo release of sulpiride and sodium valproate in the Large White Pig model from 
the dual-layered oral device components 
The UPLC calibration curves for plasma sulpiride and sodium valproate are depicted in Figure 
8.7a and b. The typical chromatograms (Figure 8.8a and b) displays retention times of s 0.6 and 
0.539 minutes for sulpiride and sodium valproate respectively.  
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Figure 8.7: Calibration curves of a) sulpiride at 300nm and b) sodium valproate at 215nm.  
  
a) 
 
 
 
 
 
 
 
 
 
 
b) 
228 
 
Figure 8.8: Typical chromatograms of a) sulpiride in plasma and b) sodium valproate in plasma; 
with their respective internal standards. 
 
The comparative plasma concentration profiles of sulpiride display discernible differences when 
administered as the optimized s-IPN xerogel matrix oral device or as the conventional capsules 
as illustrated in Figure 8.9. Although conventional capsules achieved a higher maximum plasma 
concentration (Cmax) of sulpiride (Cmax= 842ng/mL) as compared to the optimized device, where a 
Cmax of 830.58ng/mL was achieved, only the optimized device was able to achieve consistent or 
steady state plasma concentrations throughout the duration of the study (Figure 8.9). As a result, 
side effects experienced due to high drug concentrations are able to be avoided, ultimately greatly 
improving patient compliance. In order to achieve steady state concentrations, conventional 
capsules are most typically administered multiple times in the day, resulting in complicated 
treatment regimens. The optimized device is able to overcome the need for multiple doses, thus 
eliminating the need for complex treatment regimens.  
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For the conventional capsules it was noted that there was an initial ascension of plasma 
concentration after 0.5 hours, with a peak plasma concentration (Cmax = 842ng/mL) being reached 
at approximately 6 hours. This was followed by a swift reduction in plasma concentration for a 
further 8 hours. Thus it can be confirmed that for the conventional system, most of the drug was 
released by an initial burst before 6 hours after administration. This may be due to the lack of 
controlling mechanisms present within the conventional systems, which are compressed powders 
of sulpiride coupled with formulation excipients embedded in a capsule. 
 
Figure 8.9: Plasma drug concentration profile depicting the release behavior over 24 hours of 
Control (Sulpiride alone), optimized s-IPN xerogel matrix oral device and, Conventional.   
 
The control system tested comprised of the optimized s-IPN xerogel and sulpiride alone; a gradual 
release of drug was noted at the onset. The observed steady increase in drug release reached a 
Cmax of 859ng/mL after 6 hours. The plasma levels decreased thereafter till the end of the 24 hour 
period. The control system displayed steady state drug release over the duration of the study, 
however, it did show release in the initial two hours similar to that of the conventional system.  
The in vivo plasma concentration profiles of the optimized device and conventional capsules 
shown in Figure 8.9 shows that for the initial two hours post dosing, minimal sulpiride is released 
from the optimized device ( 211.09ng/mL) whereas a concentration of 700ng/mL is achieved from 
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conventional capsule within the same time period. The results obtained in the initial two hours 
subsequent to oral dosing provide the ultimate evidence of the efficiency of the optimized device 
in terms of site-specific drug delivery. Owing to enhanced site-specific drug delivery, a greater 
quantity of sulpiride is released in the intestine where a higher degree of absorption is attained. 
This can be seen from a comparison of the two hour blood sample; where the plasma 
concentration of sulpiride was noticeably lower (211.09ng/mL) from the optimized device, 
consistent with the time when the drug delivery system is yet to pass through the gastric region of 
the GIT, as opposed to the four hour blood sample (300ng/mL) corresponding to when the drug 
delivery system has entered the intestine.  
Furthermore, the reduced quantity of sulpiride release in the gastric region allows for greater 
absorption and thus improved bioavailability. As illustrated in Figure 8.9, the optimized device 
achieved consistent plasma levels of sulpiride throughout the duration of the study as compared 
to conventional capsules, therefore demonstrating desirable release behavior of the optimized 
device in the large pig model. The low therapeutic levels of drug that were reached may be due 
to the in vivo absorption and distribution characteristics of the drug. According to literature, 
sulpiride has an overall low systemic bioavailability (Chitneni, et al., 2011) which is confirmable 
with the low Cmax of sulpiride obtained. However, compared to the Cmax observed for the 
conventional, the optimized device displayed an increase in bioavailability as well as prolonged 
release over the 24 hour test period. 
Figure 8.10: Plasma drug concentration profile depicting the release behavior over 24 hours of 
the optimized bioadhesive multilayered intestinal patch oral device pulsatile component and 
conventional 200mg. 
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The relative plasma concentration profiles of sodium valproate exhibit distinct differences when 
administered as the optimized bioadhesive multilayered intestinal patch oral pulsatile device 
component or as the conventional capsules as illustrated in Figure 8.10.  
Conventional capsules achieved Cmax of 1886.4ng/mL at 6.25 hours, whereas the optimized 
pulsatile release component reached a Cmax of 2371.8ngmL at approximately 15.5 hours. The 
conventional system allowed for sustained release of sodium valproate over the 24 hour period. 
The efficiency and ability of the optimized system to release drug in a pulsatile, time controlled 
manner is advantageous and is made evident by the in vivo release profile shown in Figure 8.10. 
Pulsatile drug release differs from sustained release due to drug release occurring in a step wise 
manner in accordance with a time controlled system design, there is no constant level of drug as 
compared to sustained release, where drug concentrations remain constant. Due to the pattern of 
drug release achieved by the optimized pulsatile component of the dual-layered oral device the 
occurrence of adverse drug effects at high drug concentrations may be greatly reduced. 
Ultimately, the optimized pulsatile component will highly improve patient compliance. In order to 
achieve adequate therapeutic levels of drug the conventional system characteristically requires 
multiple administrations in a day, resulting in complicated treatment regimens and resistance. The 
combination of the optimized s-IPN xerogel matrix and the bioadhesive multilayered patch 
components into the single dual-layered oral device will significantly increase the therapeutic 
outcomes of schizoaffective patients, as an assemblage of improved patient compliance by means 
of the delivery of two bioactives in a single once daily dosage form and increased bioavailability 
will greatly enhance therapeutic management of schizoaffective disorder. 
8.5.4. Interpretation of the extravascular compartmental and non-compartmental 
pharmacokinetic model analysis  
The extravascular pharmacokinetic analysis results of the compartmental analysis for sulpiride 
and sodium valproate are presented in Tables 8.2 and 8.3 respectively. Evaluation of the 
pharmacokinetic analysis revealed that sulpiride release was best described by a one 
compartmental model without Tlag which displayed the most favorable AIC and SBC values 
determined via this algorithm (Table 8.2). The most idyllic  sum of squares (SS) and standard error 
(SE) values were also determined for the one compartmental model (SS=124344.8; SE=143.95). 
The minimal values for SS and SE are an indication of a lower fit illustrating a low variability in 
data points. Assessment of the R2 values and regression residuals (R observed-predicted) values, 
displayed a negligible difference of 0.03 between the one compartment model with Tlag and that 
of the one compartment model without Tlag.  
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Sodium valproate release was most appropriately by a one compartmental model without Tlag 
with the corresponding most affirmative AIC and SBC values (Table 8.3). The most ideal SS and 
SE values were also determined within the one compartmental model (SS=1433611.69; 
SE=423.32). There was an observed difference of 0.04 between the R2 values of the 
compartmental models with and without Tlag. 
Table 8.2: Compartmental analysis of plasma sulpiride data after extravascular input without and 
with lag.  
Parameter Units Average Value Diagnostics Value 
Extravascular Model without Tlag 
A ng/mL 6780.11 r obs-pre 0.904 
ka 1/h 0.1048 SS 124344.8 
K10 1/h 0.0799 WSS 124344.8 
t 1/2ka h 6.613 R2 0.95 
t 1/2k10 h 8.668 WR2 0.95 
V/F (mg)/(ng/mL) 0.0311 SE 143.95 
CL/F (mg)/(ng/mL)/h 0.0024 AIC 111.58 
Tmax  h 10.889 SC 112.16 
Cmax ng/mL 672.96 
AUC0-t ng/mL*h 11951.25 
AUC0-inf ng/mL*h 20103.76 
AUMC Ng/mL*h2 443217.75 
MRT h 22.04 
Parameter Units Average Value Diagnostics Value 
Extravascular Model with Tlag 
A ng/mL 17162.855 r obs-pre 0.987 
ka 1/h 0.266 SS 38444.2 
K10 1/h 0.2298 WSS 38444.2 
t 1/2ka h 0.000001 R2 0.984 
t 1/2k10 h 2.6033 WR2 0.984 
V/F (mg)/(ng/mL) 3.0162 SE 98.03 
CL/F (mg)/(ng/mL)/h 0.0213 AIC 92.455 
Tmax  h 0.0048 SC 92.77 
Cmax ng/mL 4.039 
AUC0-t ng/mL*h 928.76 
AUC0-inf ng/mL*h 9784.2 
AUMC Ng/mL*h2 10224.82 
MRT h 8.1 
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Table 8.3: Compartmental analysis of plasma sodium valproate data after extravascular input 
without and with lag. 
Parameter Units Average Value Diagnostics Value 
Extravascular Model without Tlag 
A ng/mL 31736.1 r obs-pre 0.852 
ka 1/h 0.1209 SS 1433611.69 
K10 1/h 0.10029 WSS 1433611.69 
t 1/2ka h 5.7308 R2 0.945 
t 1/2k10 h 6.9109 WR2 0.945 
V/F (mg)/(ng/mL) 0.0369 SE 423.32 
CL/F (mg)/(ng/mL)/h 0.0037 AIC 161.93 
Tmax  h 9.0661 SC 1630126 
Cmax ng/mL 2182.86 
AUC0-t ng/mL*h 39926.92 
AUC0-inf ng/mL*h 54030.86 
AUMC Ng/mL*h2 985427.85 
MRT h 18.23 
Parameter Units Average Value Diagnostics Value 
Extravascular Model with Tlag 
A ng/mL 17162.855 r obs-pre 0.987 
ka 1/h 0.266 SS 38444.2 
K10 1/h 0.2298 WSS 38444.2 
t 1/2ka h 0.000001 R2 0.984 
t 1/2k10 h 2.6033 WR2 0.984 
V/F (mg)/(ng/mL) 3.0162 SE 98.03 
CL/F (mg)/(ng/mL)/h 0.0213 AIC 92.455 
Tmax  h 0.0048 SC 92.77 
Cmax ng/mL 4.039 
AUC0-t ng/mL*h 928.76 
AUC0-inf ng/mL*h 9784.2 
AUMC Ng/mL*h2 10224.82 
MRT h 18.2 
 
A: the zero time intercept associated with the Alpha phase (an initial phase of rapid decrease in 
Plasma concentration due distribution) 
ka: 1st order absorption rate constant 
k10: Elimination rate constant 
Tlag: Finite time taken for a drug to appear in systemic circulation following 
Extravascular administration 
t1/2ka: Absorption half-life rate constant 
t1/2k10: Elimination half-life rate constants 
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V/F: The volume of distribution of the absorbed fraction 
CL/F: The observed total body clearance for extravascular administration 
Tmax: Time at which the maximum concentration (Cmax) is observed 
Cmax: Maximum observed concentration occurring at Tmax 
AUC0-t: Area Under the Curve (AUC) from the dosing time to the last measurable concentration 
AUC0-inf: AUC from dosing time extrapolated to infinity 
AUMC: Area Under the Moment Curve 
MRT: Mean Residence Time is the average amount of time the drug remains in a 
compartment or system 
  
Pharmacokinetic parameters for sulpiride determined by the one compartment model without Tlag 
depicted, a first order absorption rate constant (ka) of 0.1048/h, an elimination rate constant of 
0.0799/h, and an elimination half-life of 8.668/h. Additionally, the Cmax was determined to be 
672.96ng/mL with Tmax occurring at 10.889 hours. The indicated first order absorption rate 
constant confirmed the rapid transit of the oral device into the intestine, followed by fast absorption. 
The effectiveness of the optimized s-IPN xerogel component to provide the required concentration 
of sulpiride to exert effective antipsychotic effects was proved by the observed Cmax and the MRT 
of 22.04 hours. The determined AUC0-t and AUC0-inf values also exhibited a difference of 8152.51 
ng/mL*h, thus sulpiride clearance is relatively swift.  
Pharmacokinetic compartmental analysis of the sodium valproate in vivo release determined by 
the one compartmental model without Tlag was found to be the best fit. This algorithm displayed 
a first order absorption rate constant of 1.209/h. A Cmax of 2182.86ng/mL was observed with a 
Tmax of 9.0661 hours. The effectiveness of the intestinal patch component of the dual-layered 
oral device to provide pulsatile drug release over a 24 hour period was shown by the observed 
MRT of 18.23 hours; thereby allowing for sufficient time for pulsatile release from the delivery 
system. The elimination half-life was noted to be approximately 6.9109/h. The AUC0-t and AUC0-
inf (AUC0-t=39926.92ng/mL/h-1; AUC0-inf=54030.80 ng/mL/h-1) indicates elevated plasma drug 
levels, hence providing enhanced therapeutic efficacy. Results obtained via in vivo 
pharmacokinetic compartmental analysis of the dual-layered oral device components provided 
pertinent information on the gastric-emptying and transit time of the Large White Pigs used in the 
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study as well as absorption and elimination characteristics of sulpiride and sodium valproate 
respectively. Therapeutic levels of sulpiride for the Large White Pig was attained and maintained, 
whereas the therapeutic levels of sodium valproate were attained based on a time controlled 
design, with three pulses over 24 hours, ultimately proving the therapeutic efficiency and capability 
of the dual-layered oral device. 
Table 8.4: Results of the non-compartmental analysis of plasma sulpiride and sodium valproate 
data after extravascular input.  
Parameter Unit Value 
Sulpiride Extravascular non-compartmental model 
ʎz 1/h 0.1251 
t 1/2 h 5.536 
Tmax h 15 
Cmax ng/mL 816.34 
Tlag h 0 
Clast obs/Cmax  0.3979 
AUC0-t ng/mL*h 12303.26 
AUC0-inf-obs ng/mL*h 14898.35 
AUC0-t/0-inf-obs  0.825 
AUMC0-inf-obs ng/mL*h2 229288.5 
MRT0-inf-obs h 15.390 
Parameter Unit  Value 
Sodium Valproate Extravascular non-compartmental model 
ʎz 1/h 0.1426 
t 1/2 h 4.8617 
Tmax h 12 
Cmax ng/mL 2156.64 
Tlag h 0 
Clast obs/Cmax  0.4177 
AUC0-t ng/mL*h 40882.6 
AUC0-inf-obs ng/mL*h 47701.45 
AUC0-t/0-inf-obs  0.8661 
AUMC0-inf-obs ng/mL*h2 688218.6 
MRT0-inf-obs h 14.58 
 
ʎz: 1st order rate constant of the terminal (log-linear) portion of the curve terminal elimination rate 
constant 
t1/2: Terminal phase half-life. The time it takes for the concentration levels to fall to 50% of their 
value. 
Clast: The last quantifiable concentration following dosing 
AUC0-inf obs: AUC from dosing time extrapolated to infinity based on the last observed 
concentration 
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AUMC0-inf obs: AUMC extrapolated to infinity based on the last observed concentration 
MRT0-inf obs: MRT extrapolated to infinity 
8.5.5. Establishment of an in vitro-in vivo correlation 
A level A IVIVC was established for the evaluation of sulpiride and sodium valproate release, 
which utilizes the data provided via the in vitro dissolution and in vivo absorption curves. The 
amount of sulpiride and sodium valproate absorbed following administration of the respective 
ODLS layers were calculated by employing the Wagner Nelson method by means of the linear 
trapezoidal rule. For the construction of a Level A IVIVC, the concentration of drug absorbed up 
to time t was plotted against the fractional release of drug in vitro (Figure 8.11a and b; Figure 
8.12a and b). 
 
 
237 
 
 
Figure 8.11: Drug release profiles of the in vitro and in vivo a) sulpiride and b) sodium valproate 
release from the Dual-layered oral system obtained via deconvolution analysis.  
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 8.12: Regression plot showing the relationship between the fraction of (a) sulpiride and (b) 
sodium valproate absorbed in vivo and the fraction released in vitro.  
 
 
y= 1.5703x 
R2= 0.9304 
y= 1.7041x 
R2= 0.7037 
 
(a) 
(b) 
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The pharmacokinetic data obtained from this analysis complies with the requirements of 
deconvolution via convolution, as sulpiride and sodium valproate release from the Dual-layered 
oral system was determined to via a one-compartmental pharmacokinetic model without Tlag.  
Level A IVIVC analysis for sulpiride and sodium valproate yielded levy plots with an R2 values of 
0.9486 and 0.9843 respectively. Thus in vitro data was predictive of in vivo data with 94.86 % and 
98.43% accuracy respectively for sulpiride and sodium valproate. Although the plots determined 
were not precisely superimposable, based on qualitative parameters, a Level A correlation was 
utilized. The observed results show a quicker in vivo absorption compared to the in vitro 
dissolution, this may be attributed to the gastrointestinal transit time (simulated intestinal 
conditions) employed during in vitro studies which did not directly translate to release in vivo. It 
was also noted that the enteric polymer coating of the Dual-layered oral system displayed a faster 
rate of swelling and dissolution within the context of ex vivo studies compared to in vitro analysis. 
The high protein binding capacity and bioavailability of sodium valproate could also be a 
contributing factor, with display of a steeper gradient in the sodium valproate in vivo profile, when 
compared to relative the in vitro profile. The prompt absorption of sulpiride may be attributed to 
the improved permeability as discussed in Chapter 7, Section 7.3.8. 
8.6. Concluding Remarks 
The effectiveness of the Dual-layered oral system was evaluated via the in vivo analysis in a Large 
White pig model. Site-specific delivery was achieved via the use of gastro-resistant enteric tablet 
coating solution as well bioadhesive polymers. The development of individual system layers 
ensures individualistic drug release profiles and avoidance of drug interactions. Evaluation of the 
Dual-layered oral system thus accurately proved that the formulation is effective in delivering 
sulpiride in a sustained pattern with an improvement in bioavailability with the use of P-gp efflux 
pump inhibitory excipients; and the pulsatile release of sodium valproate in a time controlled 
manner. Ultimately, the formulation allows for the combination treatment of an antipsychotic and 
mood stabilizing agent in a single dosage form with individually therapeutic suited release profiles.   
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CHAPTER 9 
CONCLUSIONS, RECOMMENDATIONS AND FUTURE OUTLOOK 
9.1. Conclusions 
The design and development of an innovative and novel drug delivery system by combining a 
myriad of pharmaceutical and scientific techniques has been demonstrated within the context of 
this study with the objective of overcoming the current limitations in clinical practices with the 
eventual aim of improving patient compliance and therapeutic outcomes in the treatment of 
schizoaffective disorder.  
Poor patient compliance has been acknowledged as a foremost cause of drug resistance in many 
disease states. The basis of poor patient compliance can principally be accredited to complex 
dosing and treatment regimens made obligatory on patients as an element of a standard 
therapeutic intervention as is the case in the treatment of schizoaffective disorder. This creates a 
greater obstacle to clinical outcomes as patients suffering from schizophrenia are already limited 
in the performance of normal daily skills.  
The dual-layered oral device formulated in this study has been developed and comprehensively 
analysed with the intention of overcoming the issues of complex regimens and poor bioavailability 
in the treatment of schizoaffective disorder. This has been undertaken via development of an 
optimized Dual-layered system with individualistic mechanisms and drug release kinetics for 2 
bioactive agents. The s-IPN xerogel layer incorporated polymers known for P-glycoprotein efflux 
transporter inhibition so as to increase bioavailability of sulpiride and allow for sustained drug 
release; in addition the pulsatile release layer of the Dual-layered system encompassed lectins 
and N-acetyl-cysteine to allow for superior bioadhesion and allow for enhanced residence time for 
pulsatile delivery of sodium valproate.  
The dual-layered oral device components were proven effective via advanced and progressive in 
vitro, ex vivo and in vivo analyses. In vitro release studies performed determined that the dual-
layered oral device components acted independently of each other once exposed to intestinal 
conditions (the respective system layers detach from each other). In vitro characterization was 
additionally utilized to ascertain pharmaceutical stability. Ex vivo studies were performed to 
determine the permeation and adhesion properties of the bioadhesive intestinal patch component 
of the dual-layered oral device.  
Furthermore, in vivo studies were undertaken on the optimized dual-layered oral system 
components. The optimized components were individually administered to pigs and drug release 
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profiles were generated according to the concentration of drugs in plasma. In vivo results showed 
a definite difference in plasma profiles between the respective conventional and optimized 
component formulations. For sulpiride, release was noticeably more controlled and provided zero-
order release as compared to the conventional. Thus, the optimized s-IPN xerogel component 
provided sustained release of sulpiride. Release of sodium valproate was distinctly different from 
that of the conventional system, as the optimized intestinal patches were intended for pulsatile 
delivery of sodium valproate. The release profile of sodium valproate followed an ideal triphasic 
release pattern, with maintenance of plasma concentrations within the required therapeutic levels 
with the added benefit of avoiding resistance to therapy.  
Pharmacokinetic modelling of in vivo results determined that sulpiride and sodium valproate 
release were best described by a one compartmental model without Tlag, with IVIVC displaying an 
ideal relation.  
This thesis thus focused on the fabrication through to preclinical analyses of a Dual-layered oral 
system for the concurrent and idiosyncratic administration of sulpiride and sodium valproate. In 
concise terms, via this research study a novel Dual-layered oral system has been developed and 
extensively characterized, with the prospect of the system clinically enhancing therapeutic 
outcomes associated with schizoaffective therapeutic regimens.  
9.2. Recommendations  
Amid the design and development all the way through to the analysis of the dual-layered oral 
system components, many points of interest and challenges in regard to schizophrenia therapy 
were considered and overcome. Although the efficacy and accomplishment of the dual-layered 
oral device components have been extensively analysed up till a preclinical standpoint, other 
factors will have to be considered for production advancement. Despite the dual-layered system 
being relatively cost-effective to formulate, the array of pharmaceutical steps required for the final 
system assemblage would necessitate specialized equipment for manufacture and general use to 
the public. The use of commercial tablet compressors and dyes would be greatly useful and 
advantageous in the assembly of the dual-layered tablet, as with the use of more specialized 
machinery the dual-layered device may be reduced in size and thus be made more acceptable to 
the patient. 
With the success of the dual-layered system detailed in this study, the adaptability to scaling of 
the system can be evaluated. Sulpiride and sodium valproate were selected as model drugs due 
to their common use in schizoaffective disorder treatment regimens and the limitations associated 
with them, which has been addressed. However, alternative drug agents may be incorporated into 
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the dual-layered system with variations in drug combinations, provided they require the drug 
release kinetics the respective layers were designed for i.e. sustained and pulsatile release.  
9.3. Future Outlook 
 While the drug delivery system has been developed for the use in treatment of 
schizoaffective disorder, it is not exclusive to this specific disease state as the system may 
be loaded with drugs of varying solubility.  
 The system also permits the versatility of combining two bioactives in a single dosage form, 
this may be applied to treatment of a single disease state requiring multiple drugs or to the 
treatment of 2 different disease states or disorders.  
 The system may also be applied to combine two drugs that are pharmaceutically 
incompatible within a single dosage form due to the functionality of the drug delivery 
system (i.e. respective system layers detach upon contact with intestinal environment and 
act independently of each other).  
 The addition of patches within the intestinal patch layer of the system may be explored, 
additional patches may be incorporated with crosslinking agents so as to allow for in situ 
crosslinking to further regulate drug release rate or for protection of incorporated drugs 
such as proteins.    
 The system may be modified to release drug based on varying stimuli so as to further 
monitor and control the drug release kinetics, such as hormonal levels, pH, and thermal 
variations and based on the circadian rhythms of a specific disease state.  
 Furthermore, the individualistic action of the device components allows the flexibility of 
employing either of the optimized system layers separately for their respective functions.  
Therefore, the research generated within the current study will provide crucial techniques, data 
and concepts that can be tailored and modified to fit various pharmaceutical research endeavours.   
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2015 International Annual AAPS Meeting and Exposition  
A Novel Dual Layered Oral Semi-Interpenetrating Polymer Network Xerogel Matrix- Bioadhesive 
Intestinal Patch System for the Individualistic Delivery of Antipsychotics and Mood Stabilizing 
Agents in Schizoaffective Disorder 
Famida Ghulam Hoosain, Viness Pillay*, Yahya Choonara, Lisa du Toit and Pradeep Kumar 
University of Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, 
Johannesburg, 2193 
Purpose:  Schizoaffective disorder is a neurodegenerative disease that affects the primary functional areas 
of the central nervous system, leading to memory dysfunction and reduction in social functionality.  
 
Methods: Preparation of Semi-IPN xerogel: Gelation by crosslinking of Poly (ethylene) oxide (PEO) and 
Gellan Gum (GG) was employed in the formulation process of the xerogel, followed by precipitation, drying, 
crushing and compression. Intestinal patches were prepared via a combination of crosslinking and polymer 
blending techniques; the drug loaded layer of the intestinal patch was synthesized via crosslinking of 
Eudragit®RS100: sodium alginate with calcium chloride. The mucoadhesive layer of intestinal patch was 
prepared via the amalgamation of lectin with a hypromellose: chitosan (citric acid) polymer blend.  
Characterization Process: Characterization studies such as Fourier Transform Infrared spectrometry, 
Differential Scanning Calorimetry, In vitro drug release studies, Textural Analysis and Scanning Electron 
Microscopy were conducted on the synthesized semi-IPN xerogel and intestinal patch mucoadhesive and 
drug loaded layers. To evaluate the properties of the synthesized system components as compared to crude 
polymers employed.  
 
Results: The xerogel matrix component displayed zero-order sustained release kinetics, extending over a 
period of 24 hours. A 100% drug release was achieved at 24 hours. Water uptake between 450-500% 
indicated a controlled rate of swelling and erosion further allowing for sustained release. Surface 
morphology depicted a porous structure formed by interpenetrating networks of polymers, allowing a greater 
degree of controlled penetration into the system thus sustaining drug release. Brinells hardness ranged from 
200-238 which illustrates structural integrity under compression. Endothermic melting peaks for all design 
formulations remained within a stable, constant range between 106-107˚C, in addition prominent peaks at 
a temperature of 215˚C relating to crosslinking was observed in all formulations. FTIR data plots displays 
peaks at 3276 cm-1 which is characteristic of the additional NaOH group due to crosslinking with 
epichlorohydrin. An erosion of 80-86 % was observed in all formulations at the 24 hour mark. The intestinal 
patch component displayed pulsatile release, with desired 3 pulses in 6 hour intervals over a 24 hour period. 
Percentage swelling for the drug loaded and mucoadhesive layers were respectively were satisfactory for 
the required purpose ranging between 150-400%. Mucoadhesion was between 61.2 -88.1% displaying 
appropriate mucoadhesion. The tensile strength of the drug loaded and mucoadhesive layers in respect of 
Young’s Modulus were 0.15 and 0.09, indicating excellent flexibility.  
 
Conclusion: The currently proposed system was successful in delivering the model drugs according to the 
desired drug release kinetics. All characterization studies proved that the system possesses good chemical 
and mechanical stability required for oral drug delivery.   
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The Academy of Pharmaceutical Sciences of South Africa Conference 2015 (APSSA) 
A Novel Dual-layered Oral Device for Delivery of Two Bioactives in the Treatment of 
Schizoaffective Disorder 
Famida Ghulam Hoosain, Viness Pillay*, Yahya Choonara, Lisa du Toit and Pradeep 
Kumar 
University of Witwatersrand, Department of Pharmacy and Pharmacology, 7 York Road, 
Johannesburg, 2193 
 
Purpose: Schizoaffective disorder is a neurodegenerative disorder that affects the primary 
functional areas of the central nervous system, resulting in dysfunction of memory and social 
functioning. Clinical treatment involves therapeutic regimens of antipsychotic and mood stabilizing 
agents. The present delivery system provides individualistic release of 2 bioactives within a single 
oral dosage. The developed system is aimed to enhance management of schizoaffective disorder 
and overcome related therapeutic limitations.  
 
Methods: Box-Behnken experimental designs were generated for statistical optimization of the 
respective components of the dual-layered system. The semi-Interpenetrating polymer network 
xerogel (s-IPN) was fabricated by the crosslinking of Gellan Gum and Polyethylene oxide (PEO) 
to formulate the sustained release matrix layer. The bioadhesive multilayered intestinal patch 
component was prepared via a combination of crosslinking, polymer blending and conjugation 
reactions to pulsatile release. Characterization studies such as Fourier Transform Infrared 
spectrometry (FTIR), Differential Scanning Calorimetry (DSC), in vitro drug release studies, 
Textural Analysis, Scanning Electron Microscopy (SEM) and in vivo studies were conducted.  
 
Results: The s-IPN xerogel matrix component showed zero-order sustained release kinetics, 
extending over 24 hours. Swelling in the range of 450-500% indicated controlled rate of swelling 
further allowing for sustained release. Surface structure indicated porosity formed by 
interpenetrating networks of polymers, proving the formation of an IPN. Brinell hardness number 
ranged from 200-238 which displays structural integrity under compression. DSC melting peaks 
for all design formulations remained within a stable, constant range of 106-107˚C, distinctive peaks 
at a temperature of 215˚C relating to crosslinking was observed in all formulations. FTIR spectra 
displayed peaks at 3276 cm-1 which is characteristic of the additional NaOH group due to 
crosslinking with epichlorohydrin. The intestinal patch component displayed pulsatile release, with 
the observed 3 pulses in 6 hour intervals over a 24 hour period. Degree of swelling for the drug-
loaded and mucoadhesive layers were satisfactory for the required purpose ranging between 150-
400%.  
Mucoadhesion was found to range between 61.2-88.1%. Tensile testing of the drug-loaded and 
mucoadhesive layers in respect of Young’s Modulus was 0.15 and 0.09, respectively, indicating 
excellent flexibility of the polymeric patch layers.  
 
Conclusion: Clinical management of schizoaffective disorder involves the use of combination 
therapy to combat precipitating symptoms of the schizophrenia and the coexisting mood disorder. 
The advantage of a single dosage form able to deliver 2 bioactives lays in reduced pill burdens. 
The enhanced bioavailability of both agents will enhance compliance and therapeutic outcomes. 
The proposed system was successful in delivering the model drugs in accordance with desired 
release kinetics.  
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School of Therapeutic Sciences Research Day 2015 
A Novel Dual Layered Oral Matrix System for the Individualistic Delivery of Antipsychotics and Mood 
Stabilizing Agents in Schizoaffective Disorder 
Famida Ghulam Hoosain, Viness Pillay, Yahya Choonara, Lisa du Toit and Pradeep Kumar 
 
Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, University of Witwatersrand 
Schizoaffective disorder is a neurodegenerative disease that affects functional areas of the CNS. Treatment 
regimens are complex, thus an oral dual-layered system for the concurrent-individualistic delivery of two 
bioactives was prepared via crosslinking, blending and solvent casting techniques. Box-Behnken and 
Central Composite design programs were employed for generation of a series of formulations with varying 
compositions for establishment of optimized s-IPN xerogel-bioadhesive intestinal patch components. 
Sulpiride and Valproic acid were employed as prototype drugs for experimental design. Subsequently, 
optimized formulations were characterized for physiomechanical, physiochemical, drug release and 
mucoadhesive properties. In vitro evaluation indicated that formulations met desired pharmaceutical 
requirements, such as tensile strength, swelling, mucoadhesion and drug release kinetics individualistic to 
each component. For the s-IPN xerogel component; in vitro and in vivo studies displayed zero-order 
sustained release extending over the 24 hour test period, with 100% drug released at 24 hours. A porous 
surface morphology of the xerogel was observed due to polymer interpenetration, and allows for drug 
entrapment and controlled release. The intestinal patch component displayed pulsatile release three pulses 
at 6 hour intervals. Mucoadhesion ranged between 61.2-88.1% appropriate for prolonged residence time 
required. The tensile strength of the patch layers was 0.09-0.15 indicating excellent flexibility.  
Keywords: Xerogel, s-IPN, Bioadhesive Intestinal Patch, Sustained release, Pulsatile release.  
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11.3. Animal Ethics Clearance Certificate for ex vivo and in vivo studies (clearance was granted 
for 5 animals, hence the same 5 animals were used after a wash out period of 3 days between 
dosing, each test group thus consisted of the same 5 animals, and there were 3 groups, n=15) 
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